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Abstract 
 
The translocator protein (TSPO) is an 18 kDa molecule spanning the outer mitochondrial membrane. 
Structural predictions, reported physical interactions and experimental data from diverse models 
suggest that TSPO is involved in apoptosis, proliferation and steroidogenesis. 
TSPO is up-regulated in several human cancers and its high levels are frequently associated with 
advanced disease and poor outcome. TSPO was shown to be up-regulated in astrocytomas and this 
was correlated with high tumour grade and shorter patient survival. 
Here it is confirmed that TSPO is highly expressed in astrocytomas and this is correlated with tumour 
grade. TSPO expression is significantly higher in astrocytic tumours than in oligodendrogliomas and 
this differential expression is epigenetically driven. Low TSPO expression in oligodendrogliomas is 
associated with frequent promoter methylation, whereas in astrocytomas, where TSPO is expressed at 
high levels, the promoter typically remains unmethylated. As oligodendrogliomas and astrocytomas 
have very different biology and prognosis, and several TSPO ligands, including those enabling 
positron emission tomography (PET) scanning, are in development, we propose pre-operative PET 
imaging to differentiate these two histotypes. 
TSPO is not an independent prognostic factor in our patient population. The main cell population 
expressing TSPO within the tumour bulk are neoplastic cells.  
Consistent with no evidence for TSPO as a strong prognostic factor in gliomas, no alteration in 
proliferation, cell cycle progression and baseline or induced apoptosis following TSPO siRNA knock-
down in an in vitro astrocytoma model is demonstrated. Furthermore, there was no evidence of 
cortisol production by several astrocytoma cell lines in vitro despite TSPO protein expression.  
Out of the examined MPTP-related binding and functional partners of TSPO (VDAC1, ANT, HK I 
and II) only HKII up-regulation appears be reproducibly related to patient outcome in gliomas. 
Consistently, targeting hexokinases in vitro in a glioma model inhibited proliferation and increased 
apoptosis.  
6 
 
Contents 
Dedication ............................................................................................................................................... 2 
Acknowledgements ................................................................................................................................. 3 
Declaration .............................................................................................................................................. 4 
Abstract ................................................................................................................................................... 5 
Contents .................................................................................................................................................. 6 
List of figures ........................................................................................................................................ 12 
List of tables .......................................................................................................................................... 16 
Abbreviations ........................................................................................................................................ 18 
1 Chapter 1: Introduction ................................................................................................................. 22 
1.1 Gliomas ..................................................................................................................................... 23 
1.1.1 Incidence of brain tumours ................................................................................................... 23 
1.1.2 Definition and WHO classification of gliomas ..................................................................... 23 
1.1.3 Risk factors ........................................................................................................................... 26 
1.1.4 Localization of gliomas ......................................................................................................... 26 
1.1.5 Clinical presentation and prognosis of diffusely infiltrating gliomas ................................... 27 
1.1.5.1 Symptoms ..................................................................................................................... 27 
1.1.5.2 Age at onset ................................................................................................................... 27 
1.1.5.3 Tumour progression ...................................................................................................... 27 
1.1.5.4 Prognosis ....................................................................................................................... 27 
1.1.6 Imaging of gliomas ............................................................................................................... 28 
1.1.7 Histopathological features of gliomas ................................................................................... 28 
1.1.7.1 Diffusely infiltrating astrocytomas (WHO grade II, III and IV astrocytomas) ............. 28 
1.1.7.1.1 Diffuse astrocytomas ................................................................................................ 28 
1.1.7.1.2 Anaplastic astrocytomas ........................................................................................... 29 
1.1.7.1.3 Glioblastomas ........................................................................................................... 29 
1.1.7.2 Oligodendrogliomas ...................................................................................................... 29 
1.1.7.2.1 WHO grade II oligodendrogliomas .......................................................................... 30 
1.1.7.2.2 Anaplastic oligodendrogliomas ................................................................................ 30 
1.1.8 Genetic alterations in gliomas ............................................................................................... 30 
1.1.8.1 Overview of hallmark genomic events during glioma progression .............................. 30 
1.1.8.2 Grade- and histotype-specific genetic abnormalities in gliomas .................................. 30 
1.1.8.2.1 WHO grade II astrocytomas ..................................................................................... 30 
1.1.8.2.2 Anaplastic astrocytomas ........................................................................................... 31 
1.1.8.2.3 Glioblastomas ........................................................................................................... 31 
1.1.8.2.4 Oligodendrogliomas ................................................................................................. 32 
7 
 
1.1.9 Treatment of gliomas ............................................................................................................ 32 
1.1.9.1 General medical management ....................................................................................... 32 
1.1.9.2 Specific therapy in gliomas ........................................................................................... 33 
1.1.9.2.1 Low grade gliomas ................................................................................................... 33 
1.1.9.2.2 High-grade gliomas .................................................................................................. 33 
1.1.9.2.2.1 Temozolomide as a chemotherapeutic agent in the treatment of gliomas ......... 34 
1.1.10 Prognostic and predictive markers in gliomas .................................................................. 35 
1.2 Epigenetics ................................................................................................................................ 36 
1.2.1 Epigenetic modifications....................................................................................................... 36 
1.2.1.1 DNA methylation .......................................................................................................... 36 
1.2.1.1.1 Principles of DNA methylation analysis .................................................................. 37 
1.2.1.2 Histone modifications ................................................................................................... 37 
1.2.1.3 Non-coding RNAs......................................................................................................... 38 
1.2.2 Epigenetic alterations in cancer ............................................................................................ 38 
1.2.3 Epigenetic changes in gliomas .............................................................................................. 39 
1.2.3.1 DNA methylation in gliomas ........................................................................................ 39 
1.2.3.2 Role of microRNA in gliomas ...................................................................................... 40 
1.3 The Translocator Protein ........................................................................................................... 42 
1.3.1 Nomenclature ........................................................................................................................ 42 
1.3.2 TSPO gene ............................................................................................................................ 42 
1.3.3 TSPO protein – structural predictions ................................................................................... 43 
1.3.4 TSPO expression in normal and neoplastic tissues ............................................................... 44 
1.3.4.1 TSPO ligands ................................................................................................................ 44 
1.3.4.2 TSPO expression in normal tissues and in non-neoplastic disorders ............................ 44 
1.3.4.2.1 TSPO expression in various tissues outside the CNS .............................................. 44 
1.3.4.2.2 TSPO expression in the CNS ................................................................................... 47 
1.3.5 TSPO expression in cancer ................................................................................................... 48 
1.3.5.1 TSPO expression in human neoplasias ......................................................................... 48 
1.3.5.1.1 TSPO expression in neoplastic tissues outside the CNS .......................................... 48 
1.3.5.1.2 TSPO expression in brain tumours ........................................................................... 49 
1.3.5.1.2.1 TSPO expression as assessed using binding ligands ......................................... 49 
1.3.5.1.2.2 Immunohistochemical assessment of TSPO expression .................................... 53 
1.3.5.1.2.3 TSPO and microglia in gliomas ......................................................................... 54 
1.3.6 TSPO – functional predictions and evidence ........................................................................ 54 
1.3.6.1 TSPO role in steroid production ................................................................................... 54 
1.3.6.2 TSPO as an MPTP component – role in apoptotic cell death and glucose 
metabolism..... ............................................................................................................................... 56 
1.3.6.2.1 Cell death .................................................................................................................. 57 
1.3.6.2.1.1 Apoptotic cell death ........................................................................................... 58 
1.3.6.2.1.1.1 Mitochondrial membrane permeabilisation ................................................ 58 
1.3.6.3 TSPO binding partners and their role in cell death and metabolism ............................. 60 
1.3.6.3.1 ANT .......................................................................................................................... 60 
1.3.6.3.2 VDAC....................................................................................................................... 61 
1.3.6.3.2.1 VDAC role in apoptosis .................................................................................... 62 
1.3.6.3.2.2 VDAC role in metabolite, ion and lipid trafficking and metabolism ................ 63 
1.3.6.3.3 Hexokinase ............................................................................................................... 63 
8 
 
1.3.6.3.3.1 Role of hexokinase and hexokinase/ VDAC interaction in glucose metabolism 
and apoptosis ..................................................................................................... 63 
1.3.7 In vitro models of TSPO impact on the cancer cell behaviour in human neoplasia, including 
CNS tumours ......................................................................................................................... 64 
1.3.7.1 Studies on TSPO function in human cancer models ..................................................... 64 
1.3.7.1.1 Breast cancer models ................................................................................................ 64 
1.3.7.1.2 Colon cancer models ................................................................................................ 65 
1.3.7.1.3 Hepatocellular carcinoma model .............................................................................. 65 
1.3.7.2 Functional studies on TSPO role in glioma cell lines and a xenograft model .............. 66 
1.3.7.2.1 Rodent glioma cell line model .................................................................................. 66 
1.3.7.2.2 Human glioma cell line models ................................................................................ 66 
1.3.7.2.3 Xenograft model ....................................................................................................... 67 
1.4 Principal aims of the study ........................................................................................................ 68 
2 Chapter 2: Materials and methods ................................................................................................ 69 
2.1 Selection of cases ...................................................................................................................... 70 
2.2 Immunohistochemistry.............................................................................................................. 71 
2.2.1 Immunoperoxidase methods ................................................................................................. 71 
2.2.2 Evaluation of peroxidase immunohistochemistry ................................................................. 76 
2.2.2.1 Quantitative computer-assisted analysis of peroxidase immunohistochemistry ........... 76 
2.2.2.2 Semi-quantitative computer-assisted analysis of peroxidase immunohistochemistry .. 76 
2.2.2.3 Semi-quantitative analysis of peroxidase immunohistochemistry ................................ 77 
2.2.3 Immunofluorescence techniques ........................................................................................... 78 
2.2.3.1 Double immunofluorescence on tissue samples ........................................................... 78 
2.2.3.2 Immunofluorescence on cultured cells .......................................................................... 79 
2.2.3.2.1 Immunofluorescence on cultured cells with mitochondrion selective probe ........... 79 
2.3 Molecular biology ..................................................................................................................... 81 
2.3.1 Western blotting .................................................................................................................... 81 
2.3.1.1 Protein extraction from cultured cells ........................................................................... 81 
2.3.1.2 Protein quantification .................................................................................................... 81 
2.3.1.3 Electrophoresis, transfer of proteins and immunoblotting ............................................ 81 
2.3.2 Nuclear/ cytosolic fractionation of cultured cells ................................................................. 83 
2.3.3 Parallel determination of the relative levels of apoptosis-related proteins ........................... 83 
2.3.4 Methylation analysis ............................................................................................................. 84 
2.3.4.1 DNA isolation ............................................................................................................... 84 
2.3.4.2 Methylation specific polymerase chain reaction (MSP) of TSPO promoter ................. 85 
2.3.4.3 Pyrosequencing of TSPO promoter .............................................................................. 87 
2.4 Tissue culture experiments........................................................................................................ 89 
2.4.1 Reagents ................................................................................................................................ 89 
2.4.2 Cell lines and culture conditions ........................................................................................... 89 
2.4.3 Subculturing of adherent cells............................................................................................... 89 
2.4.4 Sulphorhodamine B colourimetric assay .............................................................................. 90 
2.4.5 Determination of IC50 for TMZ ............................................................................................. 90 
9 
 
2.4.6 Cell growth inhibition following MJ exposure and MJ IC50 ................................................. 91 
2.4.7 TSPO siRNA knock-down experiments in U-87MG cells ................................................... 91 
2.4.7.1 TSPO siRNA knock-down ............................................................................................ 91 
2.4.7.2 Cell growth following TSPO siRNA knock-down in U-87MG cell line ...................... 92 
2.4.7.3 TMZ cytotoxicity assay following TSPO siRNA knock-down in U-87MG cell line ... 92 
2.4.7.4 Caspase activation assay after TMZ treatment in U-87MG cells following TSPO 
siRNA knock-down....................................................................................................... 92 
2.4.7.5 Cell growth inhibition following TSPO siRNA knock-down in U-87MG cell line in 
low serum conditions .................................................................................................... 93 
2.4.7.6 Cell growth of U-87MG cells following TSPO knock-down and MJ exposure ........... 93 
2.4.8 Clonogenic assay .................................................................................................................. 93 
2.4.9 Flow cytometry ..................................................................................................................... 94 
2.4.10 Cortisol EIA ...................................................................................................................... 95 
2.5 Microarray data set analysis ...................................................................................................... 96 
2.6 Statistical analysis ..................................................................................................................... 97 
2.7 Buffers and solutions ................................................................................................................ 98 
3 Chapter 3: TSPO expression, regulation and clinicopathological correlates in astrocytomas and 
oligodendrogliomas ....................................................................................................................... 99 
3.1 Introduction ............................................................................................................................. 100 
3.2 Results ..................................................................................................................................... 102 
3.2.1 TSPO expression in glioma tissue samples ......................................................................... 102 
3.2.1.1 Pattern of staining ....................................................................................................... 104 
3.2.1.2 The association between TSPO levels and histopathological features in gliomas ...... 107 
3.2.2 TSPO methylation patterns delineate glioma histotypes .................................................... 108 
3.2.3 TSPO expression and patient overall survival in gliomas .................................................. 109 
3.2.4 TSPO methylation status and patient overall survival in gliomas ...................................... 110 
3.2.5 Validation of TSPO clinicopathological association in independent microarray data sets .... 112 
3.2.5.1 Differential expression of TSPO in glioma histotypes ............................................... 112 
3.2.5.2 TSPO expression and patient survival ........................................................................ 114 
3.2.5.3 TSPO expression in molecular subtypes of gliomas ................................................... 115 
3.2.6 TSPO and glioma infiltrating microglia .............................................................................. 117 
3.2.6.1 Extent and pattern of Iba1and CD68 staining ............................................................. 117 
3.2.6.2 The association between microglial markers and glioma clinicopathological features as 
well as TSPO levels .................................................................................................................... 120 
3.2.6.3 Neoplastic cells as the main cell population expressing TSPO .................................. 124 
3.3 Discussion ............................................................................................................................... 126 
4 Chapter 4: Functional characterization of TSPO in gliomas ...................................................... 130 
4.1 Introduction ............................................................................................................................. 131 
4.2 Results ..................................................................................................................................... 133 
10 
 
4.2.1 TSPO expression in human glioma cell lines ..................................................................... 133 
4.2.2 Subcellular localization of TSPO ........................................................................................ 133 
4.2.3 TSPO function in glioma cell growth and apoptotic cell death .......................................... 135 
4.2.3.1 The efficiency of the siRNA TSPO knock-down........................................................ 135 
4.2.3.2 TSPO depletion does not affect U-87MG growth rates .............................................. 138 
4.2.3.3 TSPO depletion has no effect on the colony forming ability of U-87MG cells .......... 140 
4.2.3.4 TSPO knock-down does not alter U-87MG cell cycle progression ............................ 140 
4.2.3.5 Are TSPO effects on cancer cell survival /proliferation revealed in response to specific 
stimuli?.......... .............................................................................................................. 141 
4.2.3.5.1 Effects of TSPO silencing on U-87MG cells growth in low serum conditions...... 141 
4.2.3.5.2 Effects of TSPO silencing on chemotherapy-induced cell death ........................... 142 
4.2.4 TSPO and cortisol production ............................................................................................. 146 
4.2.4.1 The expression of steroidogenic proteins in glioma tissue samples and cell lines ...... 146 
4.2.4.1.1 The expression of steroidogenic enzymes in glioma tissue samples ...................... 146 
4.2.4.1.2 The expression of steroidogenic enzymes in glioma cell lines .............................. 148 
4.2.4.2 No evidence of cortisol production by human glioma cells in vitro ........................... 149 
4.3 Discussion ............................................................................................................................... 151 
5 Chapter 5: TSPO binding partners .............................................................................................. 155 
5.1 Introduction ............................................................................................................................. 156 
5.2 Results ..................................................................................................................................... 158 
5.2.1 ANT, VDAC1 and hexokinases expression in glioma tissue samples ................................ 158 
5.2.1.1 VDAC1 but not ANT is highly expressed in gliomas ................................................. 158 
5.2.1.2 Hexokinases ................................................................................................................ 162 
5.2.2 TSPO binding partners‟ expression and patient survival .................................................... 164 
5.2.2.1 The expression of VDAC1 and ANT and patient survival ......................................... 164 
5.2.2.2 The expression of hexokinases and patient survival ................................................... 166 
5.2.2.2.1 Hexokinase I ........................................................................................................... 168 
5.2.2.2.2 Hexokinase II ......................................................................................................... 168 
5.2.2.2.3 Validation of the prognostic significance of hexokinases in independent microarray 
data sets...... ............................................................................................................... 170 
5.2.2.2.3.1 High-grade gliomas (GSE4412) ...................................................................... 170 
5.2.2.2.3.2 High-grade astrocytomas (GSE4271) .............................................................. 171 
5.2.2.2.3.3 Glioblastoma data set from The Cancer Genome Atlas (TCGA) Data Portal . 173 
5.2.3 In vitro effects of hexokinase/ VDAC1 complex targeting ................................................ 174 
5.2.3.1 Hexokinase/ VDAC1 expression in an in vitro glioma model .................................... 174 
5.2.3.2 Targeting hexokinase/VDAC1 complex in vitro ........................................................ 175 
5.2.3.2.1 Decreased human glioma cell viability following exposure to MJ ........................ 175 
5.2.3.2.2 MJ inhibits the clonogenic capacity of human glioma cells ................................... 178 
5.2.3.2.3 Features of G2/M cell cycle arrest after treatment with MJ ................................... 179 
5.2.3.2.4 Alterations in the expression of apoptosis-related proteins following MJ 
exposure.......... .......................................................................................................... 180 
5.2.4 TSPO silencing effects on the expression of VDAC1 and hexokinases and cell death induced 
by hexokinase/ VDAC1 complex targeting ........................................................................... 183 
5.2.4.1 TSPO silencing has no impact on VDAC1 and hexokinases levels in vitro ............... 183 
11 
 
5.2.4.2 TSPO knock-down does not alter response to MJ ...................................................... 184 
5.3 Discussion ............................................................................................................................... 185 
6 Chapter 6: Final discussion ......................................................................................................... 189 
6.1 Synopsis of major findings ..................................................................................................... 190 
6.2 Contribution to the field .......................................................................................................... 191 
6.2.1 TSPO and its binding partners ............................................................................................ 191 
6.2.2 Gliomas ............................................................................................................................... 193 
6.3 Future directions ..................................................................................................................... 193 
6.3.1 Pre-clinical studies .............................................................................................................. 193 
6.3.2 Histopathological studies .................................................................................................... 195 
6.3.3 Clinical studies .................................................................................................................... 195 
6.4 Concluding remarks ................................................................................................................ 196 
References ........................................................................................................................................... 197 
Appendix I Control staining for peroxidase immunohistochemistry................................................. 215 
 
Appendix II Clinicopathological characteristics of the patient population used for 
immunohistochemical analysis of HKI and HKII expression............................................................ 217  
Appendix III The average pixel densities of 35 apoptosis-related proteins determined in untreated 
cells and following MJ exposure........................................................................................................ 219 
 
 
  
12 
 
List of figures 
Figure 1.1 Cortisol biosynthesis pathway ............................................................................................. 56 
Figure 1.2 Molecular architecture of the mitochondrial permeabilty transition pore  .......................... 59 
Figure 2.1 Quantitative evaluation of TSPO peroxidase immunohistochemistry ................................. 76 
Figure 2.2 Quantitative evaluation of CD68 and Iba1 peroxidase immunohistochemistry .................. 77 
Figure 2.3 The localization of MSP primer sets in the region of TSPO CpG island - MethPrimer 
output .................................................................................................................................................... 85 
Figure 3.1 TSPO expression in glioma tissue samples ....................................................................... 105 
Figure 3.2 TSPO expression in glioma tissue samples ....................................................................... 106 
Figure 3.3 TSPO expression and histopathological features of gliomas............................................. 107 
Figure 3.4 TSPO CpG island methylation in gliomas......................................................................... 109 
Figure 3.5 TSPO expression and patient survival ............................................................................... 110 
Figure 3.6 TSPO methylation status and patient survival ................................................................... 111 
Figure 3.7 TSPO expression in normal brain and gliomas ................................................................. 113 
Figure 3.8 TSPO expression and patient survival in astrocytomas – analysis of microarray data sets
 ........................................................................................................................................................... .114 
Figure 3.9 Iba1 expression in glioma tissue samples .......................................................................... 118 
Figure 3.10 CD68 expression in glioma tissue samples ..................................................................... 119 
Figure 3.11 Extent of microglial infiltrate and histopathological features of gliomas ....................... 120 
Figure 3.12 Extent of microglial infiltrate (Iba1 expression) and patient survival ............................. 121 
Figure 3.13 Extent of microglial infiltrate (CD68 expression) and patient survival ........................... 122 
Figure 3.14 Representative images from TSPO/ GFAP double immunofluorescence in a glioblastoma 
(case 29) .............................................................................................................................................. 124 
Figure 3.15 Representative images from TSPO/ Iba1 double immunofluorescence in a glioblastoma 
(case 26) .............................................................................................................................................. 125 
13 
 
Figure 4.1 TSPO expression in human glioma cell lines as assessed using Western blotting ............ 133 
Figure 4.2 Localization of TSPO in U-87MG human glioma cells analysed by immunofluorescence 
 ............................................................................................................................................................ 134 
Figure 4.3 Subcellular localization of TSPO in U-87MG human glioma cells as analysed by 
nuclear/cytoplasmic fractionation ....................................................................................................... 135 
Figure 4.4 The efficiency of siRNA-mediated TSPO knock-down assessed by Western blotting ..... 136 
Figure 4.5 The efficiency of siRNA-mediated TSPO knock-down assessed at 72 hours post 
transfection .......................................................................................................................................... 136 
Figure 4.6 The efficiency of siRNA-mediated TSPO knock-down assessed by immunofluorescence
 ............................................................................................................................................................ 137 
Figure 4.7 U-87MG cell growth in baseline conditions over 5-day period ........................................ 138 
Figure 4.8 TSPO knock-down does not alter U-87MG cell growth in baseline conditions ............... 139 
Figure 4.9 Clonogenic capacity of U-87MG cells following TSPO knock-down as determined using 
clonogenic assay ................................................................................................................................. 140 
Figure 4.10 TSPO knock-down does not impact on the U-87MG cell cycle progression assessed using 
propidium iodide staining and flow cytometry analysis ..................................................................... 141 
Figure 4.11 TSPO knock-down does not alter U-87MG cell growth in low serum conditions .......... 142 
Figure 4.12 The 50% inhibitory concentration (IC50) of TMZ in U-87MG cells ............................... 143 
Figure 4.13 TSPO knock-down does not alter U-87MG cell growth following TMZ exposure ........ 144 
Figure 4.14 TSPO knock-down effects on caspase-3 and caspase-7 activity in TMZ treated cells.... 145 
Figure 4.15 P450scc expression in glioma tissue samples .................................................................. 146 
Figure 4.16 P450c17A1 expression in glioma tissue samples ............................................................ 147 
Figure 4.17 Expression of steroidogenic enzymes P450scc and P450c17A1 in tumour cells of  a 
glioblastoma (case 29) ........................................................................................................................ 148 
Figure 4.18 P450scc and P450c17A1 expression in a panel of human glioma cell lines ................... 149 
Figure 4.19 Standard curve for the cortisol EIA ................................................................................. 150 
Figure 5.1 ANT expression in glioma tissue samples ......................................................................... 160 
14 
 
Figure 5.2 VDAC1 expression in glioma tissue samples .................................................................... 161 
Figure 5.3 ANT, VDAC1 and TSPO expression in gliomas .............................................................. 161 
Figure 5.4 Hexokinase I expression in glioma tissue samples ............................................................ 163 
Figure 5.5 Hexokinase II expression in glioma tissue samples  ......................................................... 163 
Figure 5.6 Expression of HKI and HKII in gliomas ........................................................................... 164 
Figure 5.7 VDAC1 and ANT expression and patient survival ........................................................... 165 
Figure 5.8 Hexokinase expression and patient survival ...................................................................... 167 
Figure 5.9 Hexokinase expression and patient survival ...................................................................... 169 
Figure 5.10 Hexokinase expression and patient survival in astrocytoma series from GSE4271 
microarray data set .............................................................................................................................. 172 
Figure 5.11 Expression of hexokinases and patient survival in glioblastoma series from The Cancer 
Genome Atlas (TCGA) Data Portal .................................................................................................... 173 
Figure 5.12 Expression of hexokinases and VDAC1 in a panel of human glioma cell lines.............. 174 
Figure 5.13 Localization of hexokinases and VDAC1 in U-87MG human glioma cells analysed by 
immunofluorescence ........................................................................................................................... 175 
Figure 5.14 GaMG cell growth in baseline conditions over 5-day period .......................................... 176 
Figure 5.15 Decrease of glioma cell viability after exposure to MJ ................................................... 177 
Figure 5.16 The 50% inhibitory concentration (IC50) of MJ in glioma cells ...................................... 178 
Figure 5.17 Inhibition of the clonogenic capacity of U-87MG cells by MJ as determined using 
clonogenic assay ................................................................................................................................. 179 
Figure 5.18 Features of G2/M cell cycle arrest after treatment with MJ as assessed using propidium 
iodide staining and flow cytometry analysis ....................................................................................... 180 
Figure 5.19 Alterations in expression of apoptosis-related proteins following MJ exposure ............. 181 
Figure 5.20 Survivin expression following 24-hour exposure to MJ .................................................. 182 
Figure 5.21 Cleaved caspase-3 expression following 24-hour exposure to MJ .................................. 182 
Figure 5.22 VDAC1 and hexokinase expression remains unaffected following TSPO silencing ...... 183 
15 
 
Figure 5.23 TSPO silencing does not alter response to MJ ................................................................ 184 
 
  
16 
 
List of tables 
Table 1.1 WHO Classification of Tumours of the Central Nervous System - Tumours of 
neuroepithelial tissue ............................................................................................................................ 24 
Table 1.2 TSPO expression in various species and tissues assessed using ligands .............................. 45 
Table 1.3 TSPO expression in brain tumours assessed using TSPO ligands ........................................ 51 
Table 2.1 Details of primary antibodies ................................................................................................ 73 
Table 2.2 Details of secondary antibodies ............................................................................................ 74 
Table 2.3 Details of the immunohistochemical reactions ..................................................................... 75 
Table 2.4 Blocking buffers and working dilutions of the antibodies for Western blotting ................... 82 
Table 2.5 Methylation specific PCR: primer sequences, annealing temperatures and PCR product 
sizes ....................................................................................................................................................... 86 
Table 3.1 Summary of the clinical characteristics of gliomas analysed by peroxidase 
immunohistochemistry for TSPO, CD68 and Iba1 expression (cases 1-50)....................................... 102 
Table 3.2 Clinicopathological characteristics of the patient population ............................................. 103 
Table 3.3 Summary of the clinicopathological data of glioma patients from the microarray data sets 
included in the validation analysis ...................................................................................................... 112 
Table 3.4 TSPO expression in hierarchical clusters of high-grade gliomas from GSE4412 data set. 115 
Table 3.5 TSPO expression in subclasses of high-grade astrocytomas from GSE4271data set ......... 116 
Table 3.6 TSPO expression in subtypes of glioblastomas from The Cancer Genome Atlas (TCGA) 
Data Portal .......................................................................................................................................... 116 
Table 3.7 Iba1/ CD68 expression and patient survival in gliomas - multivariate Cox regression 
analysis ................................................................................................................................................ 122 
Table 3.8 Iba1/ CD68 expression and patient survival in astrocytomas - multivariate Cox regression 
analysis ................................................................................................................................................ 123 
Table 3.9 Bivariate correlation between results of TSPO, CD68 and Iba1expression analysis in 
gliomas ................................................................................................................................................ 123 
Table 5.1 Summary of the clinical characteristics of glioma cases analysed by peroxidase 
immunohistochemistry for ANT and VDAC1 expression .................................................................. 158 
17 
 
Table 5.2 Clinicopathological characteristics of the patient population (cases 51-81) ....................... 159 
Table 5.3 Summary of the clinical characteristics of glioma cases included in the 
immunohistochemical analysis of hexokinase expression .................................................................. 162 
Table 5.4 Expression of hexokinases as four categories and patient survival – log rank and 
multivariate Cox regression analysis .................................................................................................. 166 
Table 5.5 Expression of hexokinases and patient survival - results of multivariate Cox regression 
analysis ................................................................................................................................................ 170 
Table 5.6 Expression of hexokinases and patient survival in high-grade glioma series from GSE4412 
microarray data set .............................................................................................................................. 171 
  
18 
 
Abbreviations 
  
[
18
F]FDG-PET [
18
F]fluorodeoxyglucose positron emission tomography 
3βHSD1/2 3-β-hydroxysteroid dehydrogenase 
ABC avidin biotin complex 
AD Alzheimer‟s disease 
ADP adenosine diphosphate 
AIF apoptosis inducing factor 
AKT/mTOR serine/ threonine-specific protein kinases/mammalian target of rapamycin 
ANT adenine nucleotide translocator 
Apaf1 apoptotic protease activating factor 1 
APS ammonium persulphate 
ATCC American Type Culture Collection 
ATP adenosine triphosphate 
Bcl-2 B-cell lymphoma-2 
bp base pair 
BMI body mass index 
BRCA1 breast cancer susceptibility gene 1 
BSA albumin from bovine serum 
CDKN2A/ p16
INK4a
 cyclin-dependent kinase inhibitor 2A 
CDKN2B/ p15
INK4b
 cyclin-dependent kinase inhibitor 2B 
CG cytosine guanine 
CGH comparative genomic hybridization 
CI confidence interval 
cIAP-2 cellular inhibitor of apoptosis protein 2 
CNS central nervous system 
CRAC cholesterol recognition/interaction amino acid consensus 
CT computed tomography 
DAB 3,3-diaminobenzidine tetrahydrochloride 
DAPI 4‟, 6-diamidino-2-phenylindole 
DAPK1 death-associated protein kinase 1 
DBI diazepam-binding inhibitor 
DMEM Dulbecco's Modified Eagle Medium 
DMSO dimethylsulphoxide 
DNA deoxyribonucleic acid 
DNMTs DNA methyltransferases 
19 
 
DPX Depex polystyrene 
DSMZ German Collection of Microorganisms and Cell Cultures 
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
EGFR epidermal growth factor receptor 
EIA enzyme immunoassay 
EMP3 epithelial membrane protein 3 
EORTC European Organisation for Research and Treatment of Cancer 
FADD Fas-associated death domain protein 
FBS foetal bovine serum 
FFPE formalin fixed paraffin embedded 
FISH fluorescence in situ hybridization 
G-6-P glucose-6-phosphate 
GEO Gene Expression Omnibus 
GFAP glial fibrillary acidic protein 
HBRC Human Biomaterials Resource Centre 
HIF1 hypoxia inducible factor 1 
HIV Human Immunodeficiency Virus 
HKI hexokinase I 
HKII hexokinase II 
HO-2 heme oxygenase 2 
HR hazard ratio 
HSP27 heat shock protein 27 kDa 
HSP60 heat shock protein 60 kDa 
IAP inhibitor of apoptosis proteins 
Iba1 ionized calcium binding adaptor molecule 1 
IBP isoquinoline-binding protein 
IC50 half maximal inhibitory concentration 
IDH1 isocitrate dehydrogenase 1 
IDH2 isocitrate dehydrogenase 2 
IF immunofluorescence 
IHC peroxidase immunohistochemistry 
IMM inner mitochondrial membrane 
LDS lithium dodecyl sulphate 
LOH loss of heterozygosity 
MALDI-TOF MS matrix assisted laser desorption ionization time of flight mass spectroscopy 
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MAPK mitogen activated protein kinase 
MGMT O
6
-methylguanine-DNA methyltransferase 
miRNAs microRNAs 
MJ methyl jasmonate 
MLH1 mutL homolog 1 
MPTP mitochondrial permeability transition pore 
MRI magnetic resonance imaging 
mRNA messenger ribonucleic acid 
MRS magnetic resonance spectroscopy 
MS multiple sclerosis 
MSP methylation specific polymerase chain reaction 
MTIC 5-(3-methyl)1-triazen-1-yl-imidazole-4-carboxamide 
NCIC National Cancer Institute of Canada 
NICE National Institute for Health and Clinical Excellence 
NSCLC non-small cell lung carcinoma 
OMM outer mitochondrial membrane 
P450c11B1 steroid 11-β –hydroxylase 
P450c17A1 steroid 17-α –hydroxylase 
P450c21 steroid 21-hydroxylase 
P450scc cytochrome P450 side chain cleavage enzyme 
PAP7 peripheral-type benzodiazepine receptor -associated protein 
PBR peripheral benzodiazepine receptor 
PBS phosphate buffered saline 
PBS/T phosphate buffered saline with 0.1% Tween 20 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PCV procarbazine, lomustine and vincristine 
PDGF platelet-derived growth factor 
PDGFR platelet-derived growth factor receptor 
PET positron emission tomography 
PI propidium iodide 
PK11195 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-1-isoquinoline
 
carboxamide 
PKARIα cAMP-dependent protein kinase catalytic subunit α 
PON 2 paraoxonase 2 
PTEN phosphatase and tensin homolog 
RB1 retinoblastoma 1 
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RIPA radioimmunoprecipitation assay 
RISC RNA- induced silencing complex 
RNA ribonucleic acid 
SCID severe combined immunodeficient 
SDS sodium dodecyl sulphate 
SEM standard error of the mean 
shRNA short-hairpin RNA 
siRNA small interfering RNAs 
SRB sulphorhodamine B 
StAR steroidogenic acute regulatory protein 
TCA trichloroacetic acid 
TCGA The Cancer Genome Atlas 
TEMED N,N,N′,N′-tetramethylethylenediamine 
TMZ temozolomide 
TP53 tumour protein p53 
TRAILR1/ DR4 tumour necrosis factor related apoptosis inducing ligand receptor 1/death 
receptor 4 
TSPO translocator protein 
TSPO-S translocator protein isoform 2 
TUNEL terminal deoxynucleotidyl transferase dUTP nick end labelling 
UK United Kingdom 
VDAC voltage dependent anion channel  
VHL von Hippel-Lindau tumour suppressor 
WB Western blotting 
WHO World Health Organisation 
XIAP X-linked inhibitor of apoptosis protein 
  
22 
 
Chapter 1: Introduction 
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1.1 Gliomas 
1.1.1 Incidence of brain tumours 
Central nervous system (CNS) tumours account for about 2% of all cancers. Although relatively 
uncommon, they are associated with disproportionately high morbidity and mortality. In the United 
Kingdom about 4500 patients are newly diagnosed with tumours of the CNS each year with 3611 
deaths caused by these neoplasms in 2007. The estimated lifetime risk of developing CNS cancer is 1 
in 133 for men and 1 in 185 for women (Burnet et al. 2005; Cancer Research UK 2007).  
1.1.2 Definition and WHO classification of gliomas 
Gliomas are the most frequent primary CNS cancers (Prayson 2005). They form a heterogeneous 
group, included in the category of neuroepithelial tissue tumours of the World Health Organisation 
(WHO) Classification of Tumours of the CNS (Louis 2007). The classification of tumours of 
neuroepithelial tissue is presented in Table 1.1. Diffusely infiltrating astrocytomas and 
oligodendrogliomas, that are subject of this study, represent the most common histotypes of gliomas 
in adult patients (Fletcher 2007; Louis 2007).  
The WHO Classification of the Tumours of the CNS distinguishes the following types of diffusely 
infiltrating astrocytic tumours: diffuse astrocytoma (WHO grade II astrocytoma), anaplastic 
astrocytoma (WHO grade III astrocytoma) and glioblastoma (glioblastoma multiforme, WHO grade 
IV astrocytoma). WHO grade III and IV astrocytic tumours are considered as high-grade 
astrocytomas (Louis 2007).  
According to the current WHO grading system there are two grades of oligodendroglial neoplasms 
with oligodendroglioma classified as WHO grade II and anaplastic oligodendroglioma corresponding 
histologically to WHO grade III (Louis 2007).   
“Glioma” is used throughout this work to refer to diffusely infiltrating astrocytomas (WHO grade II-
IV) and oligodendrogliomas (WHO grade II-III). WHO grade I astrocytomas (pilocytic astrocytomas 
and subependymal giant cell astrocytomas), pleomorphic xanthoastrocytomas (WHO grade II) and 
pilomyxoid astrocytomas (WHO grade II) do not belong to diffusely infiltrating gliomas and are not 
considered here. 
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WHO grade Tumours of Neuroepithelial Tissue 
 
  
Astrocytic tumours  
 Pilocytic astrocytoma I 
 Subependymal giant cell astrocytoma I 
 Pleomorphic xanthoastrocytoma II 
 Diffuse astrocytoma II 
 Anaplastic astrocytoma III 
 Glioblastoma IV 
 Gliomatosis cerebri III 
   
Oligodendroglial tumours  
 Oligodendroglioma II 
 Anaplastic oligodendroglioma III 
   
Oligoastrocytic tumours  
 Oligoastrocytoma II 
 Anaplastic oligoastrocytoma III 
   
Ependymal tumours  
 Subependymoma  I 
 Myxopapillary ependymoma I 
 Ependymoma II 
 Anaplastic ependymoma III 
   
Choroid plexus tumours  
 Choroid plexus papilloma  I 
 Atypical choroid plexus papilloma II 
 Choroid plexus carcinoma III 
   
Other neuroepithelial tumours  
 Astroblastoma not established 
 Chordoid glioma of the third ventricle II 
 Angiocentric glioma I 
   
Neuronal and mixed neuronal-glial tumours  
 Dysplastic gangliocytoma of cerebellum I 
 Desmoplastic infantile astrocytoma/ ganglioglioma I 
 Dysembryoplastic neuroeipthelial tumour  I 
 Gangliocytoma  I 
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Table 1.1  
WHO Classification of Tumours of the Central Nervous System - Tumours of neuroepithelial 
tissue  
Adapted from Louis et al. (Louis 2007).  
  
   
 Ganglioglioma I 
 Anaplastic ganglioglioma  III 
 Central neurocytoma II 
 Extraventricular neurocytoma II 
 Cerebellar liponeurocytoma II 
 Papillary glioneuronal tumour I 
 Rosette-forming glioneuronal tumour of the fourth ventricle I 
 Paraganglioma I 
   
Tumours of the pineal region  
 Pineocytoma I 
 Pineal parenchymal tumour of intermediate differentiation II and III 
 Pineoblastoma IV 
 Papillary tumour of the pineal region II and III 
   
Embryonal tumours  
 Medulloblastoma IV 
 CNS primitive neuroectodermal tumour IV 
 Atypical teratoid/ rhabdoid tumour IV 
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1.1.3 Risk factors 
Previous exposure to ionising radiation is the only definite environmental risk factor identified for 
glioma (Fisher et al. 2007). The link between the risk of developing a glioma and other factors, such 
as occupation and head injury, has not been fully established (Ohgaki et al. 2005a). People with atopy 
appear to have a reduced risk of glioma and patients with glioblastoma who have elevated IgE levels 
are likely to survive longer than those with normal IgE levels (Linos et al. 2007; Wrensch et al. 2006). 
Higher body mass index (BMI) and height were associated with an increase of incidence of all CNS 
tumours including gliomas in an analysis of large cohort of middle-aged women (Benson et al. 2008).  
Few hereditary syndromes of increased glioma incidence are described. Turcot syndrome type 1 
(glioma-polyposis) is a hereditary autosomal dominant disorder caused by mutations in DNA 
mismatch repair genes where glioma coincides with hereditary nonpolyposis colorectal carcinoma. 
Patients with Turcot syndrome type 1 develop anaplastic astrocytomas or glioblastomas earlier than 
the general population, usually before the age of 30. WHO grade II-IV astrocytomas are also 
associated with Li-Fraumeni syndrome caused by germline TP53 mutations. Neurofibromatosis type 1 
and 2, caused by mutations of the neurofibromin 1 and neurofibromin 2 gene respectively, are other 
familial tumour syndromes with glioma prevalence higher than in the general population (Louis 
2007).  
1.1.4 Localization of gliomas 
Diffusely infiltrating astrocytomas and oligodendrogliomas most frequently develop supratentorially 
in the frontal and temporal cerebral lobes. Localization of a diffusely infiltrating glioma in the 
cerebellum is uncommon. Glioblastoma arises most frequently in the white matter of the cerebral 
hemispheres, typically with combined fronto-temporal localization. Brain stem, cerebellum and spinal 
cord are rare localization for WHO grade IV astrocytomas (Louis 2007; Prayson 2005).  
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1.1.5 Clinical presentation and prognosis of diffusely infiltrating gliomas 
1.1.5.1 Symptoms 
Clinical presentation of a diffusely infiltrating glioma depends on the localization and growth rate of 
the tumour. Patients suffering from gliomas involving cerebral cortex typically present with seizures. 
Other symptoms may include focal neurological deficits (speech difficulties, disturbances in sensation 
and/ or vision, and motor changes) and personality changes. Increased intracranial pressure results in 
headaches, nausea, vomiting and visual disturbances. Low grade gliomas are slowly growing lesions 
and the tumour may not produce any clinical signs for months. Clinical history of high-grade glioma 
is usually short, unless the neoplasm has developed from a lower grade lesion (Louis 2007). 
1.1.5.2 Age at onset 
WHO grade II astrocytomas usually occur in the third and fourth decades of life (mean age 35 years), 
anaplastic astrocytomas typically manifest in the fourth and fifth decades (mean age 45 years) and the 
peak incidence of glioblastomas is in the fifth and sixth decades. The peak incidence is between 40 
and 45 years for WHO grade II oligodendrogliomas and between 45 and 50 years for anaplastic 
oligodendrogliomas (Fletcher 2007). 
1.1.5.3 Tumour progression 
WHO grade II and III astrocytomas tend to undergo progression to higher grade lesions and ultimately 
to glioblastoma. The mean time interval between the diagnosis of WHO grade II astrocytoma and 
progression to glioblastoma is 4-5 years and anaplastic astrocytoma tends to progress to glioblastoma 
after approximately 2-year interval. WHO grade II oligodendroglioma may progress to anaplastic 
oligodendroglioma, although the anaplastic transformation is less frequent than in WHO grade II 
astrocytoma and the mean time interval is longer (Fletcher 2007; Louis 2007). 
1.1.5.4 Prognosis 
The prognosis for a patient with diffusely infiltrating astrocytoma is dismal. The median patient 
survival time in population based studies is 5.6 years for WHO grade II astrocytoma and 1.6 years for 
anaplastic astrocytoma (Ohgaki et al. 2005b). The median progression-free survival of a patient with 
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glioblastoma is 6.9
 
months and a median overall survival 14.6 months (Stupp et al. 2005). The 
prognosis is markedly better for oligodendrogliomas as they have more indolent natural behaviour 
than astrocytomas and tend to be more sensitive to therapy (Louis 2006; Nutt et al. 2000). The median 
patient survival time is 11.6 years for WHO grade II oligodendroglioma and 3.5 years for anaplastic 
oligodendroglioma (Ohgaki et al. 2005b).   
1.1.6 Imaging of gliomas 
Magnetic resonance imaging (MRI) with or without the addition of gadolinium contrast and computed 
tomography (CT) with a contrast agent are the major imaging procedures for diagnosis of gliomas 
(Cavaliere et al. 2005; Wen et al. 2008). On CT scans low grade gliomas most often present as 
homogenous masses of low density. MRI, postulated to be the imaging technique of choice for brain 
tumours, shows hypointense masses on T1-weighted images and hyperintense lesions on T2-weighted 
scans (DeAngelis 2001). Contrast enhancement is uncommon in low grade gliomas. Almost all 
enhancing lesions are highly proliferative high-grade tumours where the blood brain barrier is 
destroyed allowing for passage of the contrast media into the brain. The use of positron emission 
tomography (PET) enables the assessment of molecular processes, such as glucose consumption, 
expression of nucleoside and amino acid transporters, as well as alterations of DNA and protein 
synthesis. Magnetic resonance spectroscopy (MRS) allows metabolites detection and quantification 
(Floeth et al. 2005). 
1.1.7 Histopathological features of gliomas 
1.1.7.1 Diffusely infiltrating astrocytomas (WHO grade II, III and IV astrocytomas) 
The main feature of WHO grade II, III and IV astrocytomas is their infiltrative growth. The 
microscopic invasion of normal brain can be distant from the tumour mass (Fletcher 2007; Louis 
2007; Prayson 2005).  
1.1.7.1.1 Diffuse astrocytomas 
Diffuse astrocytomas (WHO grade II) occur in three histological variants corresponding to 
morphological subtypes of astrocytes in normal and reactive brain tissue, namely fibrillary, 
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gemistocytic and protoplasmic. The most frequent subtype is the fibrillary astrocytoma. The 
gemistocytic variant has the strongest tendency to progress to higher grade lesions. Histopathological 
appearance of diffuse astrocytoma is characterised by low to moderate cell density. Neoplastic cells 
are well differentiated and have atypical nuclei (enlarged, irregular in shape and size, hyperchromatic) 
(Louis 2007).   
1.1.7.1.2 Anaplastic astrocytomas 
Anaplastic astrocytoma is a hypercellular lesion comprised of pleomorphic cells with atypical nuclei. 
In comparison to WHO grade II astrocytomas, anaplastic astrocytomas demonstrate brisk mitotic 
activity but lack microvascular proliferation and necrosis that are features of glioblastomas (Louis 
2007).  
1.1.7.1.3 Glioblastomas 
Histopathological features of glioblastoma include nuclear atypia, cellular pleomorphism, high mitotic 
activity, vascular thrombosis and areas of microvascular proliferation and/ or pseudopalisading 
necrosis (areas of necrosis surrounded by radially oriented, densely packed, small fusiform glial 
cells). The majority of glioblastomas are primary (de novo) glioblastomas and these are rapidly 
developing tumours without clinical or histopathological evidence of pre-existing lower grade lesions. 
Glioblastoma that developed through progression from lower grade astrocytoma is termed secondary 
glioblastoma (Louis 2007). Small cell glioblastoma, giant cell glioblastoma and gliosarcoma are 
histological variants of glioblastoma.  
1.1.7.2 Oligodendrogliomas 
Oligodendrogliomas are composed of cells with clear cytoplasm and well defined plasma membrane. 
Nuclei of neoplastic cells are hyperchromatic and uniformly round (Fletcher 2007; Louis 2007; 
Prayson 2005).   
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1.1.7.2.1 WHO grade II oligodendrogliomas 
WHO grade II oligodendrogliomas are composed of a moderate number of monomorphic cells. 
Typically they show no or low mitotic activity. Microcalcifications, mucoid/ cystic degeneration and 
dense network of branching capillaries are common (Louis 2007). 
1.1.7.2.2 Anaplastic oligodendrogliomas 
Anaplastic oligodendrogliomas are characterised by high cellularity, marked cytological atypia, high 
mitotic activity and microvascular proliferation. Tumour cells have round hyperchromatic nuclei and 
perinuclear halos (Louis 2007).  
1.1.8 Genetic alterations in gliomas 
 
1.1.8.1 Overview of hallmark genomic events during glioma progression 
Few changes common to both major glioma histotypes have been described.  Mutations of the 
isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are frequent and early genetic
 
alterations in 
astrocytomas and oligodendrogliomas (Yan et al. 2009a). Mutation in IDH1 gene were identified in 
the majority of WHO grade II and III astrocytomas, secondary glioblastomas, WHO grade II and III 
oligodendrogliomas (Parsons et al. 2008; Yan et al. 2009b). Analyses of two or more biopsies from 
the same
 
patients revealed that IDH1 mutations always preceded the acquisition of a tumour protein 
p53 (TP53) mutation in astrocytomas or loss of 1p/19q in oligodendrogliomas (Watanabe et al. 2009). 
On the basis of these findings Watanabe et al. postulated that when common glial precursor cell 
carrying IDH1 mutation acquires TP53 mutation tumour with astrocytic phenotype arises, while loss 
of 1p/19q subsequent to IDH1 mutation promotes acquisition of the oligodendroglial
 
phenotype 
(Watanabe et al. 2009).  
1.1.8.2 Grade- and histotype-specific genetic abnormalities in gliomas 
 
1.1.8.2.1 WHO grade II astrocytomas 
Mutations of TP53 represent an early event in the evolution of astrocytomas and are found in more 
than 60% of WHO grade II astrocytic tumours (Okamoto et al. 2004; Reifenberger et al. 1996; 
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Watanabe et al. 1997; Zhu et al. 2002). Mutations of genes from platelet-derived growth factor 
(PDGF)/ platelet-derived growth factor receptor (PDGFR) signalling pathway are frequent (Gladson 
et al. 2010). The most common chromosomal abnormalities are gains on chromosome 7q and 
chromosome 8q (Nishizaki et al. 1998; Schrock et al. 1996).  
1.1.8.2.2 Anaplastic astrocytomas 
Mutations of TP53 occur in 50-60% of anaplastic astrocytomas while amplification of MDM2 gene, 
an endogenous p53 inhibitor, is reported in 11% of lesions (Ohgaki et al. 2004; Reifenberger et al. 
1993). Mutations in genes regulating cell cycle progression - retinoblastoma 1 (RB1)/ cyclin-
dependent kinase inhibitor 2A (CDKN2A/ p16
INK4a
) pathway can be detected in 50% of anaplastic 
astrocytomas (Zhu et al. 2002). 
Loss of heterozygosity (LOH) of the long arm of chromosome 19 is significantly more frequent in 
anaplastic astrocytomas than in low grade astrocytic tumours (von Deimling et al. 1994). 
1.1.8.2.3 Glioblastomas 
Of all astrocytic tumours, glioblastomas display the highest number of genetic abnormalities with 
distinct pattern of genetic changes observed in primary and secondary glioblastomas (Ohgaki et al. 
2007).  
Gene encoding epidermal growth factor receptor (EGFR), located on chromosome 7p12, is amplified 
and/or mutated in approximately 40% of de novo glioblastomas but rarely amplified in secondary 
glioblastomas (Ohgaki et al. 2007). EGFR amplification is associated with EGFR over-expression. 
Genetic alterations in the EGFR gene promote glioma cell proliferation and invasion as demonstrated 
in vitro (Nishikawa et al. 1994). 
Loss of the phosphatase and tensin homolog (PTEN) gene, due to LOH of chromosome 10q and 
mutations, is also a frequent genetic alteration in glioblastoma. LOH of chromosome 10q occurs in 
60-80% of cases with similar frequencies in primary and secondary glioblastomas. PTEN is mutated 
almost exclusively in primary glioblastomas (about 30% of de novo glioblastomas and 4% of 
secondary glioblastomas) (Zhu et al. 2002). Loss of PTEN results in activation of the serine/ 
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threonine-specific protein kinases (AKT)/mammalian target of rapamycin (mTOR) pathway, which 
promotes cell survival, proliferation and invasion (Gladson et al. 2010).  
TP53 is mutated in more than 65% of secondary glioblastomas and significantly less frequently in de 
novo glioblastomas (25%) (Ohgaki et al. 2007). Genes from the RB1/CDKN2A/ p16
INK4a
 pathway are 
mutated in 80% of glioblastomas (Zhu et al. 2002).  
1.1.8.2.4 Oligodendrogliomas 
The average number of genetic aberrations increases from WHO grade II oligodendrogliomas to 
anaplastic oligodendrogliomas (Bigner et al. 1999; Jeuken et al. 2002; Kros et al. 1999; Reifenberger 
et al. 1994; Weber et al. 1996).  
The most common genetic alteration in oligodendrogliomas is LOH of chromosomes 1p and 19q. It is 
found in up to 83% of oligodendroglial tumours, and slightly less common in anaplastic 
oligodendrogliomas than in WHO grade II oligodendrogliomas (Bello et al. 1995; Bigner et al. 1999; 
Felsberg et al. 2004; Okamoto et al. 2004; Reifenberger et al. 1994; Smith et al. 1999). Frequently, 
one entire copy of 1p and 19q chromosome arm is lost due to an unbalanced translocation (Griffin et 
al. 2006; Jenkins et al. 2006).  
In contrast to astrocytic tumours, TP53 mutations are rare in oligodendrogliomas and mutually 
exclusive with 1p/19q deletion (Bigner et al. 1999; Burger et al. 2001; Maintz et al. 1997; Ueki et al. 
2002; Watanabe et al. 2002). 
1.1.9 Treatment of gliomas 
1.1.9.1 General medical management 
General medical management of patient with glioma includes the control of seizures, reduction of 
peritumoural oedema, prevention of venous thromboembolism and treatment of fatigue and cognitive 
dysfunction (Wen et al. 2006).  
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1.1.9.2 Specific therapy in gliomas 
 
1.1.9.2.1 Low grade gliomas 
The optimal treatment for low grade gliomas is not established. The more extensive surgical resection 
has a positive impact on patient outcome, whereas the efficacy and timing of radiotherapy remains 
controversial. Currently, there is an increasing recognition for chemotherapeutic treatment of low 
grade gliomas as an alternative to radiotherapy (Cavaliere et al. 2005). 
1.1.9.2.2 High-grade gliomas 
At present, the specific treatment of patients with high-grade gliomas is comprised of a maximally 
safe surgical resection, followed by radiation therapy and chemotherapy (Wen et al. 2008).  
Surgery plays an important role in both diagnosis and treatment. While stereotactic biopsy is the 
minimal requirement to determine the histology of the tumour, craniotomy, in addition to the 
cytoreductive effect, provides material that may allow obtaining more insight into the tumour 
composition and characteristics. Application of MRI guided neuronavigation, intra-operative MRI, 
functional MRI or intra-operative mapping and fluorescence guided surgery allows increasing the 
extent of resection. In patient with glioblastoma, the maximum survival benefit due to surgical 
resection is about 6 months, and 3 months in patients over the age of 65 years (Lacroix et al. 2001; 
Mitchell et al. 2005; Muacevic et al. 2003).   
Conventional radiotherapy (60 Gy of partial field external-beam irradiation) follows surgery (Wen et 
al. 2008).  
The importance of chemotherapeutic drugs in the treatment of gliomas has been postulated 
(Carpentier 2005). A phase III trial conducted by the European Organisation for Research and 
Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) comparing 
radiotherapy alone and radiotherapy with concomitant treatment with temozolomide (TMZ), followed 
by adjuvant TMZ, has shown that the combination of radiotherapy and TMZ was beneficial for 
patients with newly diagnosed glioblastomas (Stupp et al. 2005). Anaplastic oligodendrogliomas with 
1p and 19q co-deletion are sensitive to chemotherapy with the PCV regimen – procarbazine, 
lomustine and vincristine (Cairncross et al. 1998; Ino et al. 2001).  
34 
 
Despite the advances in surgical, radiotherapeutic and chemotherapeutic modalities, primary brain 
tumours are considered resistant to the most commonly used antineoplastic agents. Invasive nature of 
gliomas and their anatomical localization within brain that is exquisitely sensitive to disruption 
compromises the effectiveness of surgical treatment and complicates the delivery of effective doses of 
radiation to the tumour cells. Furthermore, the strategies for systemic chemotherapy are limited by the 
presence of the blood brain barrier, although the continuity of the brain blood barrier is frequently not 
maintained at sites of primary tumour (Mitchell et al. 2005; Muldoon et al. 2007; Stupp et al. 2007).  
 
1.1.9.2.2.1 Temozolomide as a chemotherapeutic agent in the treatment of gliomas 
Alkylating chemotherapeutic drugs, including the chloroethylnitrosoureas (carmustine, lomustine and 
fotemustine), procarbazine and TMZ, are commonly administrated in patients suffering from high-
grade gliomas.  
TMZ, an oral methylating agent, is currently recommended for the treatment of newly diagnosed 
high-grade glioma (National Institute for Health and Clinical Excellence 2007). TMZ is rapidly 
absorbed and spontaneously
 
converts to the active metabolite 5-(3-methyl)1-triazen-1-yl-imidazole-4-
carboxamide (MTIC) (Newlands et al. 1997). MTIC methylates DNA at several sites including the O
6
 
position of guanine nucleotides, thus forming O
6
-methylguanine (Gibson et al. 1984). If the methyl 
group is not removed before cell division, the incorrect base-pairing of O
6
-methylguanine and 
thymine activates DNA mismatch repair pathway signalling eventually leading to cell death (Gibson 
et al. 1984). The major determinant of chemoresistance to TMZ is the activity of a O
6
-methylguanine-
DNA methyltransferase (MGMT) (Gerson 2004). This enzyme rapidly removes methyl adducts at the 
O
6
 position of guanine, thus repairing alkylating agent-induced DNA damage. Epigenetic silencing of 
MGMT by promoter methylation was shown to be associated with low protein expression in a range 
of tumours including gliomas (Esteller et al. 1999). Non-toxic pseudosubstrate inhibitors of MGMT,
 
such as O
6
-benzylguanine, RNA interference-mediated gene
 
silencing of MGMT and dose dense TMZ 
schedule are currently under investigation as possible strategies to overcome MGMT mediated 
chemoresistance (Hegi et al. 2008; Koch et al. 2007; Quinn et al. 2009; Schold et al. 2004; Weiler et 
al. 2009). 
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1.1.10 Prognostic and predictive markers in gliomas 
Young patient age and small tumour size correlate with a more favourable clinical course. Good 
performance status of the patient and the extent of surgical resection are additional clinical factors 
associated with favourable clinical outcomes (Dehais et al. 2006) .  
Several genetic markers were postulated to have a prognostic value. Adult
 
patients with anaplastic 
astrocytomas and glioblastomas with IDH mutations
 
are younger and have better prognosis than 
patients with wild-type IDH1 and IDH2 (Yan et al. 2009b). Furthermore, IDH1 mutation was 
demonstrated to be an independent
 
favourable prognostic marker (Sanson et al. 2009). LOH of 
chromosome 10 (PTEN gene) is associated with reduced survival of glioblastoma patients. 
As already discussed, MGMT is mechanistically involved in TMZ resistance. Consistently, 
methylation of MGMT promoter is considered as a molecular predictor for response to TMZ 
treatment and associated with longer survival in glioblastoma patients. Patients with newly diagnosed 
glioblastoma and methylated MGMT promoter who are treated with TMZ and radiotherapy had 
significantly better clinical outcome than those with unmethylated MGMT promoter (Hegi et al. 
2004). Conversely, in a study on 49 newly diagnosed WHO grade II astrocytomas, methylation of the 
MGMT promoter was an independent marker of an unfavourable clinical course (Komine et al. 2003).  
Patients with oligodendroglial tumours with LOH of 1p/19q respond better to therapy and survive 
longer even after recurrence (Cairncross et al. 1998; Fallon et al. 2004; Felsberg et al. 2004; Ino et al. 
2001; Jenkins et al. 2006; van den Bent et al. 2003). 
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1.2 Epigenetics 
The term epigenetics was introduced by Waddington to describe „the causal interactions between 
genes and their products, which bring the phenotype into being‟. Currently, epigenetics is defined as 
heritable changes in gene expression without an accompanying alteration in the DNA sequence 
(Esteller 2008; Lopez et al. 2009).  
1.2.1 Epigenetic modifications  
Epigenetic mechanisms include DNA methylation, histone modifications and regulation of gene 
expression by non-coding RNAs. Unlike genetic changes, epigenetic modifications are potentially 
reversible. Different epigenetic pathways interact functionally. The sum of all epigenetic information 
is termed the 'epigenome'. Epigenetic modifications govern gene expression and chromatin structure 
in normal as well as cancer cells (Esteller 2007; Esteller 2008; Goldberg et al. 2007; Henikoff et al. 
2004; Lopez et al. 2009).  
1.2.1.1 DNA methylation 
DNA methylation is the most widely studied epigenetic marker (Herman et al. 2003). In eukaryotes, 
DNA methylation is found exclusively at cytosine residues that precede guanines (Esteller 2008; 
Lopez et al. 2009). A methyl (CH3) group from S-adenosyl-methionine is added to the fifth carbon 
position of the cytosine pyrimidine ring of the CpG dinucleotide in reactions catalysed by a conserved 
group of proteins named DNA methyltransferases (DNMTs) (Esteller 2008). CpG dinucleotides are 
not randomly distributed in the human genome but are clustered either in large repetitive sequences or 
in short cytosine guanine (CG) -rich regions called CpG islands (Lopez et al. 2009). Methylated DNA 
is preferentially found in heterochromatin regions and is believed to maintain heterochromatin 
architecture and regulate transcriptional activity of genes. CpG islands are mainly localised within 
gene promoters. In contrast to heavily methylated large repetitive sequences, CpG islands in the 
promoter regions of constitutively active housekeeping genes remain unmethylated to allow these 
genes to be transcribed in the presence of necessary transcription factors. DNA methylation patterns 
play a critical role in gene regulation and chromatin organisation during embryogenesis and 
gametogenesis (Surani et al. 2007). 
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1.2.1.1.1 Principles of DNA methylation analysis 
Methylation specific polymerase chain reaction (MSP) of sodium bisulphite modified DNA is the 
most frequently used assay to assess DNA methylation. In this method genomic DNA is treated with 
sodium bisulphite, which reproducibly converts unmethylated cytosine into uracil (Herman et al. 
1996). Methylated cytosines remain unchanged. Bisulphite treatment thus turns epigenetic differences 
into sequence-based information and modified DNA is then used as a template for polymerase chain 
reaction (PCR). MSP has a high analytical sensitivity and is a cost effective method to determine 
methylation pattern of CpG islands (Kristensen et al. 2009).  
Quantitative data on methylation status of individual CpG dinucleotides can be obtained by 
pyrosequencing (Esteller 2007; Kristensen et al. 2009).  
In addition to PCR-based methods that use sodium bisulphite treated
 
DNA as a template, DNA 
methylation profile can be determined by immunocapturing of methylated DNA with an antibody 
against 5-methyl-cytidine (Weber et al. 2005). Recent technological advances such as microarray-
based DNA methylation analysis platforms allow high resolution DNA methylation profiling of the 
whole genome and are actively developed by several companies, however are not well suited for the 
study of selected CpG island in particular regions (Bibikova et al. 2006a; Bibikova et al. 2006b; 
Down et al. 2008).  
1.2.1.2 Histone modifications 
Chromatin structure is modified by post-translational modification of histones. Epigenetic 
modifications of histones include covalent (histone acetylation, methylation, phosphorylation, 
sumoylation and ubiquitination) and non-covalent changes (chromatin remodelling and the 
incorporation of specialised histone variants). Covalent histone modifications might affect 
accessibility of DNA for transcription factors. Acetylation and phosphorylation of histones can reduce 
electrostatic interactions between DNA and histones, leading to changes in chromatin structure. 
Histone acetylation catalysed by lysine acetyltransferases is associated with gene activity, whereas 
histone deacetylation catalysed by histone deacetylases is linked to transcriptional repression. Histone 
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acetylation is involved in the regulation of gene expression and plays a role in DNA replication and 
DNA repair (Esteller 2008; Lopez et al. 2009).  
Histone modifications can be determined with high accuracy using mass spectrometry or chromatin 
immunoprecipitation (Esteller 2007). 
1.2.1.3 Non-coding RNAs 
Gene expression is also regulated by various classes of non-coding RNAs including long- and small 
non-coding RNAs (microRNAs, endogenous small-interfering RNAs and piwi-interacting RNAs) 
(Heo et al. 2009; Mercer et al. 2009). The RNA class best linked to gene expression regulation in 
humans are microRNAs (miRNAs) which are estimated to regulate translation of over 30% of 
mRNAs. In the cytoplasm, miRNAs are incorporated into RNA-induced silencing complex (RISC) 
and bind to the partially complementary target sites in the 3‟-untranslated regions of target mRNA. 
Following binding, miRNAs inhibit translation or cause mRNA degradation (Esquela-Kerscher et al. 
2006).  
1.2.2 Epigenetic alterations in cancer 
Epigenetic events play a fundamental role in cancer. Tumours display changes in DNA methylation 
pattern, including region-specific hypermethylation and genome-wide hypomethylation (Esteller 
2007; Jones et al. 2002; Lopez et al. 2009; Weber et al. 2005). Methylation associated silencing of 
genes is the most frequently studied epigenetic modification in cancer cells and is now considered to 
be a common hallmark of all types of human tumours (Esteller 2008; Lopez et al. 2009). Promoter 
hypermethylation is frequently responsible for silencing of tumour suppressor genes involved in cell 
cycle (CDKN2A/p16
INK4a
), DNA repair (mutL homolog 1, MLH1; breast cancer susceptibility gene 1, 
BRCA1; MGMT), cell-cell interactions (cadherins), apoptosis (apoptotic protease activating factor 1, 
APAF1; caspase-8) and angiogenesis (Soengas et al. 2001; Teitz et al. 2000). On the other hand, 
substantial hypomethylation was found in the genomes of cancer cells compared with their normal 
counterparts (Feinberg et al. 1983; Goelz et al. 1985). The level of DNA methylation decreases during 
the tumour progression with the hypomethylated areas mainly localised in the repetitive DNA 
sequences of cancer cell genomes (Weber et al. 2005). Two explanations for role of DNA 
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hypomethylation in cancer progression have been proposed. Hypomethylation of DNA may promote 
cancer through effects on chromosomal stability (Eden et al. 2003; Gaudet et al. 2003; Karpf et al. 
2005; Rodriguez et al. 2006) or result in the expression of inserted viral genes and other normally 
silenced genes of potentially oncogenic properties (Esteller 2008; Lopez et al. 2009).  
Several miRNAs act as tumour suppressors by silencing expression of oncogenes as well as have 
oncogenic role by reducing the expression of tumour suppressors (Croce 2009).   
Importantly, unlike genetic alterations, epigenetic changes are reversible and, therefore, therapies 
directed towards the reversal of the epigenetic changes that occur in various malignancies have been 
developed pre-clinically and entered clinical trials. Expression of genes silenced by hypermethylation 
can be restored using demethylating agents, such as 5-azacytidine and 5-aza-2‟-deoxycytidine 
(decitabine). Histone deacetylase inhibitors (e.g. suberoylanilide hydroxamic acid) can inhibit 
enzymes responsible for the removal of acetyl groups from specific residues on histone chains. It has 
been proposed that they promote acetylation of histones and, therefore, activate transcription of 
silenced genes. Epigenetic strategies represent a novel approach that could work synergistically with 
currently used chemotherapeutic regimens (Lopez et al. 2009; Mack 2006). 
It is anticipated that the methylation profiles of circulating tumour cells in bodily fluids may be used 
in diagnostics (Lopez et al. 2009).   
1.2.3 Epigenetic changes in gliomas 
 
1.2.3.1 DNA methylation in gliomas 
A number of genes have been reported to be silenced by methylation in gliomas including classic 
tumour suppressor genes (CDKN2A/ p16
INK4a
; cyclin-dependent kinase inhibitor 2B, CDKN2B/ 
p15
INK4b
; 
 
RB1; TP73; von Hippel-Lindau tumour suppressor, VHL; epithelial membrane protein 3, 
EMP3), DNA repair genes (MGMT and MLH1) and genes playing role in tumour invasion and 
apoptosis (death-associated protein kinase 1, DAPK1; tissue inhibitor of metalloproteinase 3, TIMP3; 
cadherin 1, CDH1; target of methylation-induced silencing-1,  TMS1/ASC) (Costello et al. 1996; 
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Dong et al. 2001; Fueyo et al. 1996; Kunitz et al. 2007; Park et al. 2000; Stone et al. 2004; Watanabe 
et al. 2001a; Watanabe et al. 2001b; Wolter et al. 2001).  
As mentioned above, one of the well studied genes silenced by epigenetic modifications in gliomas is 
MGMT. Methylation of MGMT promoter was demonstrated in approximately 50% of diffuse 
astrocytomas and associated with increased frequency of TP 53 mutations and in 39%-45% of 
primary glioblastomas (Eoli et al. 2007; Felsberg et al. 2009; Hegi et al. 2005; Nakamura et al. 2001). 
MGMT promoter methylation is common in oligodendrogliomas, particularly in cases with 1p/19q 
LOH (Dong et al. 2001; Mollemann et al. 2005; Watanabe et al. 2002). 
Genome-wide profile of DNA methylation was analysed in a series of 87 glioblastomas by Martinez 
et al. The authors demonstrated that methylation patterns in glioblastomas are heterogeneous with 
only seven genes being epigenetically dysregulated by hypermethylation in more than 50% of the 
cases studied (frizzled homolog 9, FZD9; tumour necrosis factor receptor superfamily, member 10a, 
TNFRSF10A; mesoderm specific transcript homolog, MEST; testin, TES; protein kinase C, delta 
binding protein, PRKCDBP; CD81 and homeobox A11). Neoplastic transformation in glioblastomas 
was associated with epigenetic silencing of genes important for normal CNS processes and 
hypomethylation of genes involved in immune function (Martinez et al. 2009).  
1.2.3.2 Role of microRNA in gliomas 
MiRNAs have been shown to regulate gene expression in gliomas in addition to other epigenetic 
mechanisms (Pang et al. 2009). In glioblastomas, a total of 17 up-regulated and 33 down-regulated 
miRNAs have been identified from three independent expression profiling studies (Ciafre et al. 2005; 
Godlewski et al. 2008; Silber et al. 2008), 8 of these were found to be dysregulated in at least two 
studies. MiR-21, whose targets include TP53 and genes involved in mitochondrial apoptosis (Gabriely 
et al. 2008; Papagiannakopoulos et al. 2008), was reported to be the most frequently up-regulated 
miRNA in glioblastomas, with 44–100% of tumours showing this aberration (Chan et al. 2005; Ciafre 
et al. 2005; Conti et al. 2009; Gabriely et al. 2008; Godlewski et al. 2008; Silber et al. 2008). Elevated 
levels of miR-451 and miR-486 have been reported in de novo glioblastomas (Godlewski et al. 2008).  
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Fourteen miRNAs were associated with malignant progression of astrocytomas. MiR-184 and miR-
328, showing reduced expression upon progression, were confirmed to have miRNA-specific effects 
on the viability, proliferation, apoptosis and invasive growth properties of A172 and T98G glioma 
cells in vitro (Malzkorn et al. 2009). 
Increased expression of miR-9 and decreased levels of miRNA-124 in oligodendrogliomas were 
shown as compared to non-neoplastic brain (Nelson et al. 2006). 
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1.3 The Translocator Protein  
 
1.3.1 Nomenclature 
The existence of receptors for benzodiazepines outside the CNS was described for the first time in 
1977 (Braestrup et al. 1977). They were named peripheral type benzodiazepine receptor (PBR) or 
peripheral type benzodiazepine recognition site. The PBR was characterised as a receptor 
pharmacologically, anatomically, structurally and physiologically distinct from the central 
benzodiazepine binding site (Casellas et al. 2002). 
Further studies revealed that the PBR is a multiprotein complex consisting of isoquinoline-binding 
protein (IBP, 18 kDa), voltage dependent anion channel (VDAC) and adenine nucleotide translocator 
(ANT) (McEnery et al. 1992). Nomenclature became inaccurate and misleading as the name PBR was 
used in scientific reports on PBR considered as a complex of proteins as well as the IBP (gene and 
protein) alone. In addition, other alternative names were used to refer to PBR including mitochondrial 
benzodiazepine receptor, mitochondrial diazepam-binding inhibitor (DBI) receptor complex, 
PK11195-binding sites, pk18 and ω3 receptor, which still has to be considered when attempting 
literature searches. The new nomenclature was introduced in 2006 (Papadopoulos et al. 2006). The 
minimal functional unit (binding site) of all known PBR ligands, regardless of its functional 
associations with other proteins in the complex was named translocator protein (TSPO), an 18 kDa 
protein primarily localised in the outer mitochondrial membrane (Papadopoulos et al. 2006).  
1.3.2 TSPO gene  
The human TSPO gene has been mapped to chromosome 22 (22q13.31) (Chang et al. 1992; Riond et 
al. 1991). The 13-kbp gene is composed of four exons (Lin et al. 1993). Exon 1 encodes only 5‟ 
untranslated segment and is separated from the rest of the gene by an intron of approximately 6 kbp 
(Lin et al. 1993). The 100 bp upstream of the gene lack TATA or CAAT boxes but are very GC rich 
and contain six copies of the G(A)GGCGG(A) site, which  is a recognition site for the ubiquitous 
transcription factor Sp-1. The functional importance of Sp1/Sp3 transcription factor binding sites in 
the TSPO gene was revealed in the mouse cell lines (MA-10, Y1 and NIH-3T3) (Giatzakis et al. 
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2004). The transcriptional start site of human TSPO was mapped to one major site, 25 bp upstream 
from the first exon/ intron junction (Lin et al. 1993). The presence of additional TSPO transcription 
initiation sites in mouse testis and mouse Leydig Tumour MA-10 cells was reported (Giatzakis et al. 
2004).  
TSPO mRNA is alternatively spliced into two isoforms: TSPO (TSPO isoform 1) and a short form 
that lacks all of exon 2 and is named TSPO-S (TSPO isoform 2). TSPO-S mRNA is translated from a 
different open reading frame and the resulting protein is structurally and functionally unrelated to 
TSPO (TSPO isoform 1) and thus not a subject of this study. However, it is interesting that more than 
90% of TSPO mRNA was reported to be alternatively spliced to form TSPO-S (Lin et al. 1993).  
1.3.3 TSPO protein – structural predictions 
Amino acid sequences of TSPO from various species have a high degree of homology indicative of 
evolutionary conservation (Gavish et al. 1999). Human TSPO is a 169 amino acid outer mitochondrial 
membrane protein with a molecular weight of 18 kDa (Anholt et al. 1986). TSPO amino terminus is 
localised within the mitochondria and the carboxyl terminus in the cytoplasm external to mitochondria 
(Bernassau et al. 1993). The transmembrane domain of the receptor is a five α-helical structure and 
spans the entire mitochondrial membrane bilayer (Bernassau et al. 1993; Joseph-Liauzun et al. 1998; 
Murail et al. 2008). A common cholesterol recognition/interaction amino acid consensus pattern (-
L/V-(X)(1-5)-Y-(X)(1-5)-R/K-), (CRAC) responsible for cholesterol binding was identified in the 
carboxyl terminus of TSPO (Jamin et al. 2005; Li et al. 1998; Li et al. 2001).  
Formation of TSPO polymers comprising covalently bound 2-6 TSPO molecules has been postulated 
(Delavoie et al. 2003; Papadopoulos et al. 1994). In this model, TSPO monomer was suggested to 
form polymers in response to reactive oxygen species (Delavoie et al. 2003).   
As already mentioned the protein encoded by TSPO-S mRNA is unrelated structurally to TSPO and 
does not encode a protein with binding properties characteristic for TSPO (Lin et al. 1993). 
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1.3.4 TSPO expression in normal and neoplastic tissues 
 
1.3.4.1 TSPO ligands 
TSPO expression has been frequently determined by radioligand binding and autoradiographic 
studies. Radioligand binding experiments can be performed on tissue sections, membranes or 
homogenates and provide the information on molar quantity of radioligand bound per mg of protein. 
Autoradiography allows to localise the distribution of radioactivity to the detailed structure of the 
specimen (Wharton et al. 1993). For PET imaging radioligands are labelled with short lived positron 
emitters, called radionuclides, such as carbon-11 and fluorine-18 (Dolle et al. 2009). 
TSPO radioligands can be classified on the basis of their chemical structure into seven groups: 
benzodiazepines (e.g. Ro5-4864), isoquinoline-3-carboxamides (e.g. 1-(2-chlorophenyl)-N-methyl-N-
(1-methylpropyl)-1-isoquinoline
 
carboxamide known as PK11195 and PK14105), quinoline-2-
carboxamides (analogues of PK11195), N-benzyl-N-(2-phenoxyaryl) acetamides (analogues of Ro5-
4864), vinca minor alkaloids (vinpocetine), alpidem derivatives and 2-aryl-8-oxodihydropurines 
(Dolle et al. 2009).  
1.3.4.2 TSPO expression in normal tissues and in non-neoplastic disorders 
 
1.3.4.2.1 TSPO expression in various tissues outside the CNS 
Results of studies evaluating TSPO expression using autoradiographic and radioligand binding assays 
are summarised in Table 1.2.  
Immunohistochemical studies in human tissues confirmed wide TSPO expression with the highest 
level in the adrenal cortex. Strong immunostaining was also observed in lungs (pneumocytes/ 
macrophages and bronchial glands), colon (basal crypts), liver (Kupffer cells and bile ducts) and the 
ovary (surface epithelium) (Bribes et al. 2004). Examination of human skin revealed positivity in 
keratinocytes, Langerhans cells, hair follicles and dermal vascular endothelial cells (Stoebner et al. 
1999).  
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TSPO ligand Species Visualized tissues and structures Reference 
    
diazepam rat, guinea pig heart (left ventricle, right ventricle and interventricular septum > left and right atrium) (Davies et al. 1981) 
    
diazepam  rat blood plates (Wang et al. 1980) 
    
flunitrazepam rat kidney (cortex) (Regan et al. 1981) 
    
Ro5-4864 rat kidney (cortex and medulla), brain (choroid plexus and in the ependymal lining of all the cerebral ventricles 
including the cerebral aqueduct) 
(Gehlert et al. 1983) 
    
Ro5-4864 rat brain (low expression, highest in pons)  
liver, testis, lung and heart (high expression)  
kidney (the highest) 
(Marangos et al. 1982) 
    
Ro5-4864 rat nasal epithelium, testis, kidney, lower levels in the lung, heart, liver, spleen, olfactory bulb (Anholt et al. 1984) 
  
mice olfactory receptor cells, brain (the ependymal linings of the lateral, third, and fourth ventricles and over the 
choroid plexus, rim of the olfactory bulb), nasal epithelium, kidney 
  
guinea pig,  
cat, dog 
nasal epithelium, kidney 
    
Ro5-4864 rat pituitary gland (highest concentrations in the posterior pituitary), adrenals (adrenal cortex, with highest density 
in the zona glomerulosa and significantly lower concentrations in the zona fasciculata and zona reticularis), 
testis (mainly  over the interstitial tissue; low concentrations over the epithelium of the seminiferous tubules, 
absent from the tubular lumen) 
(De Souza et al. 1985) 
 
    
Ro5-4864 rat brain (olfactory bulb with the highest binding density, high in the pituitary, the cerebral cortical, striatal and 
hippocampal areas lowest), kidney 
(Schoemaker et al. 1983) 
    
Ro5-4864 rat peritoneal mast cells, lung, liver, kidney (Taniguchi et al. 1980) 
    
Ro5-4864 rat 
 
increased binding in kainate-lesioned striatum  (Owen et al. 1983) 
  
AD patients  increased binding in the temporal cortex  
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Ro5-4864 rat spinal cord (Villiger 1984) 
    
Ro5-4864 rat kidney, liver, lung (Braestrup et al. 1977) 
    
Ro5-4864 rat cerebral cortical membranes (Schoemaker et al. 1981) 
    
Ro5-4864 guinea pig ileal longitudinal muscle strip (Hullihan et al. 1983) 
    
Ro5-4864 rat adrenal cortex and the skin (mainly), substantial levels in the heart, salivary glands, discrete regions of the 
kidney,
 
the epithelium of the lung, the nasal and lingual epithelia, the lining of
 
the pulmonary arteries, the 
thymus, the hair follicles of the vibrissae,
 
the tooth buds and the bone marrow 
(Anholt et al. 1985) 
    
Ro5-4864 rat heart, kidney, brain (Le Fur et al. 1983) 
    
PK11195 rat platelets, heart, adrenals, kidney, several brain regions (midbrain, hypothalamus, medulla + pons and 
hippocampus, cortex, striatum) 
 
    
PK11195 rat adrenals (Anholt et al. 1986) 
    
PK11195 rat immune organs (preferential labelling of cells of T and monocytic lineages, thymus, spleen, lymph nodes,  
Peyer patches of intestine) 
(Benavides et al. 1989) 
    
PK11195 rat brain (olfactory bulb, median eminence, choroid plexus and ependyma), kidney (Benavides et al. 1983) 
    
PK11195 rat kidney (ascending limb of the Henle's loop and in the collecting tubule) (Butlen 1984) 
    
 
Table 1.2  
TSPO expression in various species and tissues assessed using ligands 
AD, Alzheimer‟s disease   
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1.3.4.2.2 TSPO expression in the CNS 
TSPO is expressed at low levels in the normal CNS. Results of radioligand binding assays determined 
areas of increased binding in the olfactory epithelium, ependymal cells, choroid plexus and pineal 
gland, Table 1.2 (Anholt et al. 1984; Benavides et al. 1983; Gehlert et al. 1983; Schoemaker et al. 
1983).  
Using immunohistochemistry, TSPO positive cells were found in different regions of the normal brain 
including the grey and white matter, meninges and choroid plexus. In more detail, TSPO staining was 
found in the vascular endothelial and smooth muscle cells, subpial and subependymal glia (astrocytes 
and microglia), intravascular monocytes and macrophages, and ependymal cells. No detectable levels 
of TSPO have been demonstrated in neurons and oligodendrocytes (Cosenza-Nashat et al. 2009). 
In contrast to the expression in normal CNS, TSPO expression assessed by immunohistochemistry 
seems to be much more prevalent in several CNS diseases. In the brains of Human Immunodeficiency 
Virus (HIV) –positive patients with encephalitis, additional enhanced positivity was observed in 
reactive astrocytes (large swollen nuclei) and microglia (ramified glial cells), particularly in the 
regions of inflammation (Cosenza-Nashat et al. 2009). In acute multiple sclerosis (MS) TSPO 
positivity was attributed to macrophages and microglia, whereas in the chronic MS it was associated 
with reactive astrocytes. In sections from brains affected by the ischaemic infarct, TSPO positivity 
was increased in the areas of the lesion, with positivity in amoeboid microglia and reactive astrocytes 
(Cosenza-Nashat et al. 2009). In Alzheimer‟s disease (AD) TSPO expressing glial cells (astrocytes 
and microglia) were found in the hippocampus and adjacent brain regions with clusters of TSPO 
positive cells around senile plaques (Cosenza-Nashat et al. 2009). 
Similar results in the CNS diseases were obtained with TSPO ligands. Binding of TSPO ligands is 
increased in an array of pathological conditions of the CNS such as different forms of neural injury as 
well as neurodegenerative, demyelinating and neuroinflammatory diseases (Chen et al. 2008; Diorio 
et al. 1991; Messmer et al. 1998; Tomasi et al. 2008; Vowinckel et al. 1997).  
Studies combining PK11195 autoradiography with immunohistochemistry provided evidence that 
PK11195 binding is increased in microglia in neurological diseases with lower or less significant 
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contributions from astrocytes. PK11195 was suggested to be a marker of activated microglial cells in 
brains with pathological lesion (Banati 2002; Banati et al. 1997; Banati et al. 2000). In 
neuroinflammation, PK11195 binding is increased in microglia and currently TSPO ligands are used 
to image activated microglia in vivo (Venneti et al. 2006). 
1.3.5 TSPO expression in cancer 
 
1.3.5.1 TSPO expression in human neoplasias 
 
1.3.5.1.1 TSPO expression in neoplastic tissues outside the CNS 
TSPO up-regulation has been reported in several types of human cancer including breast, colon, 
prostate, liver and ovary (Batra et al. 1998; Beinlich et al. 2000; Fafalios et al. 2009; Galiegue et al. 
2004; Han et al. 2003; Hardwick et al. 1999; Katz et al. 1990; Maaser et al. 2002; Venturini et al. 
1999).  
TSPO protein is over-expressed in breast cancer tissue when compared to normal non-neoplastic 
breast components and the expression of TSPO increases with the aggressiveness of the tumour 
(Galiegue et al. 2004; Han et al. 2003; Hardwick et al. 1999). High TSPO expression in a subgroup of 
patients without axillary lymph node involvement was associated with shorter disease free survival. In 
addition, neoplastic cells undergoing mitotic division were often strongly stained with anti-TSPO 
antibody suggestive of a link with proliferation (Galiegue et al. 2004).  
Increased TSPO expression was also observed in primary and metastatic prostate cancer compared 
with normal prostate tissue and benign prostatic hyperplasia, and high TSPO levels in prostate cancer 
were correlated with disease progression (Fafalios et al. 2009; Han et al. 2003). 
Further, increased binding capacities of TSPO-specific ligands and over-expression of TSPO at 
mRNA as well as protein levels were observed in colon adenocarcinoma as compared to normal 
human colon (Han et al. 2003; Katz et al. 1990; Maaser et al. 2002). TSPO over-expression was 
identified as an independent unfavourable prognostic factor in stage III colorectal cancer (Maaser et 
al. 2002).   
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Similarly, TSPO expression was shown to be increased in lung tumours when compared to non-
malignant lung  tissue but the number of cases in the study was limited to 10 samples obtained from 
normal lungs and 8 adenocarcinoma cases (Han et al. 2003).   
Again in the case of hepatocarcinoma, immunohistochemical staining and in situ hybridization 
demonstrated that TSPO was more prominently expressed in neoplastic cells than in non-neoplastic 
tissue (Venturini et al. 1999). 
It has also been reported that the immunoreactivity for TSPO in ovarian carcinoma increases when 
compared with benign ovarian tumours and normal ovary (Batra et al. 1998; Han et al. 2003; Katz et 
al. 1990). 
Unlike in other cancers, TSPO is expressed at lower levels in skin cancers when compared to the 
normal skin epidermal cells (Han et al. 2003).  
In summary, TSPO has been reported to be up-regulated in multiple human cancers and high TSPO 
levels frequently correlated with adverse clinical outcomes. The correlation between TSPO expression 
and cancer cell behaviour was also studied in a number of in vitro approaches and this is discussed 
separately. 
1.3.5.1.2 TSPO expression in brain tumours 
 
1.3.5.1.2.1 TSPO expression as assessed using binding ligands 
It was determined that brain tumours have a higher than normal brain density of TSPO ligand binding 
sites (Benavides et al. 1988; Black et al. 1990; Black et al. 1989; Broaddus et al. 1990; Cornu et al. 
1992; Ferrarese et al. 1994; Junck et al. 1989; Miyazawa et al. 1998; Pappata et al. 1991; Starosta-
Rubinstein et al. 1987; Takada et al. 1992). The localization of binding sites was shown to correspond 
with histologically determined areas of the tumour and there was no or little binding in the necrotic 
regions (Black et al. 1990; Black et al. 1989; Cornu et al. 1992; Starosta-Rubinstein et al. 1987; 
Takada et al. 1992). In gliomas, the binding increased with tumour grade (Black et al. 1990; Ferrarese 
et al. 1994; Miyazawa et al. 1998). Results of in vitro and in vivo studies evaluating TSPO expression 
in brain tumours using TSPO ligands are summarised in Table 1.3. 
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These observations and the ability of PK11195 to cross the intact blood brain barrier led to the 
suggestion for this TSPO ligands use in imaging of gliomas (Junck et al. 1989; Starosta-Rubinstein et 
al. 1987).  
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Study Ligand Material/ Patients Results 
(Starosta-
Rubinstein et al. 
1987) 
[
3
H]flunitrazepam  rodent C6 glioma in Wistar rats  In vitro: high binding, binding 
absent or reduced in necrotic areas 
  human pheochromocytoma in 
nude athymic mice 
In vitro: very low binding 
  human neuroblastoma in nude 
athymic rats 
In vitro: no binding 
  human glioma cell lines in nude 
athymic rats 
In vitro: high binding  
 [
3
H]flunitrazepam 
in combination with 
clonazepam 
 
[
3
H]PK11195 
rodent C6 glioma in Wistar rats In vivo: high binding in viable 
tumour, minimal background in the 
non-neoplastic brain 
(Benavides et al. 
1988) 
[
3
H] PK11195 Patients with glioblastoma In vivo and in vitro: high binding 
(Junck et al. 
1989) 
[
11
C]Ro5-4864 Patients with gliomas In vivo (PET): No increased 
radioactivity in glioma compared to 
normal brain 
In vitro: little binding 
 [
11
C]PK 11195 Patients with gliomas In vivo (PET): increased 
radioactivity in glioma compared to 
normal brain 
In vitro: high binding 
(Black et al. 
1989) 
[
3
H]flunitrazepam 
in combination with 
clonazepam 
 
[
3
H]PK11195 
rodent C6 gliomas in Wistar rats  
RG-2 gliomas in Wistar rats 
In vivo: high binding in gliomas, 
moderate binding in choroid plexus, 
ependyma and pineal gland, little 
binding in other normal brain 
structures or necrotic tissue 
  Walker 256 metastatic tumours 
in Wistar rats 
In vivo: less binding than in C6 
gliomas 
(Black et al. 
1990) 
[
3
H]PK11195 human brain tumours 
(8 gliomas, 
haemangiopericytoma, 
osteosarcoma,  
4 meningiomas, 
craniopharyngioma,  
2 primitive neuroectodermal 
tumours) 
non- neoplastic brain samples 
In vitro: increased binding in brain 
tumours when compared to non-
neoplastic brain, increasing binding 
with increasing grade of malignancy 
for gliomas 
  rodent C6 glial and LK Walker 
metastatic tumours  in Wistar 
rats  
In vitro: increased binding in 
tumours when compared to normal 
brain, correlation between regions 
of binding and histologically 
verified areas of tumour  
(Broaddus et al. 
1990) 
[
3
H]PK11195 human glioblastomas 
normal human frontal cortex 
samples  
higher binding in gliomas than in 
non-neoplastic brain   
(Pappata et al. 
1991) 
[
11
C]PK 11195
 
Patient with glioblastoma In vivo (PET): higher binding in 
tumour than in normal gray matter  
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(Takada et al. 
1992) 
[
3
H]PK11195 human gliomas In vitro: higher binding in tumours 
than in normal cortex, no significant 
difference between low and high- 
grade gliomas 
  rodent C6 In vitro: higher binding in tumour 
than in normal cortex 
(Cornu et al. 
1992) 
[
3
H]PK11195 human brain tumours 
(astrocytomas, meningiomas and  
metastatic tumours) 
In vitro: increased binding densities 
in high-grade astrocytomas, 
moderately increased binding in low 
grade astrocytomas and 
meningiomas, greatly elevated 
binding in metastases of lung or 
kidney cancers, correlation between 
regions of binding and 
histologically verified areas of 
tumour  
(Ferrarese et al. 
1994) 
[
3
H]PK11195 human gliomas (3 WHO grade II 
astrocytomas, 4 anaplastic 
astrocytomas, 9 glioblastomas, 1 
anaplastic oligodendroglioma) 
In vitro: higher binding in tumours 
than in non-neoplastic tissue, 
increasing binding with increasing 
tumour grade  
(Miyazawa et al. 
1998) 
[
3
H]PK11195 low and high grade gliomas In vitro: higher binding densities in 
tumours than in normal cortex, 
increased binding with increased 
grade 
 
Table 1.3  
TSPO expression in brain tumours assessed using TSPO ligands 
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1.3.5.1.2.2 Immunohistochemical assessment of TSPO expression 
A number of studies examined TSPO ligand binding to brain tumours and TSPO expression was 
demonstrated in glial tumour cell lines. However, for a long time there was no direct evidence for 
TSPO expression in human glioma tissue samples. The first report on TSPO expression in human 
astrocytomas was published by Miettinen et al. (Miettinen et al. 1995). In this study, the expression of 
TSPO was determined in 86 human astrocytic tumours (9 WHO grade I astrocytomas; 19 WHO grade 
II astrocytomas; 21 WHO grade III astrocytomas and 37 WHO grade IV astrocytomas) using 
immunohistochemistry and in situ hybridization. The results confirmed the previous findings obtained 
in TSPO ligand binding analyses. It was reported that TSPO mRNA and protein levels were higher in 
tumour samples than in non-neoplastic brain tissue. Additionally, TSPO expression was associated 
with the histological tumour grade and the proliferative index. In low grade astrocytomas only very 
few cells immunopositive for TSPO were seen and no mRNA signal was observed, whereas high-
grade astrocytic neoplasms contained large numbers of TSPO positive cells and exhibited high level 
of TSPO mRNA. Patients with tumours of high TSPO expression had a shorter life expectancy than 
patients whose tumours showed lower TSPO, however this was not shown to be independent of 
tumour grade. 
Similar results were obtained by Vlodavsky et al. from an immunohistochemical analysis of 130 
human glioma samples (25 WHO grade I astrocytomas; 25 WHO grade II astrocytomas; 20 WHO 
grade III astrocytomas and 60 WHO grade IV astrocytomas) (Vlodavsky et al. 2007). In this study 
TSPO expression was assessed in order to determine its correlation with tumour grade, patient 
survival and apoptotic and proliferation indices. In agreement with the previous report by Miettinen et 
al., the intensity and extent of TSPO immunoreactivity increased with the tumour grade. The highest 
expression of TSPO was observed in glioblastomas, especially around areas of necrosis. There was no 
immunostaining in the adjacent areas of brain that did not show histological features of tumour. 
Furthermore, the negative correlation between the percentage of TSPO expressing cells and patient 
survival was confirmed. It was demonstrated that the intensity and extent of TSPO positivity 
correlated with both proliferative (Ki67 positive cells) and apoptotic indices (TUNEL positive cells) 
but this is likely to solely reflect the differences in numbers of apoptotic and dividing cells between 
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tumours of different grades as both the numbers of TUNEL or Ki67 positive cells and cells expressing 
TSPO were highly correlated with tumour grade.  
 
1.3.5.1.2.3 TSPO and microglia in gliomas 
Microglial cells constitute the resident macrophage population of the CNS and thereby are considered 
the immune cells of the brain. In their „resting‟ or 'surveying' state (ramified morphology) they 
constantly interpret biochemical and immune cues to screen the brain environment for structural and 
functional alterations of the CNS integrity. In response to pathology, microglia rapidly change to the 
reactive state (microglial activation). In pathological conditions engagement of microglia may be 
either neuroprotective or neurotoxic depending on the triggering changes in the microenvironment 
(Hanisch et al. 2007). Microglia/macrophages represent the largest non-neoplastic cell subpopulation 
infiltrating human gliomas (Geranmayeh et al. 2007; Hussain et al. 2006). Glioma infiltrating 
microglia appear mostly amoeboid and morphologically distinct
 
from the resting microglia present in 
the intact brain (Graeber et al. 2002). Importantly, activated microglia present within glioma tissue did 
not express TSPO in two cases of anaplastic astrocytoma as assessed by PET imaging with PK11195 
and immunohistochemistry (Takaya et al. 2007).  
1.3.6 TSPO – functional predictions and evidence 
 
1.3.6.1 TSPO role in steroid production 
High expression of TSPO in steroidogenic tissues, including adrenals and gonads, together with its 
localization within the mitochondrial membrane, were the two main reasons to associate TSPO with 
steroid synthesis. It was shown using an animal model that hypophysectomy caused a dramatic 
decrease in TSPO density in the adrenals and testis, which could be reversed upon appropriate trophic 
hormone treatment demonstrating that TSPO expression is also a subject of hormonal regulation 
(Anholt et al. 1985; Bar-Ami et al. 1989). TSPO ligands were reported to elevate steroid production in 
a range of steroidogenic cells including testicular cells, ovarian granuloma cells and cells of human 
term placenta explants as well as in isolated mitochondria supplied with exogenous cholesterol 
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(Amsterdam et al. 1991; Barnea et al. 1989; Mukhin et al. 1989; Papadopoulos et al. 1990; Ritta et al. 
1989). PK11195 was demonstrated to modulate cholesterol transport from intracellular stores into 
mitochondria (Krueger et al. 1990). Disruption of the TSPO gene in the rat R2C Leydig tumour cell 
line inhibited cholesterol transport from the outer to the inner mitochondrial membrane, leading to the 
reduction of steroid synthesis to the level of 5% as compared to TSPO wild type cells. The essential 
role of TSPO was further confirmed by demonstration that TSPO cDNA transfection restored 
steroidogenic activity of those cells (Papadopoulos et al. 1997b). Furthermore, 24-hour accumulation 
of progesterone was lower in mouse MA-10 Leydig cells stably transfected with TSPO antisense 
plasmid abrogating TSPO expression than in the control cells (Kelly-Hershkovitz et al. 1998). The 
expression of TSPO in Escherichia coli DE3 cells, that neither express TSPO, nor produce steroids, 
induced the ability for cholesterol up-take and cholesterol release upon ligand activation (Li et al. 
2001). This experimental evidence is consistent with the cholesterol recognition amino acid consensus 
(CRAC) characterised at the carboxyl terminus of the protein (Jamin et al. 2005; Li et al. 1998; Li et 
al. 2001).  
TSPO was proposed to participate in a macromolecular signalling complex comprising, apart from 
TSPO, a peripheral-type benzodiazepine receptor-associated protein (PAP7), steroidogenic acute 
regulatory protein (StAR) and cAMP-dependent protein kinase catalytic subunit α (PKARIα), 
responsible for hormone dependent cholesterol transport to the inner mitochondrial membrane and 
steroid synthesis (Liu et al. 2006).  
The first enzymatic reaction in steroids synthesis is the conversion of cholesterol to pregnenolone 
catalysed by cytochrome P450 side chain cleavage enzyme (P450scc) and auxillary electron 
transferring proteins (Figure 1.1).  
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Figure 1.1  
Cortisol biosynthesis pathway 
The first and rate-limiting enzymatic reaction in the synthesis of all steroids including cortisol is the 
conversion of cholesterol to pregnenolone by cytochrome P450 side chain cleavage enzyme in the 
inner mitochondrial membrane.  
P450scc, cytochrome P450 side chain cleavage enzyme;  P450c17A1, steroid 17-α –hydroxylase; 
3βHSD1/2, 3-β-hydroxysteroid dehydrogenase; P450c21, steroid 21-hydroxylase; P450c11B1, steroid 
11-β –hydroxylase 
Adapted from Mellon et al. (Mellon et al. 2002). 
 
To enter this pathway cholesterol needs to be transported through the mitochondrial membrane so that 
it can be accessed by P450scc localised in the inner mitochondrial membrane. Cholesterol transport 
through the mitochondrial membrane and subsequent loading of cholesterol into the P450scc active 
site is the rate-limiting step in the synthesis of steroid hormones (Jefcoate 2002). TSPO mediates 
cholesterol transport and, thereby, is a regulator of steroid synthesis. Steroid biosynthesis occurs 
mainly in adrenals, gonads and placenta (Payne et al. 2004). However, low but measurable expression 
of genes for steroidogenic enzymes in other organs including human brain suggests that steroids can 
be produced by other cells apart from cells of classical steroidogenic endocrine glands (Yu et al. 
2002).  
1.3.6.2 TSPO as an MPTP component – role in apoptotic cell death and glucose metabolism 
The essential changes that define tumour cell pathophysiology include self-sufficiency in growth 
stimuli, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, 
sustained angiogenesis, tissue invasion and metastasis (Hanahan et al. 2000). Accumulating evidence 
suggest that changes in cellular metabolism represent an important feature of tumour cells that should 
be added to this list (DeBerardinis et al. 2008) (Tennant et al. 2009).   
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Mitochondria have been implicated in various models of cell death, frequently regarded as the most 
important cell organelle in the execution of apoptosis and, at the same time, an essential compartment 
in cellular metabolism. They play an important role in Ca
2+
 homeostasis, generate reactive oxygen and 
nitrogen species and are responsible for ATP production. Mitochondria participate in the pathogenesis 
of a number of diseases including cancer (Kroemer 2006; Pilkington et al. 2008).  
TSPO, an outer mitochondrial membrane protein, has been long postulated to play an important role 
in the execution of apoptosis and this is believed to be mediated by specific physical interactions with 
mitochondrial membrane proteins. Using [H
3
]PK14105 (nitrophenyl derivative of PK11195) and 
[H
3
]flunitrazepam as photolabelling ligands, TSPO was shown to co-purify and migrate upon gel 
chromatography along with voltage dependent anion channel (VDAC) and adenine nucleotide 
translocator (ANT) (McEnery et al. 1992). Several transmembrane proteins including TSPO, VDAC 
and ANT were postulated to form mitochondrial “mega” channel at the contact site between the inner 
and the outer mitochondrial membranes important to their permeability. In addition to the outer and 
inner mitochondrial membrane proteins, the mitochondrial permeability transition pore (MPTP) 
contains hexokinase tethered to the VDAC on the cytosolic face of the outer mitochondrial membrane 
(Zamzami et al. 2001). Consistent with the mitochondrial membrane localization and apart from their 
role in apoptosis TSPO binding partners have been proposed to be functionally linked to cellular 
metabolism as presented below (including nucleotide, ion, lipid and metabolite transport and 
interactions with enzymes).    
1.3.6.2.1 Cell death 
Phenomena regarded as forms of mammalian cell death include necrosis, apoptosis and autophagic 
cell death, the latter two being highly regulated processes. During necrotic cell death proteolytic 
enzymes are released from lysosomes through compromised membranes. Contrarily, apoptosis allows 
the elimination of dying cells without affecting the neighbouring cells. Autophagy represents an 
adaptive response to starvation or deprivation of growth factors that can deplete cells of organelles 
and
 
critical proteins (Hotchkiss et al. 2009; Kroemer et al. 2009).  
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1.3.6.2.1.1 Apoptotic cell death  
Apoptotic cell death can be initiated through extrinsic (death receptor dependent), intrinsic 
(mitochondrial) or granzyme B dependent pathway (Taylor et al. 2008). Caspase activation by the 
extrinsic pathway involves the binding of extracellular death ligands (such as Fas ligand) to 
transmembrane death receptors. The recruited adaptor proteins, such as the Fas-associated death 
domain protein (FADD), promote activation of caspase-8. Subsequently, active caspase-8 
proteolytically processes and activates caspase-3 and caspase-7, provoking further caspase activation 
events that culminate in substrate proteolysis and cell death. In the intrinsic pathway one or more 
members of the pro-apoptotic B-cell lymphoma-2 (Bcl-2) protein family are activated (including Bax, 
Bad and Bak). This overcomes the inhibitory effects of the anti-apoptotic Bcl-2 family members (Bcl-
2, Bcl-xL and Bcl-w) and the outer mitochondrial membrane becomes permeable to intermembrane 
space proteins, such as cytochrome c. On release from mitochondria, cytochrome c initiates assembly 
of apoptosome comprising of APAF1 protein, caspase-9 and cytochrome c. Active caspase-9 then 
propagates a proteolytic cascade of further caspase activation events. All pathways lead to the 
activation of the major effector caspases, caspase-3, caspase-6 and caspase-7 (Cory et al. 2002; Taylor 
et al. 2008). Consequently, mitochondria are regarded as a central checkpoint in the control of cell 
fate (Kroemer et al. 2007). 
 
1.3.6.2.1.1.1 Mitochondrial membrane permeabilisation 
There is an extensive body of literature suggesting that the activation of the intrinsic apoptotic 
pathway resulting in apoptosome formation is a consequence of increased permeability of the 
mitochondrial membrane in a MPTP-dependent mechanism. The exact composition of the MPTP has 
not been fully determined. The multipore has been postulated to represent a dynamic structure 
involving direct physical interactions between tissue- and cell specific isoforms of participating 
proteins. VDAC, ANT, hexokinase, creatine kinase, TSPO and cyclophilin D are proteins proposed to 
be either a part of the MPTP or to play an important regulatory role in its structure (Schwarz et al. 
2007). The hypothetical molecular architecture of the complex is presented in Figure 1.2.  
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Figure 1.2 
Molecular architecture of the mitochondrial permeability transition pore   
The multipore has been postulated to represent a dynamic structure involving several proteins 
localised in both mitochondrial membranes and is involved in apoptosis, metabolism and transport of 
metabolites. HK is bound to MPTP via VDAC.  
OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane; VDAC, voltage 
dependent anion channel;  ANT, adenine nucleotide translocator, HK, hexokinase, TSPO, translocator 
protein  
Adapted from Zamzami et al. and Robey et al. (Robey et al. 2006; Zamzami et al. 2001).  
 
 
In physiological conditions, the permeability of both mitochondrial membranes is highly regulated. 
All constituents
 
of the mitochondrial matrix and all metabolites cross the
 
inner mitochondrial 
membrane through highly
 
selective channels or via interaction with transport proteins. Outer 
mitochondrial membrane  is freely permeable only to small metabolites and solutes
 
up to ~5 kDa 
molecular weight (Zamzami et al. 2001).  
Various biological models and experimental systems have been used to study the phenomenon of the 
mitochondrial membrane permeabilisation, its regulation and role in apoptotic cell death, and these 
provided frequently conflicting results. Bearing in mind some discrepancies, it has been well-
documented that Bax and/or Bax-like proteins induce outer mitochondrial membrane permeabilisation 
by both forming supramolecular homo-oligomeric complexes in the mitochondrial outer membrane 
and via interactions with ANT and VDAC (Shoshan-Barmatz et al. 2008). 
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1.3.6.3 TSPO binding partners and their role in cell death and metabolism 
 
1.3.6.3.1 ANT 
Adenine nucleotide translocator (ATP/ADP carrier, ANT) is an abundant protein of the inner 
mitochondrial membrane involved in metabolism and apoptosis. Four ANT isoforms with distinct 
chromosomal localization have been demonstrated in mammals: ANT1 (4q35), ANT2 (Xq24-q26), 
ANT3 (Xp22.32 and Yp11.3) and ANT4 (4q28.1). ANT (~33 kDa) forms a specific antiporter 
responsible for the stoichiometric exchange of ATP and ADP across the inner mitochondrial 
membrane (Zamzami et al. 2001). It is assumed that ANT changes its conformation during the 
transport of ATP (synthesised in the mitochondrial matrix) and ADP (derived from ATP 
consumption) to orientate the substrate binding site towards the cytoplasm or the matrix (Pebay-
Peyroula et al. 2004). ANT may also function as a non-specific pore postulated to increase the inner 
mitochondrial membrane permeability. This increase results in mitochondrial matrix swelling and 
subsequent physical rapture of the outer mitochondrial membrane. The role of ANT in apoptotic cell 
death has been further supported as ANT was shown to interact directly with pro- (Bax, Bak) and 
anti-apoptotic (Bcl-2, Bcl-xL) members of the Bcl-2 protein family (Belzacq et al. 2003; Marzo et al. 
1998). A specific interaction between ANT and cyclophilin D was documented with glutathione-S 
transferase pull-down assays and, in another study, the protein complex formed by ANT and VDAC 
retained on columns containing recombinant cyclophilin D demonstrating the existence of a 
multiprotein ANT/VDAC/cyclophilin D structure (Crompton et al. 1998; Woodfield et al. 1998) (the 
presence of TSPO in those complexes was not assessed). The essential functional role of ANT in 
mitochondrial membrane permeabilisation postulated on the basis of physical interactions with 
molecules of the mitochondrial membranes including VDAC and cyclophilin D has not been however 
confirmed in models of ANT depletion. It was shown using an animal knock-out model that ANT is 
not indispensable for mitochondrial membrane permeabilisation, as mitochondria lacking Ant could 
still undergo permeability transition resulting in cytochrome c release (Kokoszka et al. 2004). Some 
of these discrepancies can be attributed to the presence of multiple ANT isoforms and possible 
redundancy.  
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ANT1 mRNA expression has been shown in the heart, skeletal muscle and brain, ANT2 was found at 
low levels in most of the tissues, ANT3 was reported to be expressed in all tissues in proportion to 
their mitochondrial oxidative phosphorylation level and ANT4 in testicular cells. Role of ANT 
isoforms was shown to be dependent on the metabolic state of cells upon various growth and 
apoptotic stimuli (Jang et al. 2006).    
The over-expression of human ANT1 and ANT3, but not of ANT2, can induce apoptosis, and the 
siRNA-mediated knock-down of ANT2 sensitises cancer cells to mitochondrial membrane 
permeabilisation-inducing agents, suggesting that ANT1 and ANT3 are pro-apoptotic proteins 
whereas ANT2 exerts pro-survival functions (Bauer et al. 1999; Le Bras et al. 2006; Zamora et al. 
2004). Also, differences were demonstrated between ANT isoforms 1 and 2 with regard to their 
ability to interact with cyclophilin D (Vyssokikh et al. 2001). ANT4 has not been investigated with 
respect to its function in regulation of apoptosis but has been indicated as a meiosis-specific protein 
(Brower et al. 2007). The expression of ANT isoforms in cancer cells has been associated with their 
metabolic properties, cell cycle events and maintenance of the potential of the inner mitochondrial 
membrane. Cells with predominant glycolytic metabolism over-express ANT2 (Giraud et al. 1998).  
1.3.6.3.2 VDAC 
Voltage dependent anion channels (mitochondrial porins, VDACs) are porin-like proteins localised in 
the outer mitochondrial membrane of all eukaryotic cells. To date three functionally active isoforms 
of VDACs have been isolated in humans, namely VDAC1 (5q31), VDAC2 (10q22) and VDAC3 
(8p11.2).  
VDAC1, VDAC2 and VDAC3 differ with respect to their physiological role and expression profile 
and the specific functions of each of VDAC isoforms are not well evaluated. It was demonstrated that 
VDAC isoforms expressed by tumour cells have identical amino acid sequences as those expressed in 
non-neoplastic cells but the expression of VDAC in tumour cells is reported to be higher than in 
normal cells (Shinohara et al. 2000; Simamura et al. 2006).  
The most abundant VDAC isoform is VDAC1. It is a 35 kDa protein localised in the outer 
mitochondrial membrane. VDAC1 was also demonstrated in the cell plasma membrane (Bahamonde 
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et al. 2003). Physical interactions between VDAC and other molecules at the mitochondrial 
membranes represent an important point of convergence between apoptotic cell death and cellular 
metabolism. 
 
1.3.6.3.2.1 VDAC role in apoptosis 
Conflicting and contradictory results on the exact function of VDACs in cell death programme can be 
found in the literature (Kumarswamy et al. 2009; Rostovtseva et al. 2005). Different models to 
explain VDAC role in mitochondrial membrane permeabilisation and/or cytochrome c release from 
the mitochondrial intermembrane space have been proposed. VDAC was shown to directly interact 
with members of the Bcl-2 family of proteins (Shoshan-Barmatz et al. 2008). The VDAC-Bax 
interaction was suggested to result in a subsequent release of cytochrome c from the mitochondria into 
the cytosol. This could occur through a “mega” channel formed by Bax and VDAC, through large 
pores comprised of oligomerised VDAC or through Bax channel alone (Banerjee et al. 2004; 
Pastorino et al. 1999; Shimizu et al. 2001; Shimizu et al. 1999; Zalk et al. 2005). However, both the 
VDAC/Bax interaction and the resulting large pore formation were questioned in other report and 
different mechanism leading to the loss of outer mitochondrial membrane integrity was proposed. In 
this model, the closure of VDAC channel is induced by Bid and the reduced permeability of VDAC 
pore restricts the flow of metabolites between mitochondria and the cytosol (Rostovtseva et al. 2004). 
VDAC was also implicated in cytochrome c release induced by oxygen radicals (Madesh et al. 2001). 
Finally, the indispensable role of VDAC in apoptotic cell death was challenged as the lack of one or 
more Vdac isoforms did not result in alterations of cell death mechanisms in murine knock-out 
models. Vdac1 and Vdac3 null mice as well as mouse embryonic fibroblasts lacking all three Vdac 
isoforms still responded to apoptotic stimuli. Similarly, cytochrome c was released from Vdac1-
Vdac3 null mitochondria in response to incubation with recombinant Bax and tBid, oxidative stress 
and Ca
2+
. Cells lacking all three Vdac isoforms showed no defects in mitochondrial membrane 
permeabilisation (Baines et al. 2007). In summary, the data on VDAC role in apoptotic cell death and 
in particular in mitochondrial membrane permeabilisation are very conflicting. 
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1.3.6.3.2.2 VDAC role in metabolite, ion and lipid trafficking and metabolism 
VDACs represent the primary pathway for metabolites and small ions trafficking through the outer 
mitochondrial membrane (Zamzami et al. 2001). The channel formed by VDAC can be gated by 
application of a membrane potential and its activity can be modulated by ligands, soluble proteins and 
the rate of glycolytic NADH production (Shoshan-Barmatz et al. 2003; Zizi et al. 1994). A link 
between mitochondrial membrane cholesterol and VDAC has been suggested. The ability of VDAC 
to influence mitochondrial membrane cholesterol distribution and transport was demonstrated using 
cholesterol affinity chromatography coupled with matrix assisted laser desorption ionization time of 
flight mass spectroscopy (MALDI-TOF MS) (Campbell et al. 2007). In addition, VDACs are the 
binding site for several enzymes including hexokinase and glycerol kinase (Mathupala et al. 2006).   
1.3.6.3.3 Hexokinase 
Hexokinase phosphorylates glucose to produce glucose-6-phosphate (G-6-P) via phosphate transfer 
from ATP (Figure 1.2). G-6-P can either enter the glycolytic pathway (glycolysis and oxidative 
phosphorylation) or be used for anabolic processes (nucleid acids biosynthesis). Four isoforms of 
hexokinase, hexokinase I (10q22), II (2p13), III (5q35.2) and IV (7p15.3-p15.1), exist in mammalian 
tissue. They differ in respect to their affinity for glucose and subcellular localization. Hexokinases I 
and II, which display mitochondrial localization and expression changes in neoplasia, are discussed 
further below. Hexokinase III is localised in the perinuclear region and hexokinase IV, named 
glucokinase, characterised by approximately 100 times lower affinity for glucose than other isoforms, 
is present in the cytosol (Mathupala et al. 2009; Wilson 2003). 
 
1.3.6.3.3.1 Role of hexokinase and hexokinase/ VDAC interaction in glucose metabolism and 
apoptosis 
The predominant mitochondrial localization is a characteristic feature of hexokinase I (HKI) and 
hexokinase II (HKII). Both isoforms have molecular weight of 102 kDa. Hexokinase is bound to 
mitochondria via VDAC (Pastorino et al. 2008). Mitochondrial localization of HKI and HKII protects 
their enzymatic activity from product inhibition that would be the case in the cytoplasm and ensures 
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access to ATP generated by ATP synthasome complex in mitochondria. HKII is normally found at 
low levels in muscle and adipose tissue and is up-regulated in tumours. HKI, found normally in brain, 
breast, kidney and retina is present also in some highly glycolytic tumours, but at very low levels 
relative to HKII. It was suggested that a possible exception are brain tumours where HKI expression 
may be higher (Pedersen et al. 2002). HKII expression is regulated at the transcriptional level by 
several cellular stimuli. Response elements for glucagon, hypoxia inducible factor 1 (HIF1) and p53 
have been localised within the HKII promoter region and this further links hexokinases with cancer 
metabolism. HKII expression is also regulated by epigenetic events. A different methylation pattern 
for HKII gene promoter in non-neoplastic cells (normal hepatocytes) versus cancer cells (hepatoma 
cells) has been reported (Goel et al. 2003; Mathupala et al. 2009).  
The hexokinase/ VDAC interaction protects tumour cells from apoptotic cell death and is involved in 
the maintenance of the outer mitochondrial membrane integrity. It has been postulated that when 
hexokinase is bound to mitochondria, the binding of Bax to the outer mitochondrial membrane is 
reduced. Furthermore, the mitochondrial localization of hexokinase suppresses the release of proteins 
from the mitochondrial intermembrane space (Mathupala et al. 2009; Robey et al. 2006). Because of 
its up-regulation in cancer and the concurrent link to metabolism and apoptosis, mitochondrial 
hexokinase is regarded as a potential therapeutic target in cancer (Galluzzi et al. 2008; Robey et al. 
2006). 
1.3.7 In vitro models of TSPO impact on the cancer cell behaviour in human neoplasia, 
including CNS tumours  
 
1.3.7.1 Studies on TSPO function in human cancer models 
 
1.3.7.1.1 Breast cancer models 
TSPO high affinity ligand PK11195 binding levels and TSPO mRNA expression were reported to be 
increased in the highly aggressive breast cancer cell line (MDA-231),
 
relative to non-aggressive breast 
cancer cell line (MCF-7) (Hardwick et al. 1999). In MDA-231 cells TSPO was
 
localised primarily in 
and around the nucleus, whereas in MCF-7 cells TSPO was mainly observed in the cytoplasm. 
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Perinuclear/ nuclear TSPO was postulated to mediate nuclear cholesterol uptake and thus regulate cell 
proliferation (Hardwick et al. 1999). MCF-7 cells stably transfected with human TSPO cDNA had 
increased proliferation rate in comparison to control cells (Li et al. 2007b). Interestingly, it was 
suggested that a certain level of TSPO expression must be exceeded in order to increase cell 
proliferation. TSPO over-expression did not cause changes in vimentin expression (mesenchymal 
marker of invasiveness and metastatic potential) or cells‟ ability to grow in soft agar (anchorage-
independent cell growth). TSPO siRNA silencing in MDA-231 cells reduced cell proliferation, 
induced cyclin dependent kinase inhibitor p21
WAF1/CIP
 and increased cleaved caspase-3 levels. On the 
basis of these results, the possible role of TSPO in the regulation of cell proliferation, cell cycle and 
apoptosis was postulated and high TSPO levels linked with aggressive cancer cell behaviour 
(Hardwick et al. 1999; Li et al. 2007b). 
1.3.7.1.2 Colon cancer models 
Human adenocolorectal cancer cell line HT29, genetically modified to under-express TSPO (stable 
and transient transfections), displayed lower levels of mitochondrial apoptosis (measured by DNA 
fragmentation and caspase-3 activation assays, and mitochondrial membrane potential assessment). 
Further, the proliferation rate of TSPO depleted cells was increased in comparison with controls. 
These in vitro findings, suggesting that high TSPO has anti-neoplastic characteristics, are inconsistent 
with those reported in breast cancer cell line models. Treatment of severe combined immunodeficient 
(SCID) mice xenografted with HT29 tumours with FGIN-1-27, postulated to be TSPO agonist, 
suppressed tumour growth. The survival rates for mice treated with FGIN-1-27 were higher when 
compared with vehicle treated animals and consequently TSPO was postulated to be important for 
tumour progression. TSPO over-expression in colorectal cancer was suggested to play a role in the 
up-regulation of mitochondria related apoptotic pathways (Shoukrun et al. 2008).  
1.3.7.1.3 Hepatocellular carcinoma model 
In hepatocellular carcinoma cell lines the perinuclear/nuclear TSPO signal correlated inversely with 
cell doubling time. The murine hepatocellular carcinoma cell line (T1) with high perinuclear/nuclear 
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TSPO proliferated in response to nanomolar concentrations of PK11195, whereas rat liver normal cell 
line (CC1) with low perinuclear/nuclear TSPO did not (Corsi et al. 2005). 
1.3.7.2 Functional studies on TSPO role in glioma cell lines and a xenograft model 
 
1.3.7.2.1 Rodent glioma cell line model 
Rat C6 glioblastoma cells were shown to express TSPO (Alho et al. 1994). Particularly high TSPO 
expression was observed in the mitochondria, endoplasmic reticulum, nuclear membranes and 
centrioles of dividing cells. TSPO was proposed to play a role in cell growth and division.  
TSPO role in apoptotic cell death and cell proliferation was further addressed using C6 cells by 
different research groups with direct comparisons of glioma cells modified to under- or over-express 
TSPO with control cells of the same cell line, but the results were inconclusive  (Levin et al. 2005; 
Rechichi et al. 2008). C6 cells with stable TSPO knock-down grew better in soft agar, forming more 
colonies than control cells (anchorage-independent colony growth) (Levin et al. 2005). In addition, 
TSPO knock-down clones had higher proliferation rates and lower apoptotic levels and were less 
sensitive to apoptosis inducing treatment with erucylphosphocholine. Contradictory results were 
obtained by another group with C6 cells transfected to over-express TSPO as these cells had higher 
proliferation rates, resistance to contact induced cell growth inhibition and were characterised by 
higher motility and transmigration capacity in comparison to control cells (Rechichi et al. 2008). 
1.3.7.2.2 Human glioma cell line models 
Difference in PK11195 binding densities between T98G and U-87MG human glioma cell lines was 
associated with in vitro tumourigenicity, proliferation rates and cell death (Veenman et al. 2004). 
T98G cells characterised by low PK11195 binding densities formed fewer and smaller colonies in soft 
agar as compared to U-87MG cells characterised by higher PK11195 density. T98G cells had lower 
proliferation rates (cell counting using haemocytometer and cell proliferation assay) and higher levels 
of cell death (trypan blue exclusion assay)/ apoptosis (DNA fragmentation) than U-87MG and this 
was interpreted by the authors as evidence for a link between TSPO and cell growth and survival 
(Veenman et al. 2004).  
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Silencing of TSPO gene in human astrocytoma ADF cells inhibited cell proliferation as assessed by 
MTS and trypan blue exclusion assays and sensitised cells to mitochondrial potential dissipation, 
measured using mitochondrial potentiometric probe JC-1. In this model, PK11195 efficiency to cause 
mitochondrial potential dissipation was dependent on TSPO expression levels (Chelli et al. 2008). 
Inconsistent with the suggestions that TSPO promotes cell survival, TSPO knock-down protected 
U118MG human glioma cells against CoCl2 (hypoxia mimicking agent) induced apoptosis (Zeno et 
al. 2009). 
1.3.7.2.3 Xenograft model 
TSPO was postulated to serve as an intracellular drug delivery target. Using a xenograft model of 
human glioma it was shown that gemcitabine conjugated to PK11195 possessed twofold higher brain 
tumour selectivity compared to gemcitabine alone (Guo et al. 2001).  
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1.4 Principal aims of the study 
 
The main hypothesis behind this work was that TSPO and its binding partners are associated with 
disease progression and clinical outcomes in gliomas and this is due to their involvement in apoptosis, 
proliferation and steroidogenesis. 
The principal aims of the study were to: 
 investigate TSPO expression pattern in astrocytomas and oligodendrogliomas to refine its 
correlation with tumour histology, grade and prognosis,  
 highlight the major cellular population expressing TSPO in gliomas, 
 establish whether TSPO is a subject of epigenetic dysregulation in gliomas, 
 study the potential functional role of TSPO in gliomas as postulated by available literature i.e. 
in apoptosis, proliferation and steroidogenesis in an in vitro model, 
 describe the expression pattern of TSPO binding partners in gliomas and determine their 
correlation with glioma clinicopathological features, 
 test the impact of an inhibition of a selected TSPO binding/functional partner in an in vitro 
model. 
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2 Chapter 2: Materials and methods 
  
70 
 
2.1 Selection of cases 
Human glioma cases were selected from the Brain Tumour Registry, Imperial College Healthcare 
NHS Trust, London, UK and the archives of the Department of Pathology, University of Liege, 
Belgium. Clinicopathological characteristics of patients and their tumours are outlined in Table 3.1, 
3.2, 5.1, 5.2, 5.3 and Appendix II. All tumours were supratentorial and patients underwent gross total 
resection. Tumours were graded according to the current WHO classification by a neuropathologist 
(Dr Federico Roncaroli) (Louis 2007). A representative block of formalin fixed paraffin embedded 
(FFPE) tissue from each case was selected and used for the study. 
Samples of FFPE human adrenal, pharyngeal tonsil, breast, kidney and colon cancer used as control 
tissues for immunostains were acquired from the Human Biomaterials Resource Centre (HBRC), 
Imperial College Healthcare NHS Trust, London, UK. 
Appropriate ethical approval for the study was obtained at the Riverside Research Ethics Committee, 
London, UK (n. 05/Q0401/3). 
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2.2 Immunohistochemistry 
2.2.1 Immunoperoxidase methods 
Immunoperoxidase method was used to evaluate the expression of proteins in FFPE tissue sections. 
Details of the antibodies including, where available, isotype, clone, epitope recognised by the 
antibody and the supplier are outlined in Table 2.1 and Table 2.2. Antigen unmasking techniques, 
blocking sera, working dilutions of the antibodies and labelling system for all the immunoreactions 
are specified in Table 2.3.  
Five µm sections were previously cut from blocks of FFPE tissue and mounted on microscope slides 
(SuperFrost Plus, VWR International, Ltd.). Prior to the immunostaining procedure, FFPE tissue 
sections were deparaffinised in xylene and re-hydrated through graded alcohols to water. The 
endogenous peroxidase activity was quenched by incubating the sections for 30 minutes in a solution 
of 0.3% hydrogen peroxide (Hydrogen peroxide 30% solution in water, Sigma-Aldrich, Inc.) in 
phosphate buffered saline, pH=7.4 (PBS), followed, if required, by antigen retrieval procedure 
performed as specified in Table 2.3. To block the non-specific background staining 10% normal 
serum diluted in PBS was applied on the tissue sections for 30 minutes. Slides were then incubated for 
12-16 hours with the working dilution of the primary antibody at 4ºC.  
Two main approaches were used to visualise the antigen-bound antibodies: either the avidin biotin 
complex (ABC) method or the Super Sensitive Polymer HRP IHC Detection System (BioGenex 
Laboratories, Inc.). In the ABC method, after the incubation with the primary antibody, appropriate 
biotin-conjugated secondary antibody was applied onto tissue sections for 1 hour (this and subsequent 
steps at room temperature). Details of the secondary antibodies used are outlined in Table 2.2. After 
this step, the tissue sections were incubated with avidin-biotin horseradish peroxidase complex 
(Vectastain Elite ABC kit, Vector Laboratories, Inc.) for 45 minutes and then the reaction product was 
revealed with 2 µg/ml 3,3-diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich, Inc.) as a 
chromogen in a 0.0075% hydrogen peroxide solution in PBS. When the Super Sensitive Polymer 
HRP IHC Detection System (BioGenex Laboratories, Inc.) was used, the incubation with the primary 
antibody was followed by applying Super Enhancer Reagent for 20 minutes (this and subsequent steps 
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at room temperature). Subsequently, slides were covered with Poly HRP Reagent for 30 minutes and 
then incubated with Substrate Solution containing chromogen (38 µl of liquid DAB in 1 ml Substrate 
Buffer). In both methods, the solution containing chromogen was left on tissue sections for 2-7 
minutes dependent on the primary antibody. Between each step in the immunostaining
 
procedure, 
sections were washed with PBS three times for 5 minutes.
  
After visualization, all immunostained sections were rinsed in distilled water and slightly 
counterstained with Mayer‟s Haematoxylin Solution (Sigma-Aldrich, Inc.). Finally, the slides were de-
hydrated through graded alcohols, cleared in xylene and coverslipped with Depex polystyrene
 
(DPX) 
(BDH Chemicals, Ltd.) mounting medium. Immunoreactions with omission of the primary antibody 
were performed as negative controls.  
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Antibody Species/Isotype* Supplier/ Cat No Clone* Epitope* Application 
ANT polyclonal goat Santa Cruz/sc-9299 N-19 N-terminal 
region 
IHC 
β-actin monoclonal mouse 
IgG2a 
Sigma-Aldrich/A5316 AC-74 N-terminal 
region 
WB 
β-tubulin polyclonal rabbit Santa Cruz/ sc-9104 H-235 AA 210-444 WB 
CD68 monoclonal mouse 
IgG3κ 
Dako Cytomation/M0876 PG-M1  IHC 
Cleaved 
caspase-3 
monoclonal mouse R&D Systems/ MAB835 269518 Asp175 
cleaved 
WB 
GFAP polyclonal rabbit Dako Cytomation/Z0334   IF 
HSP60 polyclonal rabbit Abcam/ ab-46798   WB 
HKI monoclonal mouse 
IgG2a 
Abd Serotec/MCA3166Z 5G9 AA 101-201 IHC, IF, 
WB 
HKII monoclonal rabbit  Cell Signaling 
Technology/C64G5 
  IHC, IF, 
WB 
Iba1 polyclonal rabbit WAKO/019-19741  C-terminal 
region 
IHC, IF 
Lamin A/C monoclonal mouse Millipore/ 05-714 14  WB 
P450c17A1 polyclonal goat Santa Cruz/sc-46084 N-17 N-terminal 
end 
IHC, IF, 
WB 
P450scc polyclonal goat Santa Cruz/sc-18040 D-16 internal 
region 
IHC, IF, 
WB 
Survivin polyclonal rabbit R&D Systems/ AF886   WB 
TSPO monoclonal mouse Sanofi-Aventis R&D 
(Dussossoy et al. 1996) 
8D7 C-terminal 
region 
IHC, IF, 
WB 
VDAC1 monoclonal mouse 
IgG2b 
Calbiochem/529536 89-173/033 N-terminal 
region 
IHC, IF, 
WB 
 
Table 2.1  
Details of primary antibodies 
IHC, peroxidase immunohistochemistry; IF, immunofluorescence; WB, Western blotting; AA, amino 
acids; Asp, aspartic acid; *-where available 
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Antibody Species Supplier/ Cat No Application 
anti-mouse AlexaFluor488 conjugated  goat Invitrogen/A-11001 IF 
anti-rabbit AlexaFluor488 conjugated  goat Invitrogen/A-11008 IF 
anti-rabbit AlexaFluor555 conjugated  goat Invitrogen/A-21428 IF 
anti-goat AlexaFluor488 conjugated  donkey Invitrogen/ A-11055 IF 
anti-mouse biotin conjugated horse Vector Laboratories/BA-2000 IHC 
anti-goat biotin conjugated donkey Santa Cruz/ sc-2042 IHC 
anti-mouse peroxidase conjugated  goat Dako Cytomation/ P0447 WB 
anti-rabbit peroxidase conjugated  goat Dako Cytomation/ P0448 WB 
anti-goat peroxidase conjugated goat Santa Cruz/ sc-2020 WB 
 
Table 2.2  
Details of secondary antibodies 
IHC, peroxidase immunohistochemistry; IF, immunofluorescence; WB, Western blotting; *-where 
available 
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Primary 
antibody 
Antigen retrieval 
Immunoperoxidase method Immunofluorescence 
Blocking serum Working dilution Labelling method Working dilution Secondary antibody 
ANT 
 
- donkey serum 1:75 biotinylated donkey anti-goat IgG/ABC - - 
CD68 EDTA buffer pH 8.0, 
microwave oven 
horse serum 1:200 biotinylated horse anti-mouse IgG/ABC - - 
GFAP EDTA buffer pH 8.0, 
microwave oven 
- - - 1:600 goat anti-rabbit 
AlexaFluor555 
HKI citrate buffer pH 6.0, 
steamer 
bovine serum 
albumin 
1:750 Super Sensitive Polymer HRP IHC 
Detection System 
1:200 goat anti-mouse 
AlexaFluor488 
HKII citrate buffer pH 6.0, 
steamer 
bovine serum 
albumin 
1:750 Super Sensitive Polymer HRP IHC 
Detection System 
1:200 goat anti-rabbit 
AlexaFluor488 
Iba1 citrate buffer pH 6.0, 
steamer 
bovine serum 
albumin 
1:750 Super Sensitive Polymer HRP IHC 
Detection System 
1:400 goat anti-rabbit 
AlexaFluor555 
P450c17A1 - donkey serum 1:75 biotinylated donkey anti-goat IgG/ABC 1:75 donkey anti-goat 
AlexaFluor488 
P450scc EDTA buffer pH 8.0, 
microwave oven 
donkey serum 1:75 biotinylated donkey anti-goat IgG/ABC 1:75 donkey anti-goat 
AlexaFluor488 
TSPO EDTA buffer pH 8.0, 
microwave oven 
horse serum 1:400 biotinylated horse anti-mouse IgG ABC 1:200 goat anti-mouse 
AlexaFluor488 
VDAC1 EDTA buffer pH 8.0, 
microwave oven 
horse serum 1:200 biotinylated horse anti-mouse IgG/ABC 1:100 goat anti-mouse 
AlexaFluor488 
 
Table 2.3  
Details of the immunohistochemical reactions 
For the heat treatment slides were boiled for 25 minutes in buffer.  
EDTA, ethylenediaminetetraacetic acid 
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2.2.2 Evaluation of peroxidase immunohistochemistry 
2.2.2.1 Quantitative computer-assisted analysis of peroxidase immunohistochemistry 
TSPO immunostaining was evaluated quantitatively. Ten images were captured at the original 
magnification of 400 x (Nikon Fluoroplan 0.75mm, Nikon, Ltd.) using a digital camera (DS Camera 
Control Unit DS-L1 and DS Camera Head DS-5M, Nikon, Ltd.). Necrotic and haemorrhagic areas 
and the fields at the edge of the section were avoided. Image analysis was performed by two 
independent observers (Dr Federico Roncaroli and Karolina Janczar) using Image Pro Plus software 
(Media Cybernetics, Inc.). Following the computer-assisted manual tagging of the immunolabelled 
cells and of all the nuclei present in the image, the percentage of cells expressing TSPO was 
calculated (Figure 2.1). Percentages were then averaged across observers.  
 
 
Figure 2.1 
Quantitative evaluation of TSPO peroxidase immunohistochemistry 
Images were captured using digital camera (A). Image analysis was performed using Image Pro Plus 
software (Media Cybernetics, Inc.). TSPO expressing cells (green cross) and nuclei of cells that do 
not express TSPO (red circle) were manually counted using the „manual tag‟ tool (B) and then the 
percentage of TSPO expressing cells was calculated. Scale bar: 50 µm 
For this image of glioblastoma (case 26), the count of TSPO expressing cells is 103, there are 218 
cells that do not express TSPO (total cell count 321) and the TSPO score is 32.1%. 
 
2.2.2.2 Semi-quantitative computer-assisted analysis of peroxidase immunohistochemistry 
CD68 and Iba1 immunostainings were analysed by measurement of the percent area of staining. Ten 
images were captured at the original magnification of 200 x (Nikon Eclipse 80i, Nikon, Ltd.) using a 
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digital camera (DS Camera Head DS-5M with DS Camera Control Unit DS-L1, Nikon, Ltd.). 
Necrotic and haemorrhagic areas and the fields at the edge of the section were avoided. Image 
analysis was performed using Image Pro Plus software (Media Cybernetics, Inc.) by two independent 
observers (Dr Federico Roncaroli and Karolina Janczar). The „thresholding tool‟ was used to select 
the stained area and then the remaining tissue on each image on the basis of pixel colour (Figure 2.2). 
Percentages were then averaged across observers.  
 
 
Figure 2.2 
Quantitative evaluation of CD68 and Iba1 peroxidase immunohistochemistry 
Images were captured using digital camera (A). Image analysis was performed using Image Pro Plus 
software (Media Cybernetics, Inc.). Stained (yellow) and unstained (red) areas of the image were 
selected on the basis of pixel colour using the „thresholding tool‟. The percentage of stained area was 
determined automatically by the software. Scale bar: 100 µm 
For this image of  glioblastoma (case 26) stained against Iba1, the Iba1 score is 10.9%. 
 
2.2.2.3 Semi-quantitative analysis of peroxidase immunohistochemistry 
The immunohistochemical reactions for P450scc, P450c17A1, ANT, VDAC1, HKI and HKII were 
evaluated semi-quantitatively. Quantitative computer assisted analysis was not applied as the 
threshold for all cases could not be consistently determined for these immunoreactions. Two 
observers (Dr Federico Roncaroli and Karolina Janczar) independently scored immunolabelled 
sections using
 
a scale ranging from 0 to +++ (0, <5% of positive cells, no expression; +, 5-30% of 
positive cells, weak staining;
 
++, more than 30% but less than 60% of positive cells, moderate 
staining; +++, > 60% of positive cells, intense staining) in 10 visual fields at the original 
magnification of 200 x (Nikon Eclipse 80i, Nikon, Ltd.). Necrotic and haemorrhagic areas and section 
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borders were omitted. All cases with discrepant interpretations were discussed
 
using a multi-headed 
microscope (Olympus BX50F4, Olympus Optical Co, Ltd.) and a consensus was reached.  
2.2.3 Immunofluorescence techniques 
2.2.3.1 Double immunofluorescence on tissue samples 
The co-localization studies of microglia (microglial marker, Iba1) or glioma cells (glial marker, 
GFAP) with one of the following molecules: TSPO, P450scc, P450c17A1 were performed. Details of 
the antibodies are outlined in Table 2.1 and Table 2.2. Antigen unmasking techniques, working 
dilutions of the primary antibodies and appropriate secondary antibodies for all the 
immunofluorescence reactions are specified in Table 2.3.  
Before the immunostaining procedure, the sections of FFPE tissue were deparaffinised, re-hydrated 
and, if required, subjected to the antigen retrieval appropriate for the primary antibody as specified in 
Table 2.3. Tissue sections were then treated with 10% normal goat serum in PBS for 30 minutes to 
block the non specific staining. After 12-16-hour incubation with primary antibody (TSPO, P450scc 
or P450c17A1) at 4ºC, the slides were further incubated for 1 hour with an appropriate secondary 
antibody conjugated to a fluorescent dye as specified in Table 2.3 (1:200 dilution, Alexa Fluor 488, 
Invitrogen, Ltd.). This and subsequent steps were performed at room temperature. After incubation 
with 10% normal goat serum in PBS, either the rabbit anti-GFAP antibody or the rabbit anti-Iba1 
antibody was applied for 4 hours. Following this step, the slides were incubated with the secondary 
goat anti-rabbit antibody conjugated to a fluorescent dye (1:200 dilution, Alexa Fluor 555, Invitrogen, 
Ltd.) for 1 hour. Between each step in the staining
 
procedure, sections were washed with PBS three 
times for 5 minutes.
 
To reduce the autofluorescence caused by lipophilic lipofuscin-like compounds 
tissue sections were treated with 0.3% Sudan Black B (BDH Chemicals, Ltd.) in 70% ethanol. To 
localise cell nuclei and mount slides aqueous mounting medium with 4‟, 6-diamidino-2-phenylindole 
(DAPI) (Vectashield Mounting Medium for fluorescence with DAPI, Vector Laboratories, Inc.) was 
used. Immunofluorescence staining was viewed using a Nikon epifluorescence microscope (Nikon 
Eclipse 50i, Nikon, Ltd.) with appropriate filters and images were captured with a digital camera 
(Digital Sight DS-2MBW, Nikon, Ltd.). Composite images were generated
 
using Media Cybernetics 
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Image Pro Plus software (version 5.0, Media Cybernetics, Inc.). For negative controls, the primary 
antibodies
 
were omitted. 
2.2.3.2 Immunofluorescence on cultured cells 
Details of the antibodies used for immunofluorescence staining on cultured cells are specified in 
Table 2.1 and Table 2.2. Working dilutions of the primary antibodies and appropriate secondary 
antibodies for all the immunofluorescence reactions on cultured cells are specified in Table 2.3.  
10
4
 cells per well were cultured on 10% HCl pre-treated coverslips in the wells of a 24-well plate. 
After 24 hours cell culture medium was removed; cells were washed with PBS and fixed with ice cold 
methanol for 10 minutes at -20°C. All subsequent steps were performed at room temperature. After 
rinsing in PBS cells were incubated with PBS containing 1% BSA (Albumin from bovine serum, 
Sigma-Aldrich, Inc.) for 30 minutes and then with a primary antibody for 4 hours. Cells were then 
incubated with an appropriate secondary antibody conjugated to a fluorescent dye (1:200 dilution, 
Alexa Fluor, Invitrogen, Ltd.) for 1 hour. Between each step in the immunofluorescence protocol cells 
were washed with PBS three times for 5 minutes. The coverslips were mounted on microscope slides 
(SuperFrost Plus, VWR International, Ltd.) in Vectashield mounting medium containing DAPI 
(Vectashield Mounting Medium for fluorescence with DAPI, Vector Laboratories Inc.) for the 
localization
 
of cell nuclei. Immunofluorescence staining was viewed using a Nikon epifluorescence 
microscope (Nikon Eclipse 50i, Nikon, Ltd.) with appropriate filters and images were captured with a 
digital camera (Digital Sight DS-2MBW, Nikon, Ltd.). Composite images were generated
 
using 
Media Cybernetics Image Pro Plus software (version 5.0, Media Cybernetics, Inc.). Negative control 
experiments were performed by omission of the primary antibody. 
2.2.3.2.1 Immunofluorescence on cultured cells with mitochondrion selective probe 
Mitochondrion selective probe, MitoTracker Red CMXRos (Molecular Probes, Invitrogen Ltd.), was 
used to visualise mitochondrial localization of proteins. MitoTraker Red CMXRos passively diffuses 
across the plasma membrane and accumulates in active mitochondria. The red fluorescence of 
MitoTracker Red CMXRos is well resolved from the green fluorescence of Alexa Fluor 488 probes. 
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MitoTracker Red CMXRos was dissolved in dimethylsulphoxide (DMSO) and stored at -20°C as 
1mM stock solution.  
For MitoTracker experiments 10
4
 cells per well were cultured on 10% HCl pre-treated coverslips in 
the wells of a 24-well plate. After 24 hours culture medium was removed and replaced with pre-
warmed culture medium containing 100 nM MitoTracker Red CMXRos and cells were further 
incubated at 37°C, 5% CO2 for 30 minutes. After three 5-minute washes with pre-warmed PBS cells 
were fixed using ice cold methanol for 10 minutes at -20°C, rinsed three times for 5 minutes in PBS 
and then immunofluorescence protocol was performed as already described.  
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2.3 Molecular biology  
2.3.1 Western blotting 
2.3.1.1 Protein extraction from cultured cells 
Cells were washed with ice cold PBS, disrupted and homogenised using syringe and 27G needle 
(Becton Dickinson, Ltd.) in ice cold Protein Lysis Buffer (RIPA buffer, 50 mM Tris-HCl pH=7.4, 
150mM NaCl, 1% NP 40, 2 mM EDTA, 0.1% SDS) supplemented with protease inhibitor cocktail 
(„Complete Mini‟, Roche Diagnostics, Ltd.).  
2.3.1.2 Protein quantification 
Total protein concentration in the lysates was determined using  the Bradford assay (Bradford 1976) 
(Bio-Rad Laboratories, Inc.) according to manufacturer‟s protocol with BSA as a standard.  
2.3.1.3 Electrophoresis, transfer of proteins and immunoblotting 
Samples (20-30 µg of protein), supplemented with dithiothreitol (DTT, BDH Chemicals, Ltd) to the 
final concentration of 100 mM, were solubilised in lithium dodecyl sulphate-polyacrylamide gel 
electrophoresis sample buffer (NuPAGE LDS Sample Buffer, Invitrogen, Ltd.). Following boiling for 
5 minutes, samples were electrophoretically resolved in 1D denaturing polyacrylamide gels (resolving 
gel: 8 or 15% acrylamide, 8% sucrose, 375 mM Tris HCl pH=8.8, 0.1% SDS, 0.1% APS, 0.06% 
TEMED; stacking gel: 5% acrylamide, 126 mM Tris HCl pH=6.8, 0.1% SDS, 0.1% APS, 0.05% 
TEMED) using 1 X Running Buffer (pH=8.3, 25 mM Tris base, 192 mM glycine, 0.1% SDS) and 
then transferred onto a nitrocellulose membrane (Protran BA85, Whatman Ltd.) at 100 V for 90 
minutes in 1 X Transfer Buffer (20 mM Tris base, 154 mM glycine, 20% methanol). Molecular 
weight standards (Multimark multi-colored, Invitrogen, Ltd.) were included on each gel. After 
electroblotting, the efficiency of the transfer was verified by Ponceau S solution (0.1% Ponceau S, 5% 
acetic acid) staining. Following this step, the membranes were blocked
 
with 5% non-fat dry milk 
solution in PBS with 0.1% Tween 20 (Sigma-Aldrich, Inc.) (PBS/T) or PBS/T with 5% BSA for 2 
hours at room temperature. The membranes
 
were then probed for 12-16 hours at 4°C with an 
appropriate dilution of a primary antibody. Information on the primary and secondary antibodies 
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including the supplier is specified in Table 2.1 and Table 2.2. Dilutions of the primary and secondary 
antibodies used for Western blotting and blocking conditions are outlined in Table 2.4.  
 
Antibody Blocking buffer Working dilution 
Primary   
β-actin 5% non-fat dry milk in PBS/T 1:20000 
β-tubulin 5% non-fat dry milk in PBS/T 1:1000 
Cleaved caspase-3 5% non-fat dry milk in PBS/T 1:1000 
HKI 5% non-fat dry milk in PBS/T 1:1000 
HKII 5% BSA in PBS/T 1:1000 
HSP60 5% non-fat dry milk in PBS/T 1:20000 
Lamin A/C 5% non-fat dry milk in PBS/T 1:2000 
P450c17A1 5% non-fat dry milk in PBS/T 1:500 
P450scc 5% non-fat dry milk in PBS/T 1:500 
Survivin 5% non-fat dry milk in PBS/T 1:1000 
TSPO 5% non-fat dry milk in PBS/T 1:4000 
VDAC1 5% non-fat dry milk in PBS/T 1:1000 
Secondary   
goat anti-mouse - 1:2000 
goat anti-rabbit - 1:2000 
donkey anti-goat - 1:500 
 
Table 2.4  
Blocking buffers and working dilutions of the antibodies for Western blotting 
All secondary antibodies were peroxidase conjugated. 
 
On the following day, the blots were incubated for 1 hour with an appropriate
 
peroxidase-conjugated 
secondary antibody dilution (this and subsequent steps at room temperature). After each incubation 
period, the membranes were rinsed in PBS/T three times for 5 minutes. All incubations and washings 
were done on a shaking platform. The
 
immunoreactive proteins were identified using an enhanced
 
chemiluminescence reagent system, according to the manufacturer‟s instructions (Amersham ECL 
Western Blotting Detection Reagents, GE Healthcare, Ltd.). The blots were placed in transparent 
plastic developing folders, and Amersham Hyperfilm ECL (High Performance Chemiluminescence 
Film, GE Healthcare, Ltd.) was exposed to the membranes, after which the films were developed 
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using Kodak
 
processing chemicals for autoradiography films (Kodak GBX Developer/ Replenisher 
and Fixer/ Replenisher, Sigma-Aldrich, Inc.). Anti-β-actin, anti-β-tubulin or anti-heat shock protein 
60 kDa (HSP60) antibodies were used as a protein loading control. The developed films were scanned 
with EPSON Perfection 4990 PHOTO scanner (EPSON Corp.) and, if required, the pixel densities 
obtained with GeneTools analysis software (GeneTools, Syngene, Synoptics, Ltd.). 
2.3.2 Nuclear/ cytosolic fractionation of cultured cells 
2 x 10
6 
U-87MG cells were plated into 150 mm diameter Petri dishes (Corning Science Products, Inc.) 
and grown till they reached 80% confluence. Cells were then washed with ice cold PBS and collected 
using a cell scraper into 5 ml of ice cold PBS. All the subsequent steps were performed at 4°C. Single 
cell suspension was ensured by syringing the cells through a 21G needle (Becton Dickinson, Ltd.). 
After three washes in PBS, cells were resuspended in „hypotonic buffer‟ (10 mM HEPES pH=7.9, 
1.5mM MgCl2, 10 mM KCl) and centrifuged at 1200 rpm for 5 minutes. The pellet was then 
resuspended in „hypotonic buffer‟ containing 0.5% NP 40 and lysed for 10 minutes. The homogenate 
was then centrifuged for 5 minutes at 1500 rpm,
 
and the supernatant collected and designated the 
cytoplasmic protein fraction.
 
 The pellet (nuclei) was washed three times with „hypotonic buffer‟ 
without NP 40. Finally, the pellet was lysed in nuclear extraction buffer (20 mM HEPES pH=7.9, 
1.5mM MgCl2, 0.5 M NaCl, 0.2 mM EDTA, 20% glycerol and 1% Triton X100) for 40 minutes with 
occasional vortexing. The lysate was centrifuged at 14000 rpm for 10 minutes. The supernatant was 
considered to be the nuclear protein
 fraction. „Hypotonic buffer‟ and nuclear extraction buffer were 
supplemented with protease inhibitor cocktail. For subcellular fractionation verification, rabbit anti-β-
tubulin (cytoplasmic marker) and mouse
 
anti-lamin A/C (nuclear marker) antibodies were used. 
2.3.3 Parallel determination of the relative levels of apoptosis related proteins  
2 x 10
6 
U-87MG cells were plated into 150 mm diameter dishes (Corning Science Products, Inc.), 
allowed to attach for 12-16 hours and treated with medium containing 1.5 mM MJ or vehicle 
(<0.125% DMSO) for 24 hours. The cells (both adherent and floating) were collected and lysed 
following the drug exposure. Protein concentration was determined using the Bradford assay as 
already described. Cell lysates from three independent experiments (100 µg protein each) were 
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combined and incubated at 4ºC for 16 hours with nitrocellulose arrays spotted with 35 apoptosis-
related protein capture antibodies (Proteome Profiler Human Apoptosis Array Kit, R&D Systems, 
Inc.) and further processed and developed as per manufacturer‟s protocol. The arrays were scanned 
with an EPSON Perfection 4990 PHOTO scanner (EPSON Corp.) and pixel densities obtained with 
GeneTools analysis software (GeneTools, Syngene, Synoptics, Ltd.). 
2.3.4 Methylation analysis 
2.3.4.1 DNA isolation 
Genomic DNA was extracted from FFPE tissue samples (3-5 fresh cut microtome sections of 10 µm 
thickness) using QIAmp DNA FFPE Tissue Kit (Qiagen, Inc.) according to the manufacturer‟s 
manual. A tumour cell content of at least 80% was histologically determined for each specimen used 
for DNA extraction. Genomic DNA from cases 8-10, 18-22, 33-35, 37-40, 48-50 was kindly provided 
by Dr Manuel Deprez (Laboratoire de Neuropathologie, University of Liege, Belgium). 
Genomic DNA from cultured cells was extracted using a proteinase K digestion/ phenol extraction 
method. Pelleted cells were resuspended in TNE buffer (100 mM NaCl, 10 mM Tris, pH=8.0, 1 mM 
EDTA) containing 0.5% SDS and proteinase K (100 µg/ml) and incubated at 56°C for 12-16 hours. 
After incubation, an equal volume of phenol (Rathburn Chemicals, Ltd.) was added to each sample 
and samples were gently inverted to mix for 15 minutes. This step was performed to remove protein 
from the DNA preparations. After centrifugation the top aqueous layer containing DNA was collected 
and incubated with 2 mg/ml RNase A (Invitrogen, Ltd.) for 1 hour at room temperature. Then an 
equal volume of phenol was added and the sample was gently inverted to mix for 15 minutes. After 
centrifugation the top aqueous layer containing the DNA was collected. 2.5 volumes of 100% ethanol 
were added and the mixture was placed at -80°C for 12-16 hours to allow the DNA precipitation. 
DNA was collected by centrifugation at 14000 rpm for 10 minutes and the supernatant was removed. 
The DNA pellet was washed twice with ice cold 70% ethanol, air dried and resuspended in water. The 
DNA concentration was quantified and the purity initially assessed with NanoDrop ND-1000 
Spectrophotometer (Fisher Scientific UK, Ltd.). Absorbance at 260 nm and 280 nm was measured. 
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2.3.4.2 Methylation specific polymerase chain reaction (MSP) of TSPO promoter  
Methylation in the TSPO promoter was analysed using methylation specific PCR (MSP). Primers for 
the MSP utilise the sequence differences between methylated and unmethylated DNA resulting from 
sodium bisulphite treatment. Each modified DNA sample is assessed by performing two reactions, 
one with primers set specific for the originally methylated DNA (M reaction) and second one with 
primers set specific for the originally unmethylated DNA (U reaction). The presence of PCR product 
in the U or M reaction indicates presence of unmethylated or methylated DNA in the original sample, 
respectively (Herman et al. 1996). 
CpG island at the 5‟ promoter region of TSPO gene (NM_000714) was identified using the Human 
Genome Browser Gateway (http://genome.ucsc.edu/cgi-bin/hgGateway). Primers along different 
regions of the CpG island were designed using the MethPrimer program 
(http://www.urogene.org/methprimer/index1.html) (Li et al. 2002) and purchased from Invitrogen. 
The localization of primer pairs within the CpG island is presented in Figure 2.3. Primer sequences, 
PCR product sizes and annealing temperatures are outlined in Table 2.5.  
 
 
Figure 2.3  
The localization of MSP primer sets in the region of TSPO CpG island - MethPrimer output 
MF, forward primer for the M reaction; MR, reverse primer for the M reaction; UF, forward primer 
for the U reaction; UR, reverse primer for the U reaction 
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Primer 
 
 Primer sequence Tm (˚C) Product size (bp) 
      
1 M F TATTATGGGGAGGAGGAGGAGTCGA 51.7 131 
R CGAACACTAAACCCACTCGCGTC 
U F TATTATGGGGAGGAGGAGGAGTTGA 51.7 133 
R CCCAAACACTAAACCCACTCACATC 
2 M F ATTGGATATTCGAGGGGGCGATTC 57.4 180 
R ACCACGCGACCAAAAACTAAACGTA 
U F TTGGATATTTGAGGGGGTGATTTGG 57.4 179 
R ACCACACAACCAAAAACTAAACATA 
4 M F ATTTCGCGGATGGGTAATTTTAGGC 56 111 
R AAACTATTCTCCACTACGAAACGAA 
U F TTTGTGGATGGGTAATTTTAGGTGG 56 109 
R AAACTATTCTCCACTACAAAACAAA 
6 M F GTTTTCGTCGTTGGTGAGTGAGGAC 54.3 162 
R GAACCCCAAATACTACCCCGAATCG 
U F TTTTGTTGTTGGTGAGTGAGGATGG 54.3 164 
R AACCAAACCCCAAATACTACCCCAAATCA 
 
Table 2.5  
Methylation specific PCR: primer sequences, annealing temperatures and PCR product sizes  
Tm, annealing temperature; M, methylated reaction; U, unmethylated reaction; F, forward; R, reverse 
 
1 µg of genomic DNA was subjected to sodium bisulphite conversion using EZ DNA Methylation Kit 
(Zymo Research, Genetix Ltd.) according to the manufacturer‟s instructions. Methylated and 
unmethylated human genomic DNA (Millipore/Chemicon, Corp.) were used as controls and included 
in each run of sodium bisulphite modification. The final volume of the 1 X PCR was 20µl containing 
10 µl of 2 X Thermo-Start PCR Master Mix (Thermo Fisher Scientific, Inc.), primers at 0.5 µM 
concentration and 9.8 µl of the DNA template. The samples were thermocycled using the Peltier 
Thermal Cycler (DNA Engine Dyad, Bio-Rad, Ltd.) with the following PCR conditions: 8 cycles of 
95°C for 2 minutes, 51.7-57.4°C (annealing, specific for primer pair) for 30 s, 72°C for 30 s, followed 
by 32 cycles of 95°C for 30 s, 51.7-57.4°C (annealing) for 30 s, 72°C for 30 s and a final extension at 
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72°C for 5 minutes. Bisulphite modified control methylated and unmethylated human genomic DNA 
and water blank control were run with each MSP reaction. The PCR reaction was performed three 
times for each sample. 
MSP products were separated according to size by agarose gel electrophoresis. A 100 bp DNA ladder 
(Invitrogen, Ltd.) was electrophoresed at the same time to enable determination of DNA size. Samples 
were mixed with 1/6th volume of 6 X DNA gel loading buffer and were electrophoresed through 
1.8% agarose in 1 X TAE buffer (40 mM Tris-acetate, 1 mM EDTA) gel in the presence of 0.25µg/ml 
ethidium bromide (Sigma-Aldrich, Inc.). Nucleic acids were visualised under UV light using a 
Syngene GeneGenius Bioimaging System with GeneSnap software (Syngene, Synoptics, Ltd.).  
The MSP assay including samples of unknown methylation status was only regarded successful, if 
there was a visible band in the positive control lanes (U lane for U reaction, M lane for M reaction) 
and no visible bands in the negative control (M lane for U reaction and U lane for M reaction, water 
blank control).  
The methylation status of the TSPO promoter in each sample was evaluated on the basis of the results 
obtained with four primer sets that spanned the region of the CpG island. For each primers set, 
samples were scored as U (unmethylated, product only in the U reaction), M (methylated product only 
in the M reaction) or UM (product in the U and M reaction). Those samples that scored reproducibly 
as M or UM with at least one set of primers were classified as methylated. 
2.3.4.3 Pyrosequencing of TSPO promoter 
Pyrosequencing provides quantitative information on levels of methylation at individual CpG sites, 
which in this case was previously assessed in a qualitative manner using MSP.  
For pyrosequencing 500 ng of genomic DNA was subjected to sodium bisulphite modification using 
the EZ DNA Methylation Kit (Zymo Research, Genetix Ltd.) according to the manufacturer‟s 
instruction. Pyrosequencing was conducted using PyroMarkID system and PyroMark reagents 
(Biotage AB). The primers sequences were as follows: forward primer 
GGATAGAGGGAAATTGAGG and biotinylated reverse primer AAAACCCAAACTCTACTACC. 
The annealing temperature was 56ºC and the product size was 117 bp. Analysis was performed using 
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PyromarkID Software (Biotage AB). The output data included site-specific percent methylation for 
each CpG in the analysed area as well as overall average percent methylation, which is the average of 
the CpG levels within the analysed region of the TSPO CpG island. Pyrosequencing was performed 
by Dr Christiana Lo Nigro‟s group (Laboratorio Oncologia Translazionale, Cuneo, Italy).  
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2.4 Tissue culture experiments 
2.4.1 Reagents 
Temozolomide (3-Methyl-4-oxo-8-imidazolo[5,1-d][1,2,3,5]tetrazinecarboxamide, 8-Carbamoyl-3-
methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, 4-Methyl-5-oxo-2,3,4,6,8-pentazabicyclo [4.3.0] 
nona-2,7,9-triene-9-carboxamide, Sigma-Aldrich, Inc.) was dissolved in  dimethylsulphoxide 
(DMSO) and stored at -20°C as 50 mM stock solution. Methyl jasmonate (3-Oxo-2-(2 pentenyl) 
cyclopentaneacetic acid, methyl ester, Methyl 3-oxo-2-(2-pentenyl) cyclopentaneacetate, Sigma-
Aldrich, Inc.), a racemic mixture of cis- and trans-isomeres, was diluted in DMSO and stored at -20°C 
as 1.2 M stock. Propidium iodide solution (1 mg/ml in water) purchased from Sigma-Aldrich and 
RNase DNase free (Pure Link RNase A, 20 mg/ml) from Invitrogen were used to prepare DNA 
staining solution for flow cytometric analysis.  
2.4.2 Cell lines and culture conditions 
Established human glioma cell lines GaMG and U-87MG were used for the in vitro experiments. 
GaMG cell line was purchased from the German Collection of Microorganisms and Cell Cultures 
(DSMZ) and U-87MG was obtained from American Type Culture Collection (ATCC). GaMG and U-
87MG cell lines were derived from glioblastoma specimens (WHO grade IV) obtained from 44-year 
old and 42-year old females, respectively (Akslen et al. 1988; Ponten et al. 1968; Tysnes et al. 1993). 
Cell lines were maintained in Dulbecco‟s Modified Eagle Medium (DMEM) supplemented with 10% 
foetal bovine serum (FBS, Invitrogen, Ltd.), 100 U/ml penicillin and 0.1 mg/ml streptomycin 
(Penicillin-Streptomycin, Invitrogen, Ltd.) in an atmosphere of 5% CO2 at 37°C. The cells were 
cryopreserved with a mix of 90% FBS and 10% DMSO. The material from other human glioma cell 
lines used (DBTRG-05MG, 42-MG-BA and SNB-19) was provided by Dr Nelofer Syed. 
2.4.3 Subculturing of adherent cells 
Firstly, overlying medium was removed and adherent cell monolayer was washed briefly with PBS. 
Then cells were incubated with 0.25% trypsin with 1 mM EDTA (Invitrogen, Ltd.) at 37°C for 2-3 
minutes. Cell detachment from the culture dishes was facilitated by gentle agitation and inspected 
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under the microscope. Three volumes of medium supplemented with 10% FBS were added to 
neutralise the trypsin solution. Medium with cells was pipetted several times to ensure detachment 
and single cell suspension. If required, cells were counted in a haemocytometer chamber (Neubauer 
Improved, Marienfeld GmbH & Co.) using 0.4% trypan blue solution (Sigma-Aldrich, Inc.). Cell 
suspension was diluted with medium supplemented with 10% FBS and cells were seeded into cell 
culture flasks or plates as desired. 
2.4.4 Sulphorhodamine B colourimetric assay 
Cell growth and cell growth inhibition was determined by the sulphorhodamine B (SRB) 
colourimetric assay (Vichai et al. 2006). Cells were plated in triplicate for each density/ treatment into 
wells of 96-well plates. At each time-point cells were fixed with 10% trichloroacetic acid (TCA) for 1 
hour at 4°C. Subsequently, plates were washed with water and air dried. TCA-fixed cells were stained 
for 30 minutes with 0.4% SRB (Sigma-Aldrich, Inc.) dissolved
 
in 1% acetic acid. After staining, 
unbound dye was removed by washing five times with 1% acetic acid and plates were air dried. Cell-
bound dye was solubilised with 10 mmol/l Tris
 
(pH=10.5) in a shaker for 1 hour. Finally, absorbance 
was measured at 490 or 570 nm using a microplate reader (Elx800 BioTek, Fisher Scientific UK, 
Ltd.). Absorbance readings were averaged and background absorbance was subtracted. Each 
experiment was performed three times. 
2.4.5 Determination of IC50 for TMZ 
Cell growth inhibition by TMZ was determined with
 
the SRB assay. 4000 U-87MG and GaMG cells 
per well of a 96-well plate were plated in three replicates for each treatment. 24 hours after plating 
cells were exposed to a range of TMZ concentrations (500 µM, 650 µM, 800 µM, 1000 µM, 1250 
µM). Control cells received medium containing vehicle (< 0.125% DMSO). The cells were fixed with 
10% TCA at the time of treatment and after 48 hours and processed as described above.  
The drug concentration that inhibited cell growth by 50% compared with
 
control cells at 48 hours was 
designated as the IC50. 
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2.4.6 Cell growth inhibition following MJ exposure and MJ IC50 
Cell growth inhibition following MJ exposure was determined by
 
the SRB assay. 4000 U-87MG and 
GaMG cells per well of a 96 well plate were plated in three replicates for each treatment. 24 hours 
after plating cells were exposed to a range of MJ concentrations (0.5 mM, 1.0 mM, 1.5 mM, 2.0 mM, 
2.5 mM, 3.0 mM). Control cells received medium containing vehicle (< 0.125% DMSO). After the 
24-hour exposure media (treatment media and medium containing vehicle) were removed and 
replaced with fresh medium. Cells were fixed with 10% TCA and processed as for the SRB assay at 
the time of drug addition, after 24-hour exposure to MJ (media change) and after further incubation 
with medium supplemented with 10% FBS without MJ for 24, 48, 72 and 96 hours. 
The drug concentration that inhibited cell growth by 50% compared with
 
control cells at 48 hours was 
designated as the IC50. 
2.4.7 TSPO siRNA knock-down experiments in U-87MG cells 
2.4.7.1 TSPO siRNA knock-down 
1.2 x 10
5
 U-87MG cells per well of a 6-well plate were plated in 3 ml of DMEM medium 
supplemented with 10% FBS and antibiotics. The cells were transfected with appropriate siRNA 
oligos, TSPO siGENOME Smart Pool or siGENOME Non-Targeting siRNA Pool 2 (Dharmacon, 
Thermo Fisher Scientific, Inc.) after 48 hours (at approximately 50-60% confluence). For each 
experiment 100 µl of the working dilution of appropriate siRNA oligos at the concentration of 2 µM 
in 1 X siRNA buffer (Dharmacon, Thermo Fisher Scientific, Inc.) was mixed with 100 µl Opti-MEM 
I Reduced-Serum Medium with GlutaMAX (Invitrogen, Ltd.) and incubated for 5 minutes at room 
temperature. For mock control 100 µl of 1 X siRNA buffer without siRNA oligos was used. At the 
same time 2 µl of DharmaFECT 1 transfection reagent (Dharmacon, Thermo Fisher Scientific, Inc.) 
was combined with 198 µl Opti-MEM I Reduced-Serum Medium with GlutaMAX and also incubated 
for 5 minutes at room temperature. The dilutions were subsequently combined to the final volume of 
400 µl and incubated for 20 minutes at room temperature. The cells in 6-well plates were washed with 
2 ml of PBS and 1 ml of DMEM supplemented with 10% FBS, but without antibiotics was added per 
well. After 20 minutes of incubation the dilution of transfection reagents was mixed with 600 µl of 
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DMEM medium supplemented with 10% FBS and added in a drop-wise manner to the appropriate 
well. Cells were trypsinised and replated 24 hours post transfection into 96-well plates for the growth 
curve, cytotoxicity and caspase activation assays, into 24-well plates onto coverslips for 
immunofluorescence experiments and into 6-well plates for protein extraction to verify the level of 
knock-down (by immunoblotting as described above) as well as for flow cytometric analysis and 
clonogenic assay. 
2.4.7.2 Cell growth following TSPO siRNA knock-down in U-87MG cell line  
Cell growth after TSPO siRNA knock-down was assessed with the SRB assay. 24 hours post 
transfection 4000 cells per well (TSPO Smart Pool, mock control and Non-Targeting control) of a 96-
well plate were plated in three replicates. At each of the time-points (24, 48, 72, 96 and 120 hours post 
plating) cells were fixed with 10% TCA and plates were processed as described above.  
2.4.7.3 TMZ cytotoxicity assay following TSPO siRNA knock-down in U-87MG cell line  
TMZ cytotoxicity following siRNA TSPO knock-down was assessed with the SRB assay. 24 hours 
post transfection 4000 cells per well (TSPO Smart Pool, mock control, Non- Targeting control) of a 
96-well plate were plated in triplicate for each treatment. 24 hours after plating cells were exposed to 
a range of TMZ concentrations (500 µM, 650 µM, 800 µM, 1000 µM, 1250 µM). Untreated control 
cells received medium containing vehicle (< 0.125% DMSO). The cells were fixed with 10% TCA at 
the time of treatment and after 24, 48, 72 and 96 hours and processed as described above.  
2.4.7.4 Caspase activation assay after TMZ treatment in U-87MG cells following TSPO siRNA 
knock-down 
24 hours post transfection 4000 cells per well (TSPO Smart Pool, mock control, Non- Targeting 
control) of a 96-well plate were plated in three replicates for each treatment. After 24 hours the 
medium was removed and replaced with medium containing 850 µM TMZ. Untreated control cells 
received medium containing vehicle (<0.125% DMSO). Caspase 3/7 activity was measured with a 
luminometer (LUMIstar OPTIMA, BMG Labtech, Ltd.) after 24 and 48 hours of drug exposure 
according to manufacturer‟s protocol with Caspase Glo 3/7 Assay kit (Promega UK, Ltd.). 
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Background reading (media and caspase substrate only) was subtracted and the values were 
normalised to the values for untreated control cells.  
2.4.7.5 Cell growth inhibition following TSPO siRNA knock-down in U-87MG cell line in low 
serum conditions  
Cell growth in low serum conditions following TSPO siRNA knock-down was assessed with the SRB 
assay. 24 hours post transfection 4000 cells per well (TSPO Smart Pool, mock control, Non-Targeting 
control) of a 96-well plate were plated in three replicates for each treatment. 24 hours after plating cell 
culture media was removed and replaced with low serum medium (DMEM supplemented with 0.1% 
FBS). Untreated control cells received medium supplemented with 10% FBS. The cells were fixed 
with 10% TCA at the time of treatment and after 24, 48, 72 and 96 hours and processed as described 
above. 
2.4.7.6 Cell growth of U-87MG cells following TSPO knock-down and MJ exposure 
24 hours post transfection 4000 cells per well (TSPO Smart Pool, mock control and Non-Targeting 
control) of a 96-well plate were plated in three replicates for each treatment. 24 hours after plating cell 
culture medium was removed and replaced with media containing MJ (1.0 mM, 1.5 mM, 2.0 mM). 
Control cells received medium containing vehicle (DMSO < 0.125%). Following 24-hour exposure to 
MJ media (treatment media and medium containing DMSO) were removed and replaced with fresh 
medium. At each of the time-points (24, 48, 72, 96 and 120 hours post plating) 10% TCA was added
 
to each well and plates were processed as described above.  
2.4.8 Clonogenic assay 
The long term effect of TSPO knock-down and MJ exposure on cell survival was analysed using 
clonogenic assay (Franken et al. 2006). 24 hours after transfection or following 24-hour exposure to a 
range of concentrations of MJ (1.0 mM, 1.5 mM, 2.0 mM, 2.5 mM) or medium containing vehicle 
(<0.125%DMSO) media were
 
removed, cells were washed in PBS, trypsinised, viable cells counted 
with a haemocytometer using trypan blue exclusion method and replated (500 cells per each well of a 
6-well plate) in DMEM supplemented with 10% FBS. After 14-day incubation plates were washed
 
in 
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PBS, cells were fixed with ice cold methanol for 10 minutes at -20°C, stained (0.5% crystal violet), 
rinsed with distilled water and air dried. Colonies containing 50
 
cells (as determined under 
microscope) were manually counted as one surviving colony and the results
 
were presented as a 
surviving fraction relative to untreated cells. Each condition was measured in triplicate and each 
experiment
 
performed three times. 
2.4.9 Flow cytometry 
Cell cycle was analysed using propidium iodide (PI) staining and flow cytometry (Riccardi et al. 
2006). The analysis was performed following TSPO knock-down and MJ treatment in U-87MG cells.  
24 hours post siRNA transfection cells (TSPO Smart Pool, mock control, Non-Targeting control) 
were trypsinised, counted and replated at 1.2 x 10
5 
cells per well of a 6-well plate. 24 hours after 
plating both floating and adherent cells were collected for the analysis.  
To evaluate effects of MJ exposure on cell cycle, 1.2 x 10
5 
cells per well of a 6-well plate were 
cultured for 24 hours and then treated with a range of MJ concentrations for 24 hours. After MJ 
treatment both floating and adherent cells were collected for the analysis.  
Subsequently, cells (TSPO knock-down and MJ exposure experiments) were transferred to FACS 
tubes (Becton Dickinson, Ltd.) and washed three times with PBS. After the last wash the cell pellet 
was resuspended in 500 µl of PBS and cells were fixed in 4.5 ml of 70% ice cold ethanol for 1 hour at 
4ºC (ethanol was added drop-wise while gently vortexing to ensure fixation of all cells and minimise 
clumping). After fixation, the suspension was centrifuged and supernatant containing ethanol was 
removed. After three washes in PBS cells were resuspended in 1 ml of freshly prepared DNA staining 
solution (20 µg/ml PI in PBS containing 0.2 µg/ml of DNase free RNase). Resuspended cells were 
incubated with the DNA staining solution for 12-16 hours in the dark at 4ºC. Following incubation 
cells were analysed by flow cytometry using BD FACSCanto flow cytometer (Becton Dickinson 
Biosciences, Ltd.) and BD FACSDiva Version 6.0 software. I appreciate the help of Dr Nelofer Syed 
and Dr Mingjun Sun with flow cytometry. 
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2.4.10 Cortisol EIA 
Cortisol in cell culture supernatant samples was measured using the Cortisol EIA Kit (Cayman 
Chemical) with a detection limit of approximately 12 pg/ml.  
Cells were plated at the density of 6 x 10
4
/ ml in 75 cm
2
 flasks and allowed to attach. After 16 hours 
the complete medium was replaced with serum supplemented with 0.5% FBS (low serum medium) 
and cells were further incubated at 37ºC, 5% CO2 for 24 hours. After incubation cell culture 
supernatant was collected, centrifuged for 5 minutes at 1200 rpm and filtered (pore size 0.2 µm) to 
remove cell debris. Cell culture media supplemented with 0.1% FBS was used to dilute samples and 
cortisol standards. Each sample was assayed at two dilutions (1:1 and 1:2) and each dilution was 
assayed in triplicate. The assay was performed as described in the manufacturer‟s protocol. Two 
blanks, two non specific binding wells, two maximum binding wells (Bo) and an eight point standard 
curve run in duplicate were included for quality control and further analysis. Plate was developed for 
90 and 120 minutes and read at 405 nm (Elx800 BioTek, Fisher Scientific UK, Ltd.). Cortisol 
concentration in the samples was determined using computer spreadsheet available at 
www.caymanchem.com/analysis/eia (EIA Triple, Excel Workbook for assay performed in triplicate).  
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2.5 Microarray data set analysis 
Microarray data (GSE4412, GSE4271 and GSE4290) were downloaded from Gene Expression 
Omnibus (GEO) DataSets website (http://www.ncbi.nlm.nih.gov/gds) and another glioblastoma data 
set from The Cancer Genome Atlas (TCGA) Data Portal (http://tcga-
data.nci.nih.gov/docs/publications/gbm_exp/).  
GSE4412: From the high-grade glioma microarray published by Freije et al. (Freije et al. 2004) cases 
of mixed oligoastrocytoma were excluded and the expression profiles of 67 tumour samples obtained 
during the initial resection (8 anaplastic astrocytomas, 50 glioblastomas and 9 anaplastic 
oligodendrogliomas) were examined. In cases when two replicates were available the average was 
used for the analysis (samples 975 and 975.1, 744 and 744.1, 2028 and 2029).  
GSE4290: 157 primary gliomas (7 WHO grade II astrocytomas, 19 anaplastic astrocytomas, 85 
glioblastomas, 34 WHO grade II oligodendrogliomas and 12 anaplastic astrocytomas) and 23 non-
tumoural brain samples obtained from patient suffering from epilepsy from the data set published by 
Sun et al. (Sun et al. 2006) were included in the analysis. 
GSE4271: From the high-grade astrocytoma data set from Phillips et al. (Phillips et al. 2006) 77 
tumour samples obtained during the initial resection were included in the analysis.  
186 glioblastomas from the TCGA Data Portal published by Verhaak et al. (Verhaak et al. 2010) were 
analysed. 
Reproducibility of the association between TSPO expression and glioma histotype was analysed using 
GSE4412 and GSE4290 microarray data sets. For the purpose of survival analysis clinical data were 
available for GSE4412, GSE4271 and TCGA microarray data sets (Freije et al. 2004; Phillips et al. 
2006; Verhaak et al. 2010). The summaries of the available clinical data are presented in Chapter 3 
and Chapter 5. 
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2.6 Statistical analysis 
T-test or Mann-Whitney U test was used for comparison of means between groups. The correlation 
between two numerical variables was assessed using Spearman‟s rank test. The associations between 
categorical data were tested with Fisher‟s exact test. All reported p-values are two-sided where 
applicable. P values below 0.05 were considered significant. 
Univariate survival analysis was performed with log rank test and multivariate analysis with Cox 
regression. The numerical data obtained from immunohistochemical analysis of TSPO, CD68 and 
Iba1 expression and expression data from the microarray data sets were dichotomised using median as 
a cut-off value except for the Cox regression analysis of the TSPO, CD68 and Iba1 
immunohistochemistry results that were used as continuous variables. Semi-quantitative 
immunohistochemistry results for ANT, VDAC1, HKI and HKII were categorised for survival 
analysis as specified in Chapter 5.  
All statistical analyses were performed using PASW statistics 17.0 for Windows software (SPSS Inc.) 
and Microsoft Office Excel 2007 (Microsoft Corp.).  
  
98 
 
2.7 Buffers and solutions 
Phosphate buffered saline (PBS), pH 7.4 
1.7 mM sodium dihydrogen orthophosphate dehydrate 
100 mM di-sodium hydrogen orthophosphate 12 hydrate 
2.7 mM KCl 
137 mM NaCl 
 
EDTA buffer 
10 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0 
  
Citrate buffer 
100 mM, pH 6.0 
 
6 X DNA gel loading dye 
2.3 mM Xilene cyanol 
1.9 mM bromophenol blue 
21 mM SDS 
50% v/v glycerol 
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3 Chapter 3: TSPO expression, regulation and clinicopathological correlates in astrocytomas 
and oligodendrogliomas  
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3.1 Introduction 
TSPO is up-regulated in a number of cancers (Fafalios et al. 2009; Galiegue et al. 2004; Maaser et al. 
2005). TSPO was previously shown to be over-expressed in astrocytic tumours, where an association 
between its increased levels and poor patient outcomes was suggested (Miettinen et al. 1995; 
Vlodavsky et al. 2007). However, TSPO expression in oligodendrogliomas, the second most common 
glioma histotype, has not been investigated before. Oligodendrogliomas are less aggressive and more 
chemosensitive than astroglial tumours (Louis 2006; Nutt et al. 2000). The distinction between 
oligodendroglioma and astrocytoma is therefore of great clinical importance. The relative incidence of 
the diagnoses of oligodendroglioma and astrocytoma varies widely between institutions, suggesting 
that diagnostic criteria and practice differ (Burger et al. 2001). Histopathological examination 
represents the gold standard in the distinction between these two tumour histotypes but differential 
diagnosis on the basis of pathological features only is in some cases difficult. Concurrent loss of 1p 
and 19q chromosome arms is regarded as a specific molecular/ cytogenetic marker of 
oligodendrogliomas (Burger et al. 2001). After analysing a large set of 142 gliomas including 45 
oligodendrogliomas and 97 astrocytomas of all grades McLendon et al. proposed 1p/19q analysis 
utility in „questionable‟ glioma cases (McLendon et al. 2004). 1p/19q status data can be obtained by 
comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH) and polymerase 
chain reaction (PCR)-based microsatellite analysis. Other modalities that could assist accurate 
classification or pre-operative non-invasive diagnosis of gliomas are needed. 
In this part of my project, the expression of TSPO in astrocytic and oligodendroglial tumours was 
evaluated to determine its diagnostic and prognostic significance. Further, although TSPO expression 
in cancers has been extensively studied, there are no data on the mechanism responsible for the 
regulation of TSPO expression in neoplasia. We postulated that TSPO might be a subject of 
epigenetic dysregulation in gliomas and performed methylation analysis of the TSPO promoter 
region. Finally, TSPO has been suggested to be a marker of microglial activation in 
neurodegenerative and neuroinflammatory diseases, and tumour infiltrating microglia could represent 
a cell population contributing to overall TSPO expression in gliomas. To address this possibility and 
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to understand its impact on TSPO level utility as a diagnostic and prognostic marker in gliomas, the 
extent of tumour infiltrating microglia was determined.  
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3.2 Results  
3.2.1 TSPO expression in glioma tissue samples 
TSPO expression was examined using immunohistochemistry in 30 astrocytic and 20 oligodendroglial 
tumours. The summary of the clinical characteristics of the patient groups is outlined in Table 3.1. 
The details of the clinicopathological characteristics of the patient population, including 1p/19q status 
where available, are shown in Table 3.2. 
 
Histotype (WHO grade) 
Number 
of cases 
Gender 
F/M 
Age in years 
median (range) 
Follow up time in months 
median (range) 
Astrocytomas ( II) 10 1/9 38 (25-56) 38 (10-136) 
Anaplastic astrocytomas (III) 10 5/5 39 (22-61) 35 (16-133) 
Glioblastomas (IV) 10 5/5 58 (39-68) 13 (0-120) 
Oligodendrogliomas (II) 10 5/5 34 (24-49) 44 (11-85) 
Anaplastic 
oligodendrogliomas (III) 
10 7/3 43 (21-69) 42 (14-217) 
Gliomas 50 23/27 42 (21-69) 30 (0-217) 
 
Table 3.1 
Summary of the clinical characteristics of glioma cases analysed by peroxidase 
immunohistochemistry for TSPO, CD68 and Iba1 expression (cases 1-50)  
F, female; M, male   
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Case 
ID 
Gender 
Age at diagnosis 
(years) 
Histopathology 
Follow-up 
time 
(months) 
Status 
Histotype 
Grade 
(WHO) 
 
1p/19q status* 
1 M 42 A II  163 alive 
2 M 35 A II  49 dead 
3 M 42 A II  10 dead 
4 M 56 A II  18 dead 
5 M 40 A II  44 alive 
6 M 36 A II  32 alive 
7
X
 M 37 A II  27 alive 
8 M 38 A II  27 alive 
9 F 31 A II  51 alive 
10 M 23 A II  63 alive 
11 M 40 A III  104 alive 
12 F 43 A III  28 dead 
13 M 35 A III  14 alive 
14 M 33 A III  35 dead 
15 M 38 A III  34 alive 
16 F 61 A III  28 alive 
17 F 53 A III  18 alive 
18 M 40 A III  64 alive 
19 F 37 A III  133 alive 
20 F 22 A III  62 dead 
21 M 52 A IV  120 alive 
22 M 39 A IV  14 dead 
23 F 68 A IV  0 POD 
24 M 58 A IV  11 dead 
25 F 62 A IV  37 dead 
26 F 57 A IV  26 dead 
27 M 56 A IV  16 dead 
28 F 64 A IV  11 alive 
29 F 53 A IV  3 dead 
30 M 65 A IV  5 dead 
104 
 
31 F 34 O II LOH 1p/19q 4 alive 
32 F 49 O II LOH 1p/19q 11 alive 
33 F 31 O II LOH 1p/19q 26 alive 
34 M 24 O II monosomy 19q 70 alive 
35 F 46 O II LOH 1p/19q 70 alive 
36
X
 M 43 O II  36 alive 
37 M 29 O II LOH 1p/19q 21 alive 
38 M 32 O II monosomy 19q 33 alive 
39 F 46 O II LOH 1p/19q 12 alive 
40 M 40 O II LOH 1p/19q 82 alive 
41 F 49 O III LOH 1p/19q 27 dead 
42 F 34 O III LOH 1p/19q 49 alive 
43 F 61 O III LOH 1p/19q 40 alive 
44 M 42 O III LOH 1p/19q 14 alive 
45 M 38 O III  27 alive 
46 F 44 O III no LOH 1p/19q 20 alive 
47
X
 F 59 O III monosomy 19q 34 alive 
48 F 69 O III LOH 1p/19q 44 dead 
49 M 21 O III LOH 1p/19q 217 alive 
50 F 50 O III LOH 1p/19q 54 alive 
 
Table 3.2  
Clinicopathological characteristics of the patient population 
F, female; M, male; A, astrocytoma; O, oligodendroglioma; LOH, loss of the heterozygosity; POD, 
post operative death; *-where available  
X 
indicates cases in which TSPO methylation status was not analysed by MSP 
 
3.2.1.1 Pattern of staining 
All of 50 gliomas showed cytoplasmic, granular expression of TSPO; no nuclear TSPO 
immunoreactivity was observed (Figure 3.1 and Figure 3.2). TSPO positive cells were distributed 
homogenously throughout the tumour tissue. There was no staining in reactive astrocytes, 
oligodendrocytes and neurons. Vascular endothelial cells expressed TSPO and represented an internal 
positive control for the staining. 
Representative images of control staining in human adrenal sections are shown in Appendix I.  
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Figure 3.1 
TSPO expression in glioma tissue samples  
TSPO expression was determined using peroxidase immunohistochemistry with mouse anti-TSPO 
antibody (8D7). Representative images of staining from WHO grade II astrocytoma, case 3 (A), WHO 
grade II oligodendroglioma, case 34 (B), anaplastic astrocytoma, case 14 (C), anaplastic 
oligodendroglioma, case 45 (D) and glioblastoma, case 24 (E) are shown. Scale bar: 100 µm. 
TSPO expression in astrocytic tumours increases with grade (A, C and E) but is low irrespective of 
grade in oligodendrogliomas (B and D).  
Vascular endothelial cells express TSPO and represent an internal positive control for the staining. 
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Figure 3.2 
TSPO expression in glioma tissue samples  
TSPO expression was determined using peroxidase immunohistochemistry with mouse anti-TSPO 
antibody (8D7).  Representative images of staining from WHO grade II astrocytoma, case 3 (A), 
WHO grade II oligodendroglioma, case 34 (B), anaplastic astrocytoma, case 14 (C), anaplastic 
oligodendroglioma, case 45 (D) and glioblastoma, case 24 (E) are shown. Scale bar: 50 µm. 
TSPO expression is cytoplasmic.  
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3.2.1.2 The association between TSPO levels and histopathological features in gliomas 
The results of quantitative analysis of TSPO immunostaining are presented as the percentage of cells 
expressing this protein. TSPO expression assessed by immunohistochemistry was high in astrocytic 
tumours (median score 40.9%, average 41.7%) and significantly higher in high-grade astrocytomas 
(WHO grade III and IV) as compared with diffuse astrocytomas (WHO grade II) (p=0.031). In 
contrast, oligodendrogliomas showed little TSPO positivity irrespective of the grade (median score 
11.2%, average 16.8%). TSPO expression in oligodendrogliomas was significantly lower than in 
astrocytomas, p<0.001 (Figure 3.3). 
 
 
Figure 3.3 
TSPO expression and histopathological features of gliomas 
Box plot figures represent TSPO expression (percentage of TSPO positive cells) in each of the 
examined tumour groups. The boxes contain the values between the 25th and 75th percentiles; the 
horizontal line inside the box represents the median; far outlier is indicated by a star. Whiskers are 
drawn to the largest and smallest values that are not outliers.  
A (II), WHO grade II astrocytomas; AA (III), anaplastic astrocytomas; GBM (IV), glioblastomas; O 
(II), WHO grade II oligodendrogliomas; AO (III), anaplastic oligodendrogliomas. 
TSPO expression in astrocytic tumours increases with grade but is low irrespective of grade in 
oligodendrogliomas. TSPO expression in oligodendrogliomas is significantly lower than in 
astrocytomas (p<0.001). 
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It was not statistically feasible to analyse the association between 1p/19q status and TSPO levels in 
oligodendrogliomas because of a very low number of samples without 1p/19q loss (Table 3.2). 
3.2.2 TSPO methylation patterns delineate glioma histotypes  
Although increased TSPO expression has been reported in a number of cancers, the mechanism 
underlying TSPO over-expression in neoplastic cells has not been documented so far. To test the 
hypothesis that the difference in protein expression between astrocytic and oligodendroglial tumours 
could be due to epigenetic dysregulation, MSP analysis of TSPO promoter methylation was 
performed on DNA extracted from 47 glioma tissue samples (9 WHO grade II astrocytomas, 10 
anaplastic astrocytomas, 10 glioblastomas, 9 WHO grade II oligodendrogliomas and 9 anaplastic 
oligodendrogliomas) out of 50 samples available for TSPO immunohistochemistry (Table 3.2) and 4 
human glioma cell lines (U-87MG, GaMG, DBTRG and 42MG-BA). Each of the 4 primer sets used 
in the methylation study covered a different area of the TSPO promoter CpG island (Chapter 2, Figure 
2.3).  
Methylation was detected in 21% (6 cases) of astrocytomas (4 WHO grade II astrocytomas and 2 
anaplastic astrocytomas) and 72.2% (13 cases) of oligodendrogliomas (5 WHO grade II 
oligodendrogliomas and 8 anaplastic oligodendrogliomas), p=0.00073. Interestingly, in five cases of 
oligodendroglioma (4 WHO grade II oligodendrogliomas and 1 anaplastic oligodendroglioma) where 
there was no methylation, the average expression of TSPO was 28.71%. This is significantly higher 
than the average score in the oligodendroglioma samples with promoter methylation (11%, p=0.003). 
In six astrocytoma cases that showed TSPO methylation, the average TSPO expression was 30.82% 
versus 44.8% in unmethylated samples (p= 0.036). This pattern is highly consistent across all 47 cases 
(p<0.0001). The TSPO promoter was unmethylated in all four astrocytoma cell lines tested, which is 
consistent with high protein expression (Figure 3.4 and Figure 4.1).  
 
109 
 
 
 
Figure 3.4 
TSPO CpG island methylation in gliomas  
Representative results of methylation specific polymerase chain reaction (MSP) with primer set 2 in 
tumour cases (A), human glioma cell lines (B) and control reactions (C). 
U, unmethylated reaction; M, methylated reaction; CU, unmethylated control; CM, methylated control 
 
To confirm the results obtained using MSP, DNA methylation was also assessed by pyrosequencing. 
Pyrosequencing was used to detect and quantify the degree of methylation for nine individual CpG 
sites localised in the CpG island area covered by MSP primer set 2 in 17 cases out of 47 cases used 
for MSP (4 anaplastic astrocytomas, 6 glioblastomas, 1 WHO grade II oligodendroglioma and 6 
anaplastic oligodendrogliomas). Pyrosequencing was conducted by Dr Christiana Lo Nigro‟s group 
(Laboratorio Oncologia Translazionale, Cuneo, Italy). Pyrosequencing and MSP analysis of this 
region produced similar results. The average level of methylation for samples determined as 
methylated by MSP was 37.16% and for the unmethylated samples 23.06%. It was not feasible to 
statistically verify the association between the results of MSP and pyrosequencing because of low 
number of samples evaluated with both methods.  
3.2.3 TSPO expression and patient overall survival in gliomas 
The association between TSPO expression (categorised with median as a cut-off value) and overall 
patient survival in gliomas (n=50) did not reach significance as compared by log rank test (p=0.151) 
and the Kaplan-Meier survival curves are presented in Figure 3.5A. TSPO did not predict survival in 
multivariate Cox analysis (HR 0.964, 95%CI 0.923-1.008, p=0.107). Tumour grade (HR 4.332, 
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95%CI 1.710-10.977, p=0.002) and histotype (HR 9.451, 95%CI 1.347-66.318, p=0.024) were the 
other covariates included in the multivariate analysis.  
TSPO expression did not predict survival in astrocytomas (n=30) when assessed with log rank test 
(p=0.651), neither when analysed using Cox regression multivariate model (HR 0.971, CI95% 0.928-
1.017, p=0.211) with grade as a covariate (HR 3.544, 95%CI 1.386-9.062, p=0.008). The Kaplan-
Meier survival curves are presented in Figure 3.5B.  
The survival analysis in oligodendrogliomas alone was not feasible because of low number of samples 
(n=20) and the fact that only two patients from this group died within the follow-up period. 
 
Figure 3.5 
TSPO expression and patient survival 
Kaplan-Meier estimates of overall survival of patients with gliomas, n=50 (A) and astrocytomas, 
n=30 (B) according to TSPO expression. Median TSPO expression (percentage of TSPO positive 
cells) was used to dichotomise the samples into low and high- expression groups. P values in the log 
rank test.  
 
3.2.4 TSPO methylation status and patient overall survival in gliomas  
There was a significant correlation between overall survival and TSPO methylation pattern in 47 
glioma samples analysed using MSP (log rank test, p=0.011), Figure 3.6A. However, TSPO 
methylation status did not correlate with glioma patient survival in the multivariate Cox regression 
analysis (HR 0.488, CI95% 0.096-2.467, p=0.385) with histotype (HR 1.967, CI95% 0.306-12.660, 
p=0.477) and grade (HR 2.560, CI95% 1.162-5.640, p=0.020) as covariates.  
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When only astrocytomas (n=29) were included in the analysis, there was a trend towards significance 
for longer survival of patients with astrocytic tumours with methylated TSPO with clear separation of 
Kaplan-Meier survival curves of methylated and unmethylated cases and this is presented in Figure 
3.6B (log rank test, p=0.077). However, TSPO methylation status did not correlate with astrocytoma 
patient survival in the multivariate Cox regression analysis (HR 0.299, CI95% 0.035-2.532, p=0.268) 
with grade (HR 2.044, CI95% 0.914-4.568, p=0.082) as a covariate. 
The statistical analysis of correlation between TSPO methylation status and survival for 
oligodendrogliomas was not conducted because of low number of samples (n=18) and the fact that 
only two patients from this group died within the follow-up time. 
 
 
Figure 3.6 
TSPO methylation status and patient survival 
Kaplan-Meier estimates of overall survival for gliomas, n=47 (A) and astrocytomas, n=29 (B) 
according to TSPO methylation status assessed by methylation specific PCR. P values in the log rank 
test.  
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3.2.5 Validation of TSPO clinicopathological association in independent microarray data sets  
The summary of the clinical data of glioma patients from GSE4412 (Freije et al. 2004), GSE4271 
(Phillips et al. 2006) and TCGA Data Portal (Verhaak et al. 2010) data sets is outlined in Table 3.3. 
There are no clinical data for GSE4290 data set (Sun et al. 2006). 
 
 
Table 3.3 
Summary of the clinicopathological data of glioma patients from the microarray data sets 
included in the validation analysis 
F, female; M, male 
 
 
3.2.5.1 Differential expression of TSPO in glioma histotypes 
Reproducibility of the association between TSPO expression and glioma histotype was confirmed 
using publically available glioma microarray data sets deposited in GEO (Gene Expression Omnibus). 
My analysis of the TSPO expression profile of 67 high-grade gliomas from GSE4412 (Freije et al. 
2004) confirmed the correlation between TSPO expression and tumour histotype, with significantly 
higher TSPO levels in astrocytomas versus oligodendrogliomas (p=0.03, Figure 3.7A).  
The association between glioma histotype and TSPO expression was further validated in an analysis 
of GSE4290 microarray data set comprising data on 157 gliomas (7 WHO grade II astrocytomas, 19 
anaplastic astrocytomas, 85 glioblastomas, 34 WHO grade II oligodendrogliomas and 12 anaplastic 
astrocytomas) (Sun et al. 2006). TSPO expression was significantly higher in astrocytomas when 
Data set 
Tumours  
(WHO grade) 
Number 
of cases 
Age in years 
median (range) 
Gender 
(F/M) 
Survival in weeks 
median (range) 
GSE4412 
High-grade gliomas  
(III-IV) 
67 44 (18-82) 40/27 57 (1-359) 
 
 Astrocytomas  
(III-IV) 
58 48 (18-82) 34/24 49 (1-359) 
 
 Oligodendrogliomas  
(III) 
9 36 (20-49) 6/3 100 (25-320) 
GSE4271 
High-grade astrocytomas  
(III-IV) 
77 45 (22-82) 25/52 95 (3-477) 
TCGA Data Portal Glioblastomas (IV) 186 58 (14-87) 66/121 53 (1-503) 
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compared to oligodendrogliomas (p=2x10
-6
). Furthermore, TSPO expression was significantly higher 
in gliomas than in non-neoplastic brain samples (23 epilepsy cases) from the same microarray data set 
(p values <0.01, Figure 3.7B).  
 
 
Figure 3.7 
TSPO expression in normal brain and gliomas 
TSPO expression in groups of high-grade astrocytomas and anaplastic oligodendrogliomas from 
GSE4412 microarray data set (A) and in non-neoplastic brain, astrocytomas and oligodendrogliomas 
from GSE4290 microarray data set (B) is presented as box plot figures. The boxes contain the values 
between the 25th and 75th percentiles; the horizontal line inside the box represents the median; 
outliers are indicated by open circles and far outliers by stars. Whiskers are drawn to the largest and 
smallest values that are not outliers.  
The differences between the groups are statistically significant (p<0.05). 
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3.2.5.2  TSPO expression and patient survival 
The association between TSPO expression and patient survival did not reach significance in my 
analysis of 58 high-grade astrocytomas from GSE4412 (log rank test, p=0.819), 77 high-grade 
astrocytomas from GSE4271 (log rank test, p=0.489) nor 186 glioblastomas from TCGA Data Portal 
(log rank test, p=0.965). The Kaplan-Meier survival curves are presented in Figure 3.8.  
 
Figure 3.8 
TSPO expression and patient survival in astrocytomas – analysis of microarray data sets 
Kaplan-Meier estimates of overall survival for 58 high-grade astrocytomas from GSE4412 (A), 77 
high-grade astrocytomas from GSE4271 (B) and 186 glioblastomas from TCGA Data Portal (C) 
according to TSPO expression. Median TSPO expression within each population was used to 
dichotomise the samples into low- and high- expression groups. P values in the log rank test. 
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3.2.5.3  TSPO expression in molecular subtypes of gliomas 
Interestingly, tumours classified by Freije et al. (GSE4412) (Freije et al. 2004) as a good prognosis 
group on the basis of gene expression clusters related prognosis (survival cluster 1) had significantly 
lower TSPO expression than tumours from the poor prognosis group (survival cluster 2) with p value 
of 0.0003 (Table 3.4).  
In the same study tumours were further segregated on the basis of their molecular signature into four 
hierarchical clusters: molecular signature associated with neurogenesis (HC1A), synaptic transmission 
(HC1B), proliferation (HC2A) or associated with matrix related genes (HC2B) (Freije et al. 2004). 
The highest TSPO expression was observed in the HC2B hierarchical cluster and this was 
significantly higher than in the remaining clusters (p values <0.05, Table 3.4).  
 
 
Number of cases 
Survival in days 
median (range) 
TSPO 
median 
SC1 23 1022 (96-2516) 2685.9 
SC2 44 224 (7-1089) 4610.6 
HC1A 14 1055 (389-2516) 2809.1 
HC1B 18 294 (43-1769) 3214.0 
HC2A 13 203 (64-2241) 4189.0 
HC2B 22 312 (7-1089) 6004.3 
 
Table 3.4 
TSPO expression in hierarchical clusters of high-grade gliomas from GSE4412 data set   
TSPO expression is significantly higher in tumours from the poor prognosis group (SC2) than in the 
good prognosis group (SC1) and highest in the hierarchical cluster with molecular signature 
associated with matrix related genes (HC2B). 
SC1, survival cluster 1, good prognosis; SC2, survival cluster 2, poor prognosis; HC hierarchical 
cluster of tumours with molecular signature associated with neurogenesis (HC1A), synaptic 
transmission (HC1B), proliferation (HC2A) and with matrix related genes (HC2B)  
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Three prognostic subclasses (proneural, proliferative and mesenchymal) of high-grade astrocytomas 
were defined in the study by Phillips et al. (GSE4271) (Phillips et al. 2006). In my analysis of this 
microarray data set, there were no significant differences in TSPO levels between the groups (Table 
3.5, p>0.1). 
 
Subclass of high-grade 
astrocytoma  
Number of cases 
Survival in weeks 
median (range) 
TSPO 
median 
Proneural 28 148 (17-477) 894.7 
Proliferative 23 62 (3-242) 832.1 
Mesenchymal 26 94 (32-357) 1197.8 
 
Table 3.5 
TSPO expression in subclasses of high-grade astrocytomas from GSE4271 data set 
On the basis of gene expression analysis high-grade astrocytomas were classified into three 
subclasses. The differences in TSPO expression between subclasses were not significant (p>0.1).  
 
Verhaak et al. classified glioblastomas on the basis of gene expression into four subtypes: classical, 
mesenchymal, neuronal and proneuronal (TCGA data set) (Verhaak et al. 2010). My analysis of this 
microarray data set showed that the highest TSPO expression was in the mesenchymal subclass 
(Table 3.6) and it was significantly higher when compared with other subtypes (p values <0.05).  
Subtype of 
glioblastoma  
Number of cases 
Survival in days 
median (range) 
TSPO 
median 
Classical 51 393 (8-1448) 374.1 
Mesenchymal 56 360 (14-2152) 495.2 
Neural 27 399 (15-1168) 424.1 
Proneural 52 341 (20-3524) 292.0 
 
Table 3.6 
TSPO expression in subtypes of glioblastoma from The Cancer Genome Atlas (TCGA) Data 
Portal 
On the basis of gene expression analysis glioblastomas were classified by Verhaak et al. into four 
subtypes. The highest TSPO expression was in the mesenchymal subclass (p<0.05). 
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3.2.6 TSPO and glioma infiltrating microglia 
3.2.6.1 Extent and pattern of Iba1and CD68 staining  
In order to understand if tumour infiltrating microglia represent a cell population contributing 
significantly to the TSPO immunoreactivity, the extent of tumour infiltrating microglia (as defined by 
the expression of microglial markers – Iba1 and CD68 (Ito et al. 1998; Roggendorf et al. 1996)) was 
determined in the series of 50 gliomas (Table 3.1 and 3.2).  
In glioma tissue samples Iba1 immunolabelling was determined in the cytoplasm and the perinuclear 
region (Figure 3.9). Iba1 stained ramified and activated microglia. CD68 immunoreactivity was 
localised on the inside of cell membranes and in the cytoplasm. CD68 expression was observed in 
mononuclear cells of round, ramified and amoeboid morphology consistent with microglia (Figure 
3.10). There was no Iba1or CD68 immunoreactivity in neoplastic cells.  
The distribution of Iba1 and CD68 positivity in glioma tissue samples followed a similar pattern. 
Cells expressing microglial markers were diffusely distributed in astrocytomas with prominent cuff of 
Iba1and CD68 positive cells surrounding areas of necrosis in glioblastomas. In oligodendrogliomas 
microglial staining frequently showed perilobular distribution pattern (within the discrete 
fibrovascular sheet surrounding tumour compartments, Figure 3.9 and Figure 3.10). 
Sections of pharyngeal tonsil were used as controls for both immunoreactions (Appendix I). 
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Figure 3.9  
Iba1 expression in glioma tissue samples 
Iba1 expression was determined using peroxidase immunohistochemistry with rabbit anti-Iba1 
antibody. Representative images  from WHO grade II astrocytoma, case 8 (A), WHO grade II 
oligodendroglioma, case 36 (B), anaplastic astrocytoma, case 14 (C), anaplastic oligodendroglioma, 
case 46 (D) and glioblastoma, case 26 (E) are shown.  
Scale bar: 50 µm.  
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Figure 3.10 
CD68 expression in glioma tissue samples 
CD68 expression was determined using peroxidase immunohistochemistry with mouse anti-CD68 
antibody. Representative images of staining from WHO grade II astrocytoma, case 8 (A), WHO grade 
II oligodendroglioma, case 36 (B), anaplastic astrocytoma, case 14 (C), anaplastic oligodendroglioma, 
case 46 (D) and glioblastoma, case 26 (E) are shown.  
Scale bar: 50 µm. 
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3.2.6.2 The association between microglial markers and glioma clinicopathological features as 
well as TSPO levels  
Iba1 and CD68 immunostaining results were assessed semi-quantitatively where the score represents 
percent area of staining determined using the threshold as described in Materials and Methods. 
Expression of both microglial markers was significantly higher in astrocytomas than in 
oligodendrogliomas (p=0.002 for Iba1and p=0.016 for CD68). There was a statistically significant 
difference in microglial infiltrate assessed using Iba1 and CD68 between low (WHO grade II) and 
high-grade (grade III and IV) astrocytomas with p values of 0.015 for Iba1 and 0.0002 for CD68 
(Figure 3.11).  
 
 
Figure 3.11 
Extent of microglial infiltrate and histopathological features of gliomas 
Box plot figures represent Iba1 (A) and CD68 (B) expression in each of the examined tumour groups. 
The boxes contain the values between the 25th and 75th percentiles; the horizontal line inside the box 
represents the median; outliers are indicated by open circles and far outliers by stars. Whiskers are 
drawn to the largest and smallest values that are not outliers.  
A (II), WHO grade II astrocytomas; AA (III), anaplastic astrocytomas; GBM (IV), glioblastomas; O 
(II), WHO grade II oligodendrogliomas; AO (III), anaplastic oligodendrogliomas 
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Kaplan-Meier survival analysis showed that glioma patients with high Iba1 expression (with median 
as a cut-off value) had significantly shorter overall survival than those with low Iba1 expression 
(n=50, log rank, p=0.015, Figure 3.12A). The same correlation was observed when only astrocytomas 
were analysed (n=30, log rank p=0.004, Figure 3.12B).  
 
Figure 3.12 
Extent of microglial infiltrate (Iba1 expression) and patient survival 
Kaplan-Meier estimates of overall survival for gliomas, n=50 (A) and astrocytomas, n=30 (B) 
according to Iba1 expression. Median Iba1 expression (%) was used to dichotomise the samples into 
low- and high- expression groups. P values in the log rank test. 
 
 
Similarly, there was a trend towards significance between CD68 expression (with median as a cut-off 
value) and overall survival in gliomas (n=50, log rank, p=0.074) and in the group of astrocytomas 
(n=30, log rank, p=0.053). The Kaplan-Meier survival curves are presented in Figure 3.13. 
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Figure 3.13  
Extent of microglial infiltrate (CD68 expression) and patient survival 
Kaplan-Meier estimates of overall survival for gliomas, n=50 (A) and astrocytomas, n=30 (B) 
according to CD68 expression. Median CD68 expression (%) was used to dichotomise the samples 
into low- and high- expression groups. P values in the log rank test. 
 
In the multivariate analysis high expression of neither Iba1 nor CD68 was shown to be an independent 
prognostic factor for overall survival in gliomas (Table 3.7).  
 
Marker Covariates HR 95%CI p value 
Iba1 Iba1 1.019 0.870-1.193 0.819 
 grade 2.699 0.971-7.500 0.057 
 histotype 3.361 0.692-16.315 0.133 
CD68 CD68 1.311 0.909-1.890 0.147 
 grade 2.117 0.882-5.080 0.093 
 histotype 2.529 0.484-13.230 0.272 
 
Table 3.7 
Iba1/ CD68 expression and patient survival in gliomas - multivariate Cox regression analysis  
Microglial markers expression was evaluated in gliomas (n=50) using peroxidase 
immunohistochemistry. For the purpose of multivariate Cox regression analysis the results of staining 
were used as continuous variables.  
HR, hazard ratio; CI, confidence interval 
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Similarly in the subgroup of astrocytomas, although Iba1 and CD68 expression showed a significant 
correlation with survival in univariate analysis, there was no statistical significance in the multivariate 
analysis (Figure 3.8). 
 
Marker Covariates HR 95%CI p value 
Iba1 Iba1 1.061 0.898-1.253 0.487 
 grade 1.980 0.696-5.636 0.200 
CD68 CD68 1.408 0.961-2.062 0.079 
 grade 1.655 0.666-4.111 0.278 
 
 
Table 3.8 
Iba1/ CD68 expression and patient survival in astrocytomas - multivariate Cox regression 
analysis  
Microglial markers expression was evaluated in astrocytomas (n=30) using peroxidase 
immunohistochemistry. For the purpose of multivariate Cox regression analysis the results of staining 
were used as continuous variables.  
HR, hazard ratio; CI, confidence interval 
 
Correlation analysis (Spearman‟s) revealed statistically significant link between the two microglial 
stains (r
2
=0.689). There was also a correlation between TSPO score and scores for microglial markers 
but the correlation between the microglial markers was stronger than their correlation with TSPO 
(Table 3.9).  
 TSPO CD68 Iba1 
TSPO - 0.586 0.541 
CD68 0.586 - 0.689 
Iba1 0.541 0.689 - 
 
 
Table 3.9 
Bivariate correlation between results of TSPO, CD68 and Iba1 expression analysis in gliomas  
(r
2
, Spearman‟s; all p values <0.0001) 
TSPO, CD68 and Iba1 expression was evaluated in 50 glioma tissue samples using peroxidase 
immunohistochemistry as described in Materials and Methods. 
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3.2.6.3 Neoplastic cells as the main cell population expressing TSPO 
I performed double immunofluorescence on human glioblastoma tissue samples (n=10) to document 
the cell populations contributing to TSPO staining intensity.  Glioma cells (GFAP positive) expressed 
TSPO (Figure 3.14) and TSPO positive microglia (Iba1 positive) represented only a small fraction of 
TSPO positive cells (Figure 3.15). Consequently, the main cell population expressing TSPO are 
neoplastic cells.  
 
 
Figure 3.14 
Representative images from TSPO/ GFAP double immunofluorescence in a glioblastoma (case 
29) 
To detect TSPO mouse anti-TSPO antibody (8D7) was followed by goat anti-mouse Alexa Fluor 488 
(green)-conjugated antibody. For the detection of glioma cells rabbit anti-GFAP antibody was 
followed by goat anti-rabbit Alexa Fluor 555 (red)–conjugated antibody. DAPI (blue) was used to 
counterstain total cell nuclei.  
Endothelial cells express TSPO but do not express GFAP and therefore represent an internal control 
for the staining. 
Scale bars: top panel – 100 µm, bottom panel – 50 µm. 
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Figure 3.15 
Representative images from TSPO/ Iba1 double immunofluorescence in a glioblastoma (case 26) 
To detect TSPO mouse anti-TSPO antibody (8D7) was followed by goat anti-mouse Alexa Fluor 488 
(green)-conjugated antibody. For the detection of microglia rabbit anti-Iba1 antibody was followed by 
goat anti-rabbit Alexa Fluor 555 (red)–conjugated antibody. DAPI (blue) was used to counterstain 
total cell nuclei.  
Scale bars: top panel – 100 µm, middle and bottom panels – 50 µm. 
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3.3 Discussion 
The work presented in this chapter describes TSPO expression pattern in gliomas as well as its 
correlation with tumour histology and patient outcomes. Furthermore, the possible mechanism 
responsible for differential TSPO expression between two glioma subtypes is postulated. Finally, the 
major cell population expressing TSPO in gliomas is highlighted.  
In this study, cytoplasmic localization of TSPO was observed, which is consistent with previously 
described 8D7 anti-TSPO antibody staining pattern in normal tissue samples and in 117 samples of 
breast carcinoma (Bribes et al. 2004; Galiegue et al. 2004). Similarly, in astrocytoma tissue samples 
analysed with immunohistochemistry by Miettinen et al. and Vlodavsky et al., TSPO positivity was 
observed in the cytoplasm and around the nucleus or in the cytoplasm but has not been described in 
the nucleus (Miettinen et al. 1995; Vlodavsky et al. 2007). We found no evidence for TSPO 
subcellular localization shift from the mitochondrial to the nuclear compartment during astrocytic 
tumour progression as hypothesised by Brown et al. (Brown et al. 2000b). It is of note that in the 
study by Brown et al. the nuclear localization of TSPO was only demonstrated in a single case of 
glioblastoma. 
Here, it has been confirmed that TSPO expression correlates with tumour grade in astrocytomas 
where TSPO levels are higher in high-grade than low grade lesions. In oligodendrogliomas there is no 
correlation between TSPO expression and tumour grade. The differential expression of TSPO 
between astrocytomas and oligodendrogliomas is shown for the first time. The clinical behaviour of 
both glioma histotypes differs, as astrocytic tumours are associated with higher risk of anaplastic 
transformation and resistance to treatment (Louis 2006; Nutt et al. 2000). Consequently, the accurate 
differential diagnosis between astrocytoma and oligodendroglioma has important implications for 
patient management. Neither CGH or FISH, nor PCR-based microsatellite analysis is commonly used 
in the general pathology laboratory, which limits the diagnostic utility of LOH 1p/19q status that has 
been proposed as a genomic differential marker between the two histotypes. There is a need for 
methods that would provide further assistance while making the diagnosis. Although TSPO 
expression assessed using immunohistochemistry might be inferior to 1p/19q status with respect to its 
histotype marker utility in gliomas, the binding capacity for TSPO ligands can be visualised with non-
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invasive techniques and provide information prior to surgery. A range of radiolabelled molecules 
binding with high affinity to TSPO has been described with PK11195 currently the most widely used 
(Dolle et al. 2009). The ability of PK11195 to cross the intact blood brain barrier led to its 
experimental use for functional imaging of gliomas (Broaddus et al. 1990; Junck et al. 1989; Olson et 
al. 1988; Starosta-Rubinstein et al. 1987). Non-invasive PET imaging with radiolabelled TSPO 
ligands could be thus used to facilitate non-invasive pre-operative glioma diagnostics and support 
early predictive models, and my result warrants further investigation in the clinical settings. It remains 
also to be established whether the function of TSPO, whose expression delineates glioma histotypes, 
differs between astrocytomas and oligodendrogliomas. 
Furthermore, it is demonstrated here that the epigenetic dysregulation of TSPO expression is a 
possible mechanism responsible for the differential TSPO expression between the two histotypes. 
Indeed, the differential methylation status of the TSPO promoter may represent a wider difference 
between epigenomes of these glioma subtypes and this view is supported by the fact that TSPO 
expression was different between tumours falling into different gene expression clusters in the re-
analysis of publically available glioma microarray data sets (Freije et al. 2004; Verhaak et al. 2010). 
Promoter methylation, histone modifications and other epigenetic mechanisms are crucial in normal 
development including neurogenesis. Aberrant epigenetic regulation of gene expression contributes to 
the differentiation in brain neoplasias and may well contribute to the gene expression clusters 
described above (Freije et al. 2004; Gladson et al. 2009; Martinez et al. 2009).  
My findings argue against TSPO significance as a strong prognostic marker in astrocytomas, unlike in 
some previous studies (Miettinen et al. 1995; Vlodavsky et al. 2007). The number of samples 
analysed by immunohistochemistry in the present study was limited (30 astrocytomas) and it may be 
postulated that a larger population would reveal significant association with survival. However, the 
evidence to support the previously reported relationship between TSPO expression and survival could 
also not be provided by an analysis of large publically available microarray data sets comprising high-
grade astrocytomas (Freije et al. 2004; Phillips et al. 2006; Verhaak et al. 2010). The possible 
explanation is that, in the previous studies on TSPO expression in astrocytomas, pilocytic 
astrocytomas (WHO grade I) were included (Miettinen et al. 1995; Vlodavsky et al. 2007). There 
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were 9 pilocytic astrocytomas (10% of all cases examined) in the report published by Miettinen et al. 
and 25 (19%) in the study by Vlodavsky et al. (Miettinen et al. 1995; Vlodavsky et al. 2007). In 
contrast to the diffusely infiltrating astrocytomas, pilocytic astrocytomas are slowly growing, well-
circumscribed tumours that most frequently occur in children. Malignant transformation is very rare. 
The prognosis is remarkably more favourable than for diffusely infiltrating tumours with a 10-year 
survival rate of 96% (Louis 2007; Ohgaki et al. 2005b). It might be argued that these tumours should 
not be included in studies aiming at establishing prognostic markers applicable to all astrocytomas. In 
studies by Miettinen et al. and Vlodavsky et al. pilocytic astrocytomas have the lowest TSPO 
expression among astrocytomas of different grades and this population of low TSPO/ good prognosis 
samples likely drives the significant association (Miettinen et al. 1995; Vlodavsky et al. 2007). 
Furthermore, none of the authors showed that the relationship between TSPO expression and survival 
is independent of histopathological grade (Miettinen et al. 1995; Vlodavsky et al. 2007). We 
demonstrated that TSPO has no prognostic value for survival in WHO grade II-IV astrocytomas when 
this is controlled for grade. 
The correlation between TSPO methylation status and patient survival was not independent of tumour 
histotype and grade in the multivariate analysis, although of note, there was a trend in univariate 
analysis in astrocytoma patients only. It is of interest that in glioma patients, as well as in the 
subgroup of astrocytomas, TSPO methylation status in univariate analysis was arguably better 
correlated with overall survival than TSPO levels. The relationship between TSPO methylation status 
and patient outcome could be thus related not only to its causal impact on TSPO expression but co-
occurrence with other epigenetic events. This is consistent with the fact that TSPO levels were 
associated with „poor prognosis‟ gene expression cluster in gliomas but did not predict survival in the 
same microarray data set.  
Previously published analyses of gene expression profiles described molecular subclasses of high-
grade gliomas and glioblastomas (Freije et al. 2004; Phillips et al. 2006; Verhaak et al. 2010). My 
analysis showed that TSPO expression was highest in the high-grade gliomas with molecular 
signature associated with matrix related genes (extracellular matrix components and regulators) and in 
the mesenchymal subtype of glioblastoma (defined by expression of genes linked with epithelial-to-
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mesenchymal transition). Further studies are needed to understand the significance and mechanisms 
of these associations. 
Despite the fact that microglia represent an abundant population of cells infiltrating gliomas, only one 
study has considered them to be a potential constituent of the TSPO positive cell group (Takaya et al. 
2007). Takaya et al. demonstrated the lack of TSPO expression in microglia infiltrating anaplastic 
astrocytomas. Here, although TSPO levels were significantly correlated with microglial markers, it 
was shown that tumour cells, rather than microglia, are the major cell population expressing TSPO. 
Both TSPO positivity and the proportion of microglia in gliomas increased with grade and this may 
account for the association between TSPO and microglia density. Microglial cells have been 
previously shown to be present in astrocytic tumours, although the findings of correlation between 
microglia and tumour grade were inconsistent (Geranmayeh et al. 2007; Morimura et al. 1990; 
Roggendorf et al. 1996). As previously described, microglial cells were less abundant in 
oligodendrogliomas in comparison to astrocytic tumours (Roggendorf et al. 1996). Although not 
related to the main topic of the study, it is interesting that the extent of tumour infiltrating microglia is 
related to patient survival. The possible correlation between microglial index (Iba1) and survival was 
postulated by Geranmayeh et al. in the series of 23 astrocytomas, although microglial index was not 
an independent prognostic factor (Geranmayeh et al. 2007). Conversely, in the present study the 
abundance of tumour infiltrating microglia tends to associate with worse prognosis.  
In conclusion, TSPO is an epigenetically driven marker aiding discrimination of glioma histotypes of 
a potential non-invasive imaging utility that warrants further investigation in a clinical setting. In the 
present study, in contrast to its previously postulated prognostic significance in gliomas, TSPO 
expression is not an important prognostic factor when the patient populations are sufficiently 
homogenous with regard to pathological characteristics.  
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4 Chapter 4: Functional characterization of TSPO in gliomas 
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4.1 Introduction 
As discussed in Introduction (Chapter 1) TSPO was reported to be expressed in human astrocytomas 
and its increased expression correlated with tumour grade as well as unfavourable clinical outcomes 
(Miettinen et al. 1995; Vlodavsky et al. 2007). Consistently, in the present study it was confirmed 
using immunohistochemistry that TSPO levels are elevated in high-grade astrocytomas when 
compared to low grade tumours. However, there was no compelling evidence for TSPO as an 
independent prognostic factor in our group of astrocytomas. The consequences of increased TSPO 
expression in astrocytomas and thus its potential mechanistic role in tumour progression remain to be 
elucidated.  
It has been postulated that TSPO is involved in the regulation of apoptotic cell death and cancer cell 
proliferation (Beinlich et al. 2000; Chelli et al. 2004; Hardwick et al. 1999; Li et al. 2007b; Miettinen 
et al. 1995; Rechichi et al. 2008; Vlodavsky et al. 2007). However, the literature on the function of 
TSPO in cancer cells is very conflicting. The majority of reports of the potential involvement of 
TSPO in apoptotic cell death are based on in vitro experiments utilising TSPO ligands (Veenman et 
al. 2007). In these studies PK11195 TSPO ligand, was demonstrated to have either pro-apoptotic (e.g. 
rat glioma C6 cells) or anti-apoptotic (e.g. human breast cancer MCF-7 cells) effects, or have no 
impact on apoptotic cell death (e.g. human glioma T98 cells) (Chelli et al. 2004; Strohmeier et al. 
2002; Xia et al. 2000). Furthermore, it was shown that the ability of PK11195 to modulate apoptotic 
response does not depend on TSPO and consequently a need to re-define the targets of TSPO ligands 
was stated (Gonzalez-Polo et al. 2005; Hans et al. 2005; Walter et al. 2005). Studies using cells 
engineered to over- or under-express TSPO to obtain direct evidence of TSPO function in apoptosis/ 
proliferation also did not provide conclusive results. Taking the example of glioma models, 
proliferation rate was increased and the number of apoptotic cells decreased in C6 cells manipulated 
to over-express TSPO in the study by Rechichi et al., whereas Levin et al. reported the same 
phenotype for C6 cells with reduced TSPO expression when compared to control C6 cells (Levin et 
al. 2005; Rechichi et al. 2008). Furthermore, the correlation between the number of TSPO positive 
cells and the apoptotic index shown by Vlodavsky et al. by immunohistochemical analysis of human 
astrocytoma samples may only mirror the differences in numbers of apoptotic cells between tumours 
132 
 
of different grades (Vlodavsky et al. 2007). This scarcity of coherent data is in contrast with the long 
postulated role for TSPO in the mitochondrial membrane permeabilisation or in the regulation of 
mitochondrial apoptosis based on its subcellular localization and protein interactions (Anholt et al. 
1986; McEnery et al. 1992; Zamzami et al. 2001). Several studies demonstrated that TSPO is 
involved in apoptosis through the association with mitochondrial membrane permeability transition 
pore (MPTP) (McEnery et al. 1992; Zamzami et al. 2001). Using isolated rat brain mitochondria, 
TSPO was demonstrated to be directly involved in the control of Ca
2+
 and apoptosis inducing factor 
(AIF) release form mitochondria (Azarashvili et al. 2007). In this report Ca
2+
-induced MPTP opening 
was delayed by anti-TSPO antibody. As yet there are no studies addressing the possible role of TSPO 
in glioma chemoresistance.  
Further reports linked TSPO with cell growth separately of the apoptotic phenotype. Studies by 
Brown et al. and Hardwick et al. proposed that perinuclear/ nuclear TSPO promotes cell proliferation 
(Brown et al. 2000b; Hardwick et al. 1999). Density of nuclear TSPO in different hepatic tumour cell 
lines correlated inversely with cell doubling time (Corsi et al. 2005). Induction of TSPO expression in 
MCF-7 breast cancer cells increased proliferation, whereas under-expression of TSPO in MDA-231 
breast cancer cells was associated with decrease of cell proliferation rate and cell cycle arrest at G2 
phase (Li et al. 2007b).  
Furthermore, as suggested by published reports on TSPO function in steroidogenesis (Krueger et al. 
1990; Mukhin et al. 1989; Papadopoulos et al. 1990), apart from altering apoptosis and proliferation 
rates, TSPO can potentially influence glioma cell behaviour due to modulation of steroid synthesis 
and metabolism leading to auto-, para- and endocrine effects.  
In the present study an in vitro cell line model of human glioma was utilised to study the effects of 
small interfering RNAs (siRNAs)-mediated TSPO silencing on cancer cell behaviour.  
The biological effects of TSPO depletion on the cancer traits previously linked to TSPO that is 
baseline and drug–induced apoptosis, proliferation and cell cycle progression were examined in a 
glioblastoma model. In addition, the potential function of TSPO in cortisol synthesis in gliomas was 
addressed.  
  
133 
 
4.2 Results 
4.2.1 TSPO expression in human glioma cell lines 
TSPO expression was analysed in a panel of human glioma cell lines (U-87MG, GaMG, DBTRG-
05MG, 42-MG-BA and SNB-19) using Western blotting. All examined lines expressed TSPO 
demonstrating a band of the expected 18 kDa size with no obvious difference in TSPO protein levels 
(Figure 4.1). All subsequent experiments were conducted using U-87MG cells. U-87MG is a well-
established and widely used in vitro model of human glioma (Ponten et al. 1968).  
 
 
Figure 4.1 
TSPO expression in human glioma cell lines as assessed using Western blotting 
48 hours after seeding (before cells exceeded 80% confluence) protein was extracted from U-87MG, 
GaMG, DBTRG-05MG, 42-MG-BA and SNB19 cells. TSPO expression was analysed using mouse 
anti-TSPO antibody (8D7). Mouse anti-β-actin antibody was used as a protein loading control. 
 
4.2.2 Subcellular localization of TSPO 
TSPO was previously demonstrated to be an outer mitochondrial membrane molecule (Bribes et al. 
2004; Dussossoy et al. 1996). Some authors also suggested a perinuclear/ nuclear localization of the 
TSPO protein and associated this subcellular localization with TSPO role in cell proliferation (Brown 
et al. 2000b; Corsi et al. 2005; Hardwick et al. 1999). The subcellular localization of TSPO in U-
87MG cells was examined to ensure that it is in agreement with results of previously published 
reports and further confirm the specificity of the antibody.  
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As demonstrated using immunofluorescence with a mitochondrion specific probe, TSPO was 
localised within the glioma cell mitochondria (Figure 4.2). Findings obtained from the 
immunofluorescence of U-87MG are in agreement with results of the immunohistochemical analysis 
of TSPO expression in human glioma tissue samples (Chapter 3, Figure 3.2).  
 
 
Figure 4.2 
Localization of TSPO in U-87MG human glioma cells analysed by immunofluorescence 
TSPO was localised within cell mitochondria as determined by overlay of images. 
10
4
 of U-87MG cells per well were cultured on coverslips in 24-well plate. After 24 hours cells were 
stained using mitochondrion specific probe (MitoTracker, red) and fixed. For the detection of TSPO 
mouse anti-TSPO antibody (8D7) was followed by goat anti-mouse Alexa Fluor 488 (green)–
conjugated secondary antibody. Cell nuclei were visualised using DAPI (blue). 
Scale bar: 30 µm. 
 
 
In addition to immunofluorescence analysis, nuclear/ cytoplasmic fractionation experiments coupled 
with Western blotting were conducted. Although no nuclear TSPO was observed using 
immunofluorescence, a signal for TSPO was demonstrated in both the nuclear and cytoplasmic lysates 
(Figure 4.3). This discrepancy might be due to different sensitivity of the methods. 
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Figure 4.3 
Subcellular localization of TSPO in U-87MG human glioma cells as analysed by 
nuclear/cytoplasmic fractionation 
TSPO protein is present in the nuclear and cytoplasmic fractions. 
N and C denote the nuclear and cytoplasmic fractions, respectively. Analysed by Western blotting and 
probed for Lamin A/C (nuclear marker), β-tubulin (cytoplasmic marker) and TSPO. 
 
4.2.3 TSPO function in glioma cell growth and apoptotic cell death 
4.2.3.1 The efficiency of the siRNA TSPO knock-down  
U-87MG cells were transfected with TSPO Smart Pool siRNA, non-targeting siRNA or mock 
transfected (no siRNA oligos but otherwise identical reagents) as described in Materials and Methods 
(Chapter 2). Initially, a time-course experiment was performed to assess TSPO expression following 
the transfection. TSPO silencing was already observed at 24 hours post transfection with minimal or 
no signal detected with Western blotting from 48 to 96 hours after transfection. TSPO expression in 
mock transfected and non-targeting siRNA transfected cells remained unaffected (Figure 4.4).  
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Figure 4.4 
The efficiency of siRNA-mediated TSPO knock-down assessed by Western blotting 
TSPO silencing was observed as early as 24 hours post transfection with minimal or no signal 
detected from 48 to 96 hours after transfection. 
 U-87MG cells
 
were mock transfected (MOCK), transfected with non-targeting siRNA (NT) or 
transfected with TSPO Smart Pool siRNA (siTSPO) as described in Materials and Methods. Cells 
were harvested 24, 48, 72 and 96 hours after transfection and the lysates were analysed using Western 
blotting with mouse anti-TSPO antibody (8D7). Mouse anti-β-actin antibody was used as protein 
loading control.  
 
 
The efficiency of transfections (assessed at 72 hours post transfection) was confirmed by Western 
blotting for each TSPO siRNA knock-down experiment performed. Representative results of Western 
blotting are presented in Figure 4.5. 
 
 
Figure 4.5  
The efficiency of siRNA-mediated TSPO knock-down assessed at 72 hours post transfection 
U-87MG cells
 
were mock transfected (MOCK), transfected with non-targeting siRNA (NT) or 
transfected with TSPO Smart Pool siRNA (siTSPO) as described in Materials and Methods. Cells 
were harvested 72 hours after transfection and the lysates were analysed using Western blotting with 
mouse anti-TSPO antibody (8D7). Rabbit anti-HSP60 antibody was used as protein loading control. 
Results of three independent experiments are presented. 
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The efficiency of TSPO knock-down was further confirmed by immunofluorescence analysis (Figure 
4.6).  
 
Figure 4.6 
The efficiency of siRNA-mediated TSPO knock-down assessed by immunofluorescence 
Immunostaining for TSPO is reduced in cells transfected with TSPO Smart Pool siRNA (siTSPO) as 
compared to mock (MOCK) and non-targeting siRNA (NT) transfected cells. 
U-87MG cells were mock transfected, transfected with non-targeting siRNA or TSPO Smart Pool 
siRNA as described in Materials and Methods. 24 hours post transfection 10
4 
cells per well were 
cultured on coverslips in a 24-well plate. After 24 hours cells were stained using mitochondrion 
specific probe (MitoTracker, red) and fixed. For the detection of TSPO mouse anti-TSPO antibody 
(8D7) was followed by goat anti-mouse Alexa Fluor 488 (green)–conjugated secondary antibody. Cell 
nuclei were visualised using DAPI (blue). 
Scale bar: 75 µm. 
 
 
The level of knock-down achieved appears to be more pronounced than in several reports in the 
literature (Chelli et al. 2008; Levin et al. 2005; Li et al. 2007b; Panickar et al. 2007).  
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4.2.3.2 TSPO depletion does not affect U-87MG growth rates 
Initially, the growth of U-87MG cells in baseline conditions following the seeding of various cell 
numbers was examined to find a cell density ensuring a log phase of cell growth throughout the 
timescale of subsequent experiments. 4000 cells per well of a 96-well plate was determined as the 
optimal cell number (Figure 4.7).  
 
Figure 4.7 
U-87MG cell growth in baseline conditions over 5-day period 
4000
 
cells per well of a 96-well plate was determined as the optimal cell density ensuring a log phase 
of cell growth throughout the timescale of subsequent experiments. 
U-87MG cells were plated into wells of a 96-well plate at indicated densities in three replicates. At 
each of the time-points cells were fixed using 10% TCA and quantitated by SRB assay as described in 
Materials and Methods. The experiment was conducted three times, +/- SEM. 
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To test whether TSPO plays a role in cell proliferation, the growth rates of cells following siRNA 
mediated TSPO silencing as compared to the controls were assessed using the SRB assay. No 
significant difference in growth rates between cells lacking TSPO and control cells was observed 
(Figure 4.8).  
 
Figure 4.8 
TSPO knock-down does not alter U-87MG cell growth in baseline conditions  
Following TSPO siRNA knock-down 4000 U-87MG cells (MOCK, NT or TSPO Smart Pool siRNA) 
per well of a 96-well plate were plated in three replicates. At each of the time-points cells were fixed 
using 10% TCA and quantitated by SRB assay as described in Materials and Methods. The 
experiment was conducted three times, +/- SEM.  
MOCK, mock transfected cells; NT, non-targeting siRNA transfected cells; siTSPO, TSPO Smart 
Pool siRNA transfected cells 
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4.2.3.3 TSPO depletion has no effect on the colony forming ability of U-87MG cells 
Clonogenic assay was used to determine the ability of U-87MG cells to form colonies following 
TSPO silencing. The ability to form colonies, which corresponds to cell potential for unlimited 
divisions (Franken et al. 2006), was not affected by TSPO knock-down (Figure 4.9).  
 
 
Figure 4.9 
Clonogenic capacity of U-87MG cells following TSPO knock-down as determined using 
clonogenic assay  
24 hours after transfection 500 U-87MG cells (MOCK, NT or TSPO Smart Pool siRNA) were 
replated into a well of a 6-well plate in three replicates and cultured. After 14 days cells were fixed 
with methanol, stained and the number of colonies formed by more than 50 cells was determined for 
each condition as described in Materials and Methods. Columns represent surviving fraction relative 
to mock transfected cells. The experiment was conducted three times, +/- SEM.  
MOCK, mock transfected cells; NT, non-targeting siRNA transfected cells; siTSPO, TSPO Smart 
Pool siRNA transfected cells 
 
4.2.3.4 TSPO knock-down does not alter U-87MG cell cycle progression 
As reported previously, TSPO silencing in the MDA-231 human breast cancer cell line reduced cell 
proliferation and led to cell cycle arrest in G2 phase, suggestive of TSPO involvement in the 
regulation of cell cycle (Li et al. 2007b). 
In U-87MG cells, consistent with no alteration in growth rates, there was no noticeable impact of 
TSPO knock-down on cell cycle progression, neither on the proportion of cells in the sub-G1 
apoptotic fraction (Figure 4.10). 
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Figure 4.10  
TSPO knock-down does not impact on the U-87MG cell cycle progression assessed using 
propidium iodide staining and flow cytometry analysis 
Following TSPO siRNA knock-down, 1.2 x10
5
 of U-87MG cells (MOCK, NT or TSPO Smart Pool 
siRNA) per well of a 6-well plate were plated in three replicates. After 24 hours both floating and 
adherent cells were collected, fixed, stained and analysed as described in Materials and Methods. The 
experiment was conducted three times, +/- SEM.  
MOCK, mock transfected cells; NT, non-targeting siRNA transfected cells; siTSPO, TSPO Smart 
Pool siRNA transfected cells 
 
4.2.3.5 Are TSPO effects on cancer cell survival /proliferation revealed in response to specific 
stimuli? 
We further hypothesised that TSPO depletion may only exert effects on cell proliferation and 
apoptosis in particular conditions or in response to specific stimuli. Such cues, not recapitulated in 
baseline cell culture conditions, could still be present in vivo within the tumour microenvironment.  
4.2.3.5.1 Effects of TSPO silencing on U-87MG cell growth in low serum conditions 
The removal of growth factors, hormones or cytokines can trigger cell death and many tumours are 
transiently depleted of nutrients during their growth (Antonyak et al. 2002). Serum contains several 
proteins and other molecules that are needed for proliferation of cells in culture. Deprivation of serum 
represents a cell death inducing stimulus (Lu et al. 2008; Ming et al. 2008; Schamberger et al. 2005). 
Time-course analysis of the effect of serum deprivation (DMEM supplemented with 0.1% FBS) on 
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the growth of cells following siRNA-mediated TSPO silencing was conducted. The response to serum 
deprivation was not altered by TSPO depletion as compared to control cells (Figure 4.11). 
 
 
Figure 4.11 
TSPO knock-down does not alter U-87MG cell growth in low serum conditions  
Following TSPO siRNA knock-down 4000 U-87MG cells (MOCK, NT or TSPO Smart Pool siRNA) 
per well of a 96-well plate were plated in three replicates. After 24 hours the medium was removed 
and replaced with low serum medium (0.1% FBS). At each of the time-points cells were fixed using 
10% TCA and quantitated by SRB assay as described in Materials and Methods. The experiment was 
conducted three times, +/- SEM.  
MOCK, mock transfected cells; NT, non-targeting siRNA transfected cells; siTSPO, TSPO Smart 
Pool siRNA transfected cells 
 
4.2.3.5.2 Effects of TSPO silencing on chemotherapy-induced cell death 
We further asked the question of whether TSPO modulates chemotherapy-induced cell death.  
Temozolomide (TMZ), an alkylating chemotherapeutic agent, is currently the most clinically relevant 
chemotherapeutic drug in treatment of high-grade astrocytomas (Stupp et al. 2007). The impact of 
TSPO knock-down on glioma cells TMZ response was examined. First, the TMZ half maximal 
inhibitory concentration (IC50) was established using the SRB assay and was determined to be 850µM 
at 48 hours (Figure 4.12).  
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Figure 4.12 
The 50% inhibitory concentration (IC50) of TMZ in U-87MG cells 
4000 of U-87MG cells per well of a 96-well plate were plated in three replicates. After 24 hours 
medium was removed and replaced with medium containing 500 µM, 650 µM, 800 µM, 1000 µM or 
1250 µM TMZ. The untreated cells received medium containing vehicle (<0.125% DMSO). Cell 
growth was determined with the SRB assay following 48 hours of drug exposure. The absorbance 
relative to untreated cells was designated as surviving fraction. The experiment was conducted three 
times, +/- SEM. 
 
 
For further assays a range of TMZ concentrations, including concentrations above and below the IC50, 
was selected (500 µM, 650 µM, 800 µM, 1000 µM, 1250 µM). TSPO silenced and control cells were 
exposed to TMZ and their growth rates were assessed by SRB assay for 4 days. There was no 
difference in the response to TMZ between the cells transfected with TSPO siRNA and control cells 
(Figure 4.13). 
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Figure 4.13 
TSPO knock-down does not alter U-87MG cell growth following TMZ exposure  
Following TSPO siRNA knock-down 4000 U-87MG cells (MOCK, NT or TSPO Smart Pool siRNA) 
per well of a 96-well plate were plated in three replicates. After 24 hours the medium was removed 
and replaced with medium containing 500 µM, 650 µM, 800 µM, 1000 µM or 1250 µM TMZ. The 
untreated cells received medium containing vehicle (<0.125% DMSO). At each of the time-points 
cells were fixed using 10% TCA and quantitated by the SRB assay as described in Materials and 
Methods. The absorbance relative to untreated cells was designated as surviving fraction. The 
experiment was conducted three times, +/- SEM.  
MOCK, mock transfected cells; NT, non-targeting siRNA transfected cells; siTSPO, TSPO Smart 
Pool siRNA transfected cells 
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In addition to growth analysis, the impact of TSPO knock-down on the activity of caspase-3 and 
caspase-7 after treatment with TMZ was evaluated using a luminescence-based commercial assay. As 
expected TMZ treatment (850 µM for 24 or 48 hours) resulted in elevated caspase 3/7 activity as 
compared to untreated cells. Following 24-hour TMZ exposure the fold-increase in caspase 3/7 
activity was 1.8 for mock, 2.1 for non-targeting siRNA transfected cells and 2.9 for cells following 
siRNA-mediated TSPO silencing (Figure 4.14A). After 48 hours the increase was a 2.1 fold for mock, 
2.2 for non-targeting siRNA transfected cells and 2.7 following TSPO silencing (Figure 4.14B). 
However, this subtle increase in caspase activity observed between cells following TSPO knock-down 
and control cells did not reach statistical significance (24-hour exposure: p=0.06 versus mock and 
p=0.11 versus non-targeting siRNA transfected cells; 48-hour exposure: p=0.34 versus mock and 
p=0.42 versus non-targeting siRNA transfected cells) and did not translate into differences in cell 
survival as assessed with growth curves (as shown above).  
 
A             B 
 
Figure 4.14  
TSPO knock-down effects on caspase-3 and caspase-7 activity in TMZ treated cells 
Following TSPO siRNA knock-down (MOCK, NT or TSPO Smart Pool siRNA) 4000 U-87MG cells 
per well of a 96-well plate were plated in three replicates. After 24 hours the medium was removed 
and replaced with medium containing 850 µM TMZ. The untreated cells received medium containing 
vehicle (<0.125% DMSO). Caspase-3 and caspase-7 activity was measured with a luminometer after 
24 and 48 hours of drug exposure with Caspase Glo 3/7 Assay kit (Promega). The values presented 
are relative to the values obtained for untreated cells, +/- SEM. 
MOCK, mock transfected cells; NT, non-targeting siRNA transfected cells; siTSPO, TSPO Smart 
Pool siRNA transfected cells 
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4.2.4 TSPO and cortisol production 
4.2.4.1 The expression of steroidogenic proteins in glioma tissue samples and cell lines 
4.2.4.1.1 The expression of steroidogenic enzymes in glioma tissue samples 
Given the role of TSPO as a cholesterol transporting molecule and high TSPO expression in gliomas, 
the steroidogenic potential (as defined by the expression of other key proteins in the steroidogenic 
pathway) of human gliomas was evaluated. Firstly, the expression of the steroidogenic enzymes 
(P450scc and P450c17A1) was demonstrated using immunohistochemistry in glioma tissue samples. 
The specificity of the antibodies against P450scc and P450c17A1 was confirmed on human adrenal 
sections and the representative control immunoreactions are shown in Appendix I.  
Staining for P450scc and P450c17A1 was cytoplasmic and positive cells were homogenously 
distributed throughout the tumour tissue.  
P450scc was evaluable in 48 out of 50 cases. All 48 tumours showed P450scc expression. Four cases 
(3 diffuse astrocytomas and 1 anaplastic oligodendroglioma) showed strong positivity for P450scc, in 
37.5% of tumours the expression was moderate and in 54.2% weak (Figure 4.15).  
P450scc expression assessed using immunohistochemistry did not show correlation with tumour grade 
but there was a trend towards significant difference in enzyme expression between gliomas histotypes 
with higher levels in astrocytomas (p=0.07).  
 
Figure 4.15  
P450scc expression in glioma tissue samples 
P450scc expression was determined using peroxidase immunohistochemistry with goat anti-P450scc 
antibody. Images of staining in anaplastic astrocytoma, case 18 (A) and anaplastic oligodendroglioma, 
case 47 (B) are shown. 
Scale bar: 50 µm. 
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P450c17A1 immunostaining was evaluable in 46 out of 50 tumours. Of these cases, one (WHO grade 
II oligodendroglioma) was negative, 15.2% had strong expression; whereas 17.4% and 65.2% cases 
showed moderate and weak positivity, respectively (Figure 4.16). P450c17A1 expression was 
significantly higher in high-grade astrocytomas when compared to low grade astrocytic tumours 
(p=0.006). The P450c17A1 expression correlated with tumour histotype as it was higher in 
astrocytomas when compared to oligodendrogliomas (p=0.017).  
 
 
Figure 4.16  
P450c17A1 expression in glioma tissue samples 
P450c17A1 expression was determined using peroxidase immunohistochemistry with goat anti-
P450c17A1 antibody. Images of staining in anaplastic astrocytoma, case 18 (A) and anaplastic 
oligodendroglioma, case 47 (B) are presented. 
Scale bar: 50 µm. 
 
 
There was no statistically significant correlation between expression of P450scc and P450c17A1 
(Fisher‟s exact test, p=0.508) and between TSPO expression and expression of either of the 
steroidogenic enzymes (Fisher‟s exact test, p=0.798 for P450scc and p=0.440 for P450c17A1).  
Analysis of cell population expressing P450scc and P450c17A1 in glioblastoma tissue sections (n=10) 
revealed that the immunoreactivity for steroidogenic enzymes co-localised with GFAP positivity 
(Figure 4.17). This indicates that tumour cells are the main cell population expressing steroidogenic 
enzymes.  
It was not feasible to measure cortisol concentration, as the endpoint read-out of effective 
steroidogensis, in archived FFPE glioma tissue samples. Current study in our laboratory in 
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collaboration with Dr Jonathan Bowen explores the presence of neurosteroids, including cortisol, in a 
dialysate obtained intra-operatively from gliomas. 
A 
 
B
 
Figure 4.17 
Expression of steroidogenic enzymes P450scc (A) and P450c17A1 (B) in tumour cells of a 
glioblastoma (case 29)  
For the detection of steroidogenic enzymes goat anti-P450scc or anti-P450c17A1 antibody was 
followed by donkey anti-goat Alexa Fluor 488 (green)–conjugated antibody. To detect GFAP rabbit 
anti-GFAP antibody was followed by goat anti-rabbit Alexa Fluor 555 (red)-conjugated antibody. 
DAPI (blue) was used to counterstain total cell nuclei.  
Scale bars: 50 µm. 
 
4.2.4.1.2 The expression of steroidogenic enzymes in glioma cell lines 
P450scc and P450c17A1 are expressed in glioma tissue samples. The expression of steroidogenic 
enzymes, as markers of steroidogenic capacity, was further evaluated in a panel of human glioma cell 
lines, previously shown to express TSPO, to select a potential model to subsequently study the impact 
of TSPO expression modulation on steroid production. P450scc (60kDa) and P450c17A1 (57kDa) 
protein expression was shown using Western blotting in all human glioma cell lines examined (U-
87MG, GaMG, DBTRG-05MG, 42-MG-BA and SNB-19) (Figure 4.18).  
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Collectively, this demonstrates that TSPO as well as key enzymes from the steroidogenic pathway are 
expressed in both human glioma tissue samples and established human glioma cell lines.  
 
Figure 4.18  
P450scc and P450c17A1 expression in a panel of human glioma cell lines 
48 hours after seeding (before cells exceeded 80% confluence) protein was extracted from U-87MG, 
GaMG, DBTRG-05MG, 42-MG-BA and SNB-19 cells and analysed by Western blotting. Membranes 
were probed using polyclonal goat anti-P450scc (A) or polyclonal goat anti-P450c17A1 (B) antibody. 
Mouse anti-β-actin antibody was used as protein loading control. 
 
4.2.4.2 No evidence of cortisol production by human glioma cells in vitro 
Unlike the situation with tissue samples, the levels of various molecules can be quantitatively 
measured in cell culture supernatants with assays such as enzymatic immunoassays (EIA). The 
cortisol levels in cell culture supernatants from U-87MG, GaMG, DBTRG-05MG, 42-MG-BA and 
SNB-19 cells cultured in low serum conditions (DMEM supplemented with 0.5% FBS) were 
measured. Low serum conditions were used as hormones present in serum would conceal expected 
low values of cortisol. In addition, cells were cultured in serum free growth media in previously 
published reports on neurosteroids biosynthesis (Brown et al. 2000a; Brown et al. 2000b). Enzymatic 
immunoassay used for the analysis is a commercially available tool designed to determine cortisol 
concentration in urine, plasma and cell culture supernatants. The cortisol antiserum has high 
specificity for cortisol with a detection limit of 12 pg/ml. Standard curve, based on dilution series of a 
cortisol standard, was plotted demonstrating good performance of the assay (Figure 4.19).  
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Figure 4.19 
Standard curve for the cortisol EIA 
The calibration curve of the concentrations standards plotted versus the logIt (B/Bo) values.  
LogIt B/Bo value represents the ratio of the absorbance of standard well to that of the maximum 
binding well. 
Bo, the absorbance value for the maximum binding well; B, the absorbance value for the standard 
well 
 
Cortisol could not be detected in the cell culture supernatant samples following 24 hours of culture in 
low serum conditions using the Cortisol EIA kit. This points to the lack of cortisol production in vitro 
by glioma cells or hormone levels in culture medium below the detection levels of the assay. 
Since it was not possible to demonstrate cortisol synthesis in a panel of glioma cell lines expressing 
TSPO, the impact of TSPO knock-down on the corticosteroidogenic potential of glioma cell lines was 
not studied. 
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4.3 Discussion 
Work presented in this chapter describes the functional characterization of TSPO in gliomas. 
Mitochondrial/ cytoplasmic localization of TSPO is consistent with previous work by Bribes et al. 
conducted using 8D7 anti-human TSPO antibody and electron microscopy on monocytic U937 cells, 
and numerous reports on TSPO in mitochondria (Anholt et al. 1986; Bribes et al. 2004; Panickar et al. 
2007). The presence of TSPO in the nuclear compartment was previously demonstrated in aggressive 
breast cancer, hepatocellular carcinoma and glioma cells (Brown et al. 2000b; Corsi et al. 2005; 
Hardwick et al. 1999). The apparent discrepancy between results obtained here using cellular 
immunofluorescence and Western blotting might be due to high sensitivity of Western blot analysis of 
the concentrated, denatured nuclear extract as compared to immunofluorescence studies of native 
proteins. TSPO presence not only in mitochondria but also in nuclei of U-87MG cells further 
underlies the complexity of TSPO functions in cancer cells.  
As discussed in detail in Introduction (Chapter 1) high TSPO expression in gliomas has been linked 
with high-grade disease and poor patient survival (Miettinen et al. 1995; Vlodavsky et al. 2007). As 
presented in the preceding chapter we confirmed the correlation between TSPO expression and 
astrocytic tumour grade and additionally demonstrated differential TSPO expression between 
oligodendrogliomas and astrocytomas due to epigenetic dysregulation, while there was no compelling 
evidence for TSPO as an independent prognostic factor (Chapter 3). 
The hypotheses behind the functional work presented in this chapter were, based on the available 
literature, that TSPO enhances glioma proliferation and survival, and/or promotes steroidogenesis.  
In astrocytomas elevated TSPO expression was related to high rates of cell proliferation (Miettinen et 
al. 1995; Vlodavsky et al. 2007). When the proliferation of glioma cell lines with different levels of 
PK11195 binding was assessed, the highest rates were observed in cells with highest ability to bind 
the TSPO ligand (Veenman et al. 2004). On the basis of these results, the difference in cell 
proliferation was attributed to differences in TSPO expression neglecting all other cell line specific 
features (Veenman et al. 2004). In another study, TSPO over-expression increased the proliferation 
rates of C6 glioma cells (Rechichi et al. 2008). This increase in cell proliferation was observed in 
stably transfected cells that expressed FLAG-tagged TSPO recombinant protein, but currently it is 
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becoming a standard that stable transfection experiments should be confirmed by reverting the 
phenotype with siRNA mediated silencing to exclude the impact of clonal heterogeneity (King et al. 
2000).  
Numerous other studies demonstrating the effects of TSPO on cell death or proliferation used TSPO 
ligands to manipulate TSPO function (Veenman et al. 2007). It is not sufficiently established whether 
various TSPO ligands do not exert off-target effects and consequently inhibit or stimulate other 
cellular receptors, pumps, transporters or miscellaneous molecules. Similarly, it is not clear to what 
extent their action is antagonistic or agonistic towards TSPO. Although PK11195 was classified as a 
receptor antagonist, it can induce similar effects as Ro5-4864, other TSPO ligand classified as an 
agonist (Le Fur et al. 1983). Furthermore, TSPO ligands influence cell proliferation in a 
concentration-dependent manner with inhibitory effects within the micromolar range and stimulatory 
role at nanomolar concentrations (Corsi et al. 2008).  
We decided to use siRNA-mediated TSPO knock-down to manipulate TSPO expression. The genetic 
depletion of TSPO by siRNA is a more specific approach than the exposure to TSPO ligands and 
allows to avoid
 
problems associated with clonal heterogeneity
 
that could be encountered in studies 
utilising stable transfection. However, the positive findings obtained using pooled siRNAs should be 
ultimately validated with two independent siRNA oligos. 
The efficiency of previously described TSPO knock-down experiments on glioma cell lines was most 
frequently assessed using radioligand binding assays (Chelli et al. 2008; Levin et al. 2005). Following 
antisense TSPO transfection of rat C6 glioma cells, Levin et al. observed more than twofold reduction 
in PK11195 binding between TSPO knock-down clones and control cells and similar differences in 
protein TSPO levels of whole cell extracts (Levin et al. 2005). Transient transfection of human ADF 
astrocytoma cells with TSPO siRNA resulted in 54% decrease of PK11195 binding (Chelli et al. 
2008). Here, the efficiency of TSPO silencing was determined by TSPO protein expression analysis 
with Western blotting and immunofluorescence. 
In this study, disappointingly, silencing of TSPO in glioma cells affected neither glioma cell growth 
nor caused significant alteration in the cell cycle or apoptosis rates, despite the level of knock-down 
surpassing that of most published reports (Chelli et al. 2008; Levin et al. 2005). There are several 
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explanations to the fact that TSPO is linked to advanced disease in tissue samples of human gliomas 
but this is not reflected by the alteration of basic phenotypes in cell culture. Firstly, TSPO function in 
tumourigenesis may only be revealed in vivo. Such effects could be related to immune evasion or 
paracrine signalling, angiogenesis or interactions with tumour stroma and non-neoplastic cells. 
Secondly, although not consistent with the bulk of literature and subcellular localization apart from 
one study with C6 rat glioma cell line (Rechichi et al. 2008), TSPO could be a regulator of glioma cell 
invasiveness or migratory potential rather than linked to apoptosis and/or proliferation. Finally, the 
relationship between TSPO levels and aggressive disease in gliomas may not be causative but 
secondary to some features of advanced disease or related to co-regulation of TSPO expression with 
other genes that strongly impact on glioma biology. For example, increased TSPO levels could be a 
consequence of epigenetic events simultaneously dysregulating other targets since TSPO is subject to 
differential methylation in gliomas (Chapter 3). Further studies are needed to address the 
consequences of TSPO dysregulation in glioma progression in vivo and in vitro but the data presented 
here challenge the notion that TSPO has direct effects on cancer cell apoptosis and proliferation. 
The attractive possibility was that TSPO–driven steroidogenesis impacts on autocrine signalling and 
paracrine interactions between glioma cells and the brain microenvironment (Hoelzinger et al. 2007). 
One of the consequences could be cancer cell immune evasion. Although there is evidence for tumour 
recognition by the immune system, effective immune response does not occur despite the fact that a 
significant proportion of glial tumour bulk consists of immune/microglial cells (Hussain et al. 2006). 
Although microglial cells are present within the tumour niche they fail to express co-stimulatory and 
cytotoxic molecules (Hussain et al. 2006; Takaya et al. 2007). In vitro studies showed that steroids, 
and glucocorticoids in particular, interfere with the microglial expression of molecules regarded as 
essential for an effective immune response (Drew et al. 2000; Li et al. 2007a). Immunosuppressive 
nature of the tumour microenvironment and high expression of TSPO regarded as key steroidogenic 
molecule was consistent with the potential role of the putative TSPO –steroids –microglia axis in 
glioma progression.  
In cells containing the appropriate enzymes, the presence of TSPO in the outer mitochondrial 
membrane was suggested to confer steroidogenic ability (Brown et al. 2000b). Presence of enzymes 
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from the steroid biosynthesis pathway was previously reported in the brain (Mensah-Nyagan et al. 
1999). Rodent and human glioma cells were demonstrated to be able to generate steroid hormone 
precursors but cortisol biosynthesis has not been shown in a glioma cell line model so far (Brown et 
al. 2000a; Brown et al. 2000b). We demonstrated that P450scc and P450c17A1, regarded as key 
steroidogenic enzymes (Pelletier et al. 2001), are expressed in human gliomas and yet no evidence of 
cortisol production by glioma cells in vitro was found. Previously, TSPO role in steroid synthesis was 
studied in cells of an extensively documented steroidogenic function such as adrenal or testicular cells 
(Kelly-Hershkovitz et al. 1998; Krueger et al. 1990; Papadopoulos et al. 1997b; Papadopoulos et al. 
1990). My findings argue against the relevance of corticosteroidogenesis to TSPO role in malignant 
progression. It must be noted however that cells cultured in a monolayer differ from neoplastic cells 
of the tumour in vivo and so differ the conditions they encounter. Consequently, some features of 
neoplastic cells present in the tissue may not be fully recapitulated in vitro. Accordingly, cortisol 
biosynthesis should be re-assessed in vivo in human gliomas but this is very challenging for technical 
and ethical reasons. 
Previous studies postulated a role for TSPO in the apoptotic machinery and linked high TSPO levels 
with poor survival in gliomas. In the preceding chapter it was demonstrated that TSPO levels do not 
predict outcomes in patient with glioma when this is sufficiently controlled for pathological 
characteristics. Consistently, the data presented here argue against an important role for TSPO in the 
proliferation and survival of glioma cells.  
  
155 
 
5 Chapter 5: TSPO binding partners 
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5.1 Introduction 
An important feature of TSPO, localised in the outer mitochondrial membrane, is its physical 
association with other proteins postulated to form the mitochondrial permeability transition pore 
(MPTP), namely ANT and VDAC (McEnery et al. 1992; Zamzami et al. 2001). Creatine kinase and 
cyclophilin D may represent other possible constituents of the MPTP, whereas hexokinase tethered to 
VDAC is believed to have regulatory effects on the pore (Chapter 1, Figure 1.2) (Zamzami et al. 
2001). Mitochondrial membrane permeabilisation in MPTP-dependent manner is believed to be one 
of the key steps in the intrinsic apoptotic pathway (Green et al. 2004; Zamzami et al. 2001). This is 
discussed in detail in Introduction (Chapter 1). 
Apart from their role in apoptosis, MPTP-related proteins have also been suggested to be involved in 
bioenergic metabolism (Campbell et al. 2008). Metabolism of high-grade tumours is altered as 
compared to normal tissues and aerobic glycolysis, characterised by high glucose consumption and 
lactate production, is the main aspect of this metabolic transformation of neoplastic cells (Weinberg et 
al. 2009). Although anaerobic glucose metabolism may help cells to survive periods of repeated or 
prolonged hypoxia, tumour cells rely on glycolysis to provide ATP for their metabolic requirements 
even under aerobic conditions (Warburg effect). It remains controversial why cancer cells degrade 
glucose to lactate even in normoxic conditions. The genetic mechanism behind the metabolic 
transformation of cancer cells is likely executed by transcription factor hypoxia inducible factor 1 
(HIF1) (Kim et al. 2006; Marin-Hernandez et al. 2009). In neoplastic cells HIF1 induces over-
expression of several glycolytic enzymes, including hexokinases. In cancer cells hexokinase is mainly 
bound to VDAC, and thereby, closely linked with mitochondria and MPTP (Mathupala et al. 2009). 
This interaction promotes the enzymatic activity of hexokinase due to protection from product 
inhibition and facilitates access to mitochondria-generated ATP, and, at the same time, has inhibitory 
effects on apoptosis (Flescher 2007).  
Here, the potential significance of the binding and functional partners of TSPO in human gliomas was 
investigated. The distribution of ANT, VDAC1, hexokinase I (HKI) and hexokinase II (HKII) as well 
as their clinicopathological associations in human gliomas were examined.  
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The phenotypic consequences of disrupting mitochondrial membrane hexokinase/ VDAC1 interaction 
with methyl jasmonate (MJ) were tested using an in vitro glioma model. MJ, a member of the 
jasmonates group, is a plant stress hormone that represents a novel class of anti-cancer drugs 
(Flescher 2007; Galluzzi et al. 2008; Goldin et al. 2007). A recent study reported that MJ directly 
binds to hexokinase and detaches it from VDAC1 thereby facilitating apoptosis and also leading to 
ATP depletion (Goldin et al. 2008). MJ can induce apoptotic cell death in lymphoblastic leukaemia, 
melanoma and neuroblastoma as well as prostate, breast, lung and liver cancer cells (Fingrut et al. 
2002; Kim et al. 2004; Rotem et al. 2005; Tong et al. 2008; Yeruva et al. 2008; Yeruva et al. 2006). 
MJ cytotoxicity was shown to be cancer cell specific as it did not affect normal blood lymphocytes, 
breast epithelial cells or non-transformed fibroblasts and keratinocytes (Fingrut et al. 2002; 
Kniazhanski et al. 2008; Rotem et al. 2005; Yeruva et al. 2008). Mice injected with syngeneic EL-4 
lymphoma cells survived longer following treatment with orally administrated MJ than untreated 
animals (Fingrut et al. 2002). Another in vivo study demonstrated that treatment of leukaemia bearing 
mice with MJ and adriamycin (anti-tumour anthracycline antibiotic) prolonged their survival when 
compared to mice treated with either agent alone (Heyfets et al. 2007). So far neither the potential of 
MJ to inhibit growth of human gliomas nor the mechanism of their action on human glioma cells has 
been investigated. 
Finally, the impact of TSPO silencing on the expression of TSPO binding partners as well as 
examined response of TSPO depleted cells to MJ was evaluated. In this model MJ represents a 
mitochondrial stressor promoting mitochondrial outer membrane permeabilisation, which is the 
apoptotic mechanism where TSPO has been long proposed to play a role (Veenman et al. 2007). 
  
158 
 
5.2 Results 
5.2.1 ANT, VDAC1 and hexokinase expression in glioma tissue samples  
5.2.1.1 VDAC1 but not ANT is highly expressed in gliomas  
The immunohistochemical evaluation of ANT and VDAC1 expression was conducted in 81 glioma 
cases. The summary of the clinical characteristics of this patient population is outlined in Table 5.1. 
The detailed clinicopathological characteristics are presented in Table 3.2 in Chapter 3 (cases 1-50, a 
panel previously used to examine TSPO expression) and Table 5.2 (cases 51-81). Kidney was used as 
a positive control for ANT staining and breast samples for VDAC1. The representative images of the 
control stainings are presented in Appendix I. The results of immunohistochemical staining in gliomas 
were scored as described in Materials and Methods. 
 
Histotype (WHO grade) 
Number 
of cases 
Gender 
F/M 
Age in years 
median (range) 
Follow up time in months 
median (range) 
Astrocytomas ( II) 10 1/9 38 (25-56) 38 (10-136) 
Anaplastic astrocytomas (III) 10 5/5 39 (22-61) 35 (16-133) 
Glioblastomas (IV) 41 19/22 57 (32-84) 14 (1-120) 
Oligodendrogliomas (II) 10 5/5 34 (24-49) 44 (11-85) 
Anaplastic 
oligodendrogliomas (III) 
10 7/3 43 (21-69) 42 (14-217) 
Gliomas 81 37/44 46 (21-84) 25 (1-217) 
 
Table 5.1 
Summary of the clinical characteristics of glioma cases analysed by peroxidase 
immunohistochemistry for ANT and VDAC1 expression  
F, female; M, male 
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Case 
ID 
Gender 
Age at diagnosis 
(years) 
Histopathology 
Follow up 
time 
(months) 
Status 
Histotype 
Grade 
(WHO) 
 
51 M 50 A IV 13 dead 
52 M 32 A IV 18 dead 
53 F 57 A IV 14 dead 
54 M 36 A IV 5 dead 
55 M 43 A IV 86 alive 
56 M 60 A IV 41 dead 
57 M 63 A IV 21 dead 
58 F 50 A IV 10 dead 
59 M 66 A IV 17 dead 
60 F 79 A IV 9 dead 
61 F 47 A IV 46 alive 
62 F 53 A IV 22 dead 
63 F 53 A IV 28 dead 
64 F 54 A IV 32 dead 
65 F 43 A IV 10 dead 
66 F 67 A IV 3 dead 
67 M 51 A IV 12 alive 
68 M 84 A IV 2 dead 
69 M 65 A IV 14 dead 
70 M 46 A IV 17 alive 
71 F 63 A IV 10 dead 
72 M 61 A IV 14 alive 
73 M 56 A IV 5 dead 
74 M 76 A IV 1 dead 
75 M 45 A IV 15 alive 
76 F 45 A IV 1 dead 
77 F 65 A IV 11 alive 
78 F 60 A IV 12 alive 
79 M 72 A IV 3 dead 
80 M 52 A IV 24 dead 
81 F 40 A IV 3 dead 
 
Table 5.2  
Clinicopathological characteristics of the patient population (cases 51-81) 
F, female; M, male; A, astrocytoma 
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ANT expression was evaluated using a polyclonal antibody that recognises three protein isoforms 
(ANT1-ANT3). ANT staining was cytoplasmic and ANT positive cells were distributed 
homogenously throughout the tumour tissue. In the majority of cases there was no ANT positivity 
(29.6%) or protein expression was weak (49.4%). In 21% of glioma samples staining was moderate. 
In none of the cases protein expression was intense (Figure 5.1). There was no correlation between 
ANT expression score and tumour grade or histotype.  
 
 
Figure 5.1 
ANT expression in glioma tissue samples 
ANT expression was evaluated using peroxidase immunohistochemistry with goat anti-ANT 
antibody. Images of staining in glioblastoma, case 29 (A) and anaplastic oligodendroglioma, case 46 
(B) are shown. 
Scale bar: 50 µm. 
 
Both astrocytic and oligodendroglial tumours expressed VDAC1 and the staining was uniformly 
cytoplasmic. Intense protein expression was observed in 56.8% of tumour samples. There were 32.1% 
cases showing moderate staining intensity and 11.1% were scored as weakly positive (Figure 5.2).  
There was no correlation between VDAC1 expression level and tumour grade or histotype.  
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Figure 5.2 
VDAC1 expression in glioma tissue samples 
VDAC1 expression was evaluated using peroxidase immunohistochemistry with mouse anti-VDAC1 
antibody. Images of staining in anaplastic astrocytoma, case 11 (A) and anaplastic oligodendroglioma, 
case 46 (B) are shown.Scale bar: 50 µm. 
VDAC1 positive cells are distributed homogenously throughout the tumour tissue. 
 
There was no significant correlation between the immunostaining results for ANT, VDAC1 and 
TSPO in 50 glioma cases stained with all three proteins, suggestive of no expression changes of 
MPTP proteins compensatory to the loss or low expression of other members and no common 
regulation. Figure 5.3 demonstrates the expression distribution of ANT, VDAC1 and TSPO in 
gliomas.  
 
 
Figure 5.3 
ANT, VDAC1 and TSPO expression in gliomas 
Protein expression was evaluated using peroxidase immunohistochemistry in 50 glioma cases. Results 
for each case were classified as negative (less than 5% of cells expressing protein), weak (5-30% of 
cells expressing protein), moderate (more than 30% but less than 60% of cells expressing protein) or 
intense (more than 60% of cells expressing protein) immunostaining. 
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5.2.1.2 Hexokinases 
Expression of both hexokinase isoforms, HKI and HKII, was evaluated in 66 glioma cases out of 81 
cases available for ANT and VDAC1 (6 WHO grade II astrocytomas, 4 anaplastic astrocytomas, 41 
glioblastomas, 7 WHO grade II oligodendrogliomas and 8 anaplastic oligodendrogliomas). The 
summary of the clinical characteristics of gliomas included in the analysis is presented in Table 5.3. 
The detailed clinicopathological characteristics of patients are outlined in Appendix II. 
 
Histotype (WHO grade) 
Number 
of cases 
Gender 
F/M 
Age in years 
median (range) 
Follow up time in months 
median (range) 
Astrocytomas ( II) 6 1/5 36 (25-42) 55 (27-163) 
Anaplastic astrocytomas (III) 4 0/4 37 (33-40) 35 (16-84) 
Glioblastomas (IV) 41 19/22 56 (32-84) 14 (1-120) 
Oligodendrogliomas (II) 7 3/4 35 (27-46) 47 (19-85) 
Anaplastic 
oligodendrogliomas (III) 
8 6/2 47 (34-69) 34 (14-66) 
Gliomas 66 29/37 50 (25-84) 21 (1-163) 
 
Table 5.3 
Summary of the clinical characteristics of glioma cases included in the immunohistochemical 
analysis of hexokinase expression  
F, female; M, male 
 
 
The immunostaining was optimised using breast tissue as a positive control for HKI and colon cancer 
for HKII. The representative results of control reactions are presented in Appendix I.  
Both HKI and HKII staining was cytoplasmic (Figure 5.4 and 5.5). The majority of glioma cases 
examined expressed HKI (69%) and HKII (64%) as shown in Figure 5.6. In glioblastomas HKII 
positivity was particularly intense around areas of necrosis.  
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Figure 5.4  
Hexokinase I expression in glioma tissue samples 
HKI expression was determined using peroxidase immunohistochemistry with mouse anti-HKI 
antibody. Images of staining in glioblastoma, case 23 (A) and anaplastic oligodendroglioma, case 48 
(B) are shown. Scale bar: 50 µm. 
 
 
 
 
 
 
Figure 5.5 
Hexokinase II expression in glioma tissue samples 
HKII expression was determined using peroxidase immunohistochemistry with rabbit anti-HKII 
antibody. Representative images of staining in glioblastoma, case 24 (A) and anaplastic 
oligodendroglioma, case 48 (B) are shown. In glioblastoma (A) the enzyme is not detected in the 
tumour vasculature. 
Scale bar: 50 µm. 
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Figure 5.6  
Expression of HKI and HKII in gliomas 
Expression of HKI and HKII was evaluated using peroxidase immunohistochemistry in 66 glioma 
tissue samples. Results for each case were classified as negative (less than 5% of cells expressing 
protein), weak (5-30% of cells expressing protein), moderate (more than 30% but less than 60% of 
cells expressing protein) or intense (more than 60% of cells expressing protein) immunostaining.    
 
 
There was a positive correlation between the expression levels of both hexokinase isoforms 
(p=0.012). Both hexokinase isoforms were expressed at higher levels in astrocytomas when compared 
to oligodendrogliomas (p=0.0002 for HKI and p=0.046 for HKII). Furthermore, there was a positive 
correlation between astrocytic tumour grade and the expression of HKI and HKII (p=0.00007 for HKI 
and p=0.004 for HKII). There was no correlation between VDAC1 and HKI (p=0.09) or HKII 
(p=0.58) expression, neither between ANT and HKI (p=0.78) or HKII (p=0.43) expression.  
There was a correlation between HKI  and TSPO expression in 35 glioma cases (6 WHO grade II 
astrocytomas, 4 anaplastic astrocytomas, 10 glioblastomas, 7 WHO grade II oligodendrogliomas and 
8 anaplastic oligodendrogliomas) for which the immunostaining against both proteins was available 
(p=0.042). In the same group of tumours HKII did not correlate with TSPO expression (p=1.00). 
5.2.2 TSPO binding partners’ expression and patient survival 
5.2.2.1 The expression of VDAC1 and ANT and patient survival 
For the purpose of survival analysis, glioma tissue samples (n=81) were classified on the basis of 
immunohistochemistry results into high or low expression subgroups. For VDAC1 analysis samples 
of no, weak and moderate staining were grouped together (n=35) and compared against samples with 
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intense staining (n=46). For ANT analysis tumours were dichotomised into those with no ANT 
expression (n= 24) versus tumours showing weak and moderate protein expression (n=57). No other 
division of the samples would ensure balanced sizes of populations to be compared for each protein. 
Neither VDAC1 (p=0.66) nor ANT (p=0.87) expression was associated with patient overall survival 
in log rank analysis. The survival curves are presented in Figure 5.7. Because of a lack of any 
indication for a trend for survival association these were not carried forward to multivariate analysis.  
 
Figure 5.7 
VDAC1 and ANT expression and patient survival 
Kaplan-Meier estimates of overall survival for gliomas (n=81) according to VDAC1 (A) or ANT (B) 
expression. For VDAC1/ survival analysis samples of no, weak and moderate staining were grouped 
together (n=35) and compared against samples with intense staining (n=46). For ANT/ survival 
analysis tumours were dichotomised into those with no ANT expression (n= 24) versus tumours 
showing weak and moderate protein expression (n=57). P values in the log rank test. 
166 
 
5.2.2.2 The expression of hexokinases and patient survival 
Results of the statistical analysis of the correlation between hexokinases (either HKI or HKII) 
expression and survival when 4 groups of patients (corresponding to immunoscores of 0, 1, 2 and 3) 
were distinguished are presented in Table 5.4 and Figure 5.8 and this is not discussed further.  
In the statistical analysis presented in detail below, patients were dichotomised into 2 groups, either 
expressing hexokinase (immunohistochemical scores 1, 2 and 3) or negative (score 0).  
 
 
Protein 
 
Analysis 
 
Covariate(s) 
 
HR 
 
95%CI 
 
p value 
      
HKI log rank 
 
- - - 1.23x10
-4
 
 multivariate Cox regression HKI 1.447 0.855-2.449 0.168 
  
 
histotype 0.692 0.066-7.217 0.758 
  grade 8.739 1.457-52.401 0.018 
      
HKII log rank 
 
- - - 0.002 
 multivariate Cox regression 
 
HKII 1.131 0.733-1.746 0.579 
  
 
histotype 0.731 0.067-7.946 0.797 
  grade 9.614 1.543-59.890 0.015 
 
Table 5.4 
Expression of hexokinases as four categories and patient survival – log rank and multivariate 
Cox regression analysis 
Expression of hexokinase was evaluated in gliomas (n=66) using peroxidase immunohistochemistry. 
Results for each case were classified as negative (less than 5% of cells expressing protein), weak (5-
30% of cells expressing protein), moderate (more than 30% but less than 60% of cells expressing 
protein) or intense (more than 60% of cells expressing protein) immunostaining.  
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Figure 5.8 
Hexokinase expression and patient survival 
Kaplan-Meier estimates of overall survival for gliomas, n=66, according to HKI (A) or HKII (B) 
expression. Hexokinase expression was evaluated using peroxidase immunohistochemistry (negative, 
weak, moderate or intense immunostaining). There were no cases with intense HKI staining. P values 
in the log rank test. HKI, hexokinase I; HKII, hexokinase II 
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5.2.2.2.1 Hexokinase I 
Absence of immunohistochemical expression of HKI predicts longer survival in gliomas (n=66) when 
assessed with log rank test (p=0.00004), Figure 5.9A. However, HKI expression did not reach 
significance in a multivariate survival analysis when grade and histotype were used as covariates. 
Results of multivariate Cox regression analysis are presented in Table 5.5.  
Lack of HKI expression was also associated with better overall patient survival when analysed using 
log rank test in the subgroup of astrocytomas (n=51, p=0.017).  
5.2.2.2.2 Hexokinase II 
Immunohistochemical negativity for HKII correlates with an increase in overall patient survival in 
gliomas (n=66) when assessed with log rank test (p=0.0002), Figure 5.9B. HKII expression is not a 
predictive factor for longer survival in a multivariate model with histotype and grade as covariates as 
outlined in Table 5.5.  
HKII expression predicts worse patient survival in the subgroup of astrocytomas (n=51) when 
survival distributions are compared using log rank test (p=0.004).  
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Figure 5.9  
Hexokinase expression and patient survival 
Kaplan-Meier estimates of overall survival for gliomas (n=66) according to hexokinase I (A) or 
hexokinase II (B) expression. Hexokinase expression was evaluated using immunohistochemistry 
(negative, weak, moderate or intense immunostaining). Tumours were dichotomised into those with 
no hexokinase expression versus tumours showing weak, moderate or intense protein expression. P 
values in the log rank test.  
HKI, hexokinase I; HKII, hexokinase II 
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Marker Covariates HR 95%CI p value 
HKI HKI 0.684 0.367-1.274 0.231 
 grade 8.778 1.420-54.286 0.019 
 histotype 0.667 0.063-7.0.23 0.736 
HKII HKII 0.881 0.548-1.417 0.601 
 grade 9.407 1.484-59.613 0.017 
 histotype 0.721 0.066-7.837 0.788 
 
Table 5.5 
Expression of hexokinases and patient survival - results of multivariate Cox regression analysis  
Hexokinase expression was evaluated in gliomas, n=66, using immunohistochemistry (negative, 
weak, moderate or intense immunostaining). Tumours were dichotomised into those with no 
hexokinase expression versus tumours showing weak, moderate or intense protein expression. 
HKI, hexokinase I; HKII, hexokinase II; HR, hazard ratio; CI, confidence interval 
 
5.2.2.2.3 Validation of the prognostic significance of hexokinases in independent microarray 
data sets 
The reproducibility of the associations between HKI and HKII expression and patient survival was 
validated using three publically available glioma microarray data sets (GSE4271 and GSE4412 
deposited in GEO and another data set from The Cancer Genome Atlas Data Portal) (Freije et al. 
2004; Phillips et al. 2006; Verhaak et al. 2010). For the purpose of the statistical analysis the median 
expression of HKI and HKII within each population was used to dichotomise the samples into high- 
and low expression groups.  
 
5.2.2.2.3.1 High-grade gliomas (GSE4412) 
There was no association between HKI and HKII expression and patient survival in 67 high-grade 
gliomas from GSE4412 (Freije et al. 2004). The results are presented in Table 5.6. 
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Marker 
 
Cases 
analysed 
 
Analysis 
 
Covariate(s) 
 
HR 
 
95%CI 
 
p value 
       
HKI high-grade 
gliomas 
(n=67) 
log rank 
 
- - - 0.164 
multivariate Cox 
regression 
HKI 0.695 0.382-1.264 0.233 
histotype 0.294 0.058-1.480 0.138 
grade 0.113 0.024-0.517 0.005 
      
high-grade 
astrocytomas 
(n=58) 
log rank 
 
- - - 0.105 
multivariate Cox 
regression 
HKI 0.671 0.352-1.278 0.225 
grade 0.085 0.012-0.632 0.016 
       
HKII high-grade 
gliomas 
(n=67) 
log rank 
 
- - - 0.439 
multivariate Cox 
regression 
HKII 1.283 0.696-2.366 0.424 
grade 0.094 0.020-0.445 0.003 
histotype 0.258 0.051-1.291 0.099 
      
high-grade 
astrocytomas 
(n=58) 
log rank 
 
- - - 0.372 
multivariate Cox 
regression 
HKII 1.090 0.575-2.068 0.791 
grade 0.077 0.01-0.580 0.013 
 
Table 5.6 
Expression of hexokinases and patient survival in high-grade glioma series from GSE4412 
microarray data set 
The association between hexokinase expression and patient survival was evaluated in high-grade 
gliomas (n=67) and in a subgroup of high-grade astrocytomas (n=58). Median hexokinase expression 
within each population was used to dichotomise the samples into low and high expression groups.  
HKI, hexokinase I; HKII, hexokinase II; HR, hazard ratio; CI, confidence interval 
 
5.2.2.2.3.2 High-grade astrocytomas (GSE4271) 
The survival analysis of 77 primary high-grade astrocytomas (Phillips et al. 2006) showed 
associations between hexokinase expression (HKI or HKII) and clinical outcomes.  
In patients with astrocytomas low HKI expression predicted shorter overall survival using log rank 
test (p=0.003), Figure 5.10A. There was a trend (HR 1.656, 95%CI 0.971-2.824, p=0.064) for shorter 
survival of patients with low HKI expression in the multivariate Cox regression model with tumour 
grade as a covariate (HR 0.378, 95%CI 0.186-0.766, p=0.007).  
172 
 
High HKII expression predicted poor patient survival in astrocytomas as assessed using log rank test 
(p=0.012). The Kaplan-Meier survival curves are presented in Figure 5.10B. The association did not 
reach significance in the multivariate Cox regression analysis (HR 0.756, 95%CI 0.437-1.308, 
p=0.317) with grade as a covariate (HR 0.363, 95%CI 0.174-0.757, p=0.007).  
 
Figure 5.10  
Hexokinase expression and patient survival in astrocytoma series from GSE4271 microarray 
data set 
Kaplan-Meier estimates of overall survival for astrocytomas (n=77) according to hexokinase I (A) or 
hexokinase II (B) expression. Median hexokinase expression within each population was used to 
dichotomise the samples into low and high expression groups. P values in the log rank test.  
HKI, hexokinase I; HKII, hexokinase II 
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5.2.2.2.3.3 Glioblastoma data set from The Cancer Genome Atlas (TCGA) Data Portal 
High HKII expression was associated with shorter overall patient survival in a large cohort of 186 
glioblastomas when assessed using log rank test (p=0.036) and it is important to stress that this 
population is homogenous for histotype and grade (Verhaak et al. 2010). HKI expression was not 
associated with clinical outcome (log rank test, p=0.983). The Kaplan-Meier survival curves are 
presented in Figure 5.11. 
 
 
Figure 5.11 
Expression of hexokinases and patient survival in glioblastoma series from The Cancer Genome 
Atlas (TCGA) Data Portal 
Kaplan-Meier estimates of overall survival for glioblastomas (n=186) according to hexokinase I (A) 
or hexokinase II (B) expression. Median hexokinase expression within each population was used to 
dichotomise the samples into low and high expression groups. P values in the log rank test.  
HKI, hexokinase I; HKII, hexokinase II 
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Although the re-analysis of two publically available microarray data sets comprising gliomas and 
astrocytomas of various grades (GSE4412 and GSE4271) did not provide evidence for the expression 
of hexokinases (neither HKI nor HKII) as an independent prognostic factor, an analysis of a large, 
homogenous group of tumours of the same grade and histotype demonstrated that low HKII 
expression predicts longer survival. It is possible that HKII did not reach significance in multivariate 
survival analyses in the GSE4271 and GSE4412 data sets and in my immunohistochemical analysis as 
the populations were much smaller than 186 patients of the TCGA data set.  
5.2.3 In vitro effects of hexokinase/ VDAC1 complex targeting  
5.2.3.1 Hexokinase/ VDAC1 expression in an in vitro glioma model 
Expression of hexokinases (HKI and HKII) and VDAC1 in a panel of human glioma cell lines (U-
87MG, GaMG, DBTRG-05MG, 42-MG-BA and SNB-19) was evaluated using Western blotting. All 
examined lines expressed VDAC1, HKI and HKII (Figure 5.12) with no noticeable variation in 
protein expression levels. All subsequent experiments were conducted using U-87MG or GaMG cells.  
The mitochondrial localization of the proteins in U-87MG cells was confirmed using 
immunofluorescence (Figure 5.13). 
 
Figure 5.12 
Expression of hexokinases and VDAC1 in a panel of human glioma cell lines 
48 hours after seeding (before cells exceeded 80% confluence) protein was extracted from U-87MG, 
GaMG, DBTRG-05MG, 42-MG-BA and SNB-19 cells. Lysates were analysed by Western blotting 
with mouse anti-HKI, rabbit anti-HKII or mouse anti-VDAC1 antibodies. Mouse anti-β-actin and 
rabbit anti-β-tubulin antibodies were used as protein loading control. 
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A 
 
B 
 
Figure 5.13 
Localization of hexokinases and VDAC1 in U-87MG human glioma cells analysed by 
immunofluorescence 
HKI, HKII (A) and VDAC1 (B) are localised within cell mitochondria as determined by overlay of 
images. 
U-87MG cells were cultured on coverslips, stained using mitochondrion specific probe (MitoTracker, 
red) and fixed. Mouse anti-HKI, rabbit anti-HKII or mouse anti-VDAC1 antibody was followed by 
appropriate Alexa Fluor 488 (green)–conjugated secondary antibody. Cell nuclei were visualised 
using DAPI (blue).  
Scale bars: A - 75 µm, B – 30 µm.  
 
5.2.3.2 Targeting hexokinase/VDAC1 complex in vitro  
5.2.3.2.1 Decreased human glioma cell viability following exposure to MJ 
As demonstrated above hexokinases, and especially HKII, have prognostic significance in human 
gliomas as the only MPTP-related markers examined. Briefly, high HKII expression correlated in a 
univariate model with poorer outcomes in the 66 tumours examined with immunohistochemistry in 
the current study and was an unfavourable prognostic factor in 186 glioblastomas from the TCGA 
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microarray data set. Consequently, we hypothesised that targeting the hexokinase/VDAC1 complex 
might exert growth inhibitory and/or pro-apoptotic effects on glioma cell lines in vitro.  
Initially, the growth of GaMG cells in baseline conditions following the seeding of various cell 
numbers was examined to find a cell density ensuring a log phase of cell growth throughout the 
timescale of subsequent experiments. 4000 cells per well of a 96-well plate was determined as the 
optimal cell number (Figure 5.14). The appropriate seeding density for U-87MG was determined in 
the previous Chapter (Figure 4.7).  
The effect of MJ on U-87MG and GaMG cell viability was evaluated with a range of drug 
concentrations that were shown previously to have anti-tumour effects on other cancer cells in vitro 
(Fingrut et al. 2002; Tong et al. 2008; Yeruva et al. 2008). The previously reported cell line IC50 
values after 24-hour exposure to MJ were 1.7-3.3 mM for cervical, 1.49-2.0mM for breast, 1.46 mM 
for pancreatic cancer and 1.35-1.39 mM for neuroblastoma (Heyfets et al. 2007; Kniazhanski et al. 
2008; Tong et al. 2008; Yeruva et al. 2008). As shown in Figure 5.15, MJ inhibited the viability of 
glioma cells in a dose-dependent manner. The IC50 value at 48 hours was 1.5 mM for both cell lines 
(Figure 5.16).  
 
Figure 5.14 
GaMG cell growth in baseline conditions over 5-day period  
4000 cells per well of a 96-well plate was determined as the optimal cell density ensuring a log phase 
of cell growth throughout the timescale of subsequent experiments. 
GaMG cells were plated into wells of a 96-well plate at indicated densities in three replicates. At each 
of the time-points cells were fixed using 10% TCA and quantitated by SRB assay as described in 
Materials and Methods. The experiment was conducted three times, +/- SEM.  
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Figure 5.15 
Decrease of glioma cell viability after exposure to MJ 
4000 of glioma cells (U-87MG or GaMG) per well of a 96-well plate were plated in three replicates 
and allowed to attach. Then the medium was removed and replaced with medium containing various 
concentrations of MJ. The untreated cells received vehicle (<0.125% DMSO). After 24-hour exposure 
media were removed and replaced with fresh medium. At each of the time-points cells were fixed 
using 10% TCA and quantitated by SRB assay as described in Materials and Methods. The 
experiment was conducted three times, +/- SEM. MJ, methyl jasmonate 
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Figure 5.16 
The 50% inhibitory concentration (IC50) of MJ in glioma cells 
4000 of glioma cells (U-87MG or GaMG) per well of a 96-well plate were plated in three replicates 
and allowed to attach. Then the medium was removed and replaced with medium containing 0.5 mM, 
1.0 mM, 1.5 mM, 2.0 mM, 2.5 mM or 3.0 mM MJ. The untreated cells received medium containing 
vehicle (<0.125% DMSO). After 24-hour exposure treatment media were removed and replaced with 
fresh medium. Cell growth was determined with SRB assay following 48 hours of drug exposure. The 
absorbance relative to untreated cells was designated as surviving fraction. The experiment was 
conducted three times, +/- SEM. MJ, methyl jasmonate 
 
5.2.3.2.2 MJ inhibits the clonogenic capacity of human glioma cells 
Clonogenic assay was used to determine the effect of MJ on colony forming ability of glioma cells. 
The clonogenic potential of U-87MG cells after exposure to MJ was diminished in a dose-dependent 
manner as shown in Figure 5.17. Number of colonies formed by cells plated after 24-hour exposure to 
1.5 mM MJ (IC50 in 48 hours growth assay) was reduced to 73.3% relative to the number of colonies 
formed by vehicle treated cells (p=0.013). Furthermore, significantly less colonies were formed by 
cells treated with 2.0 mM and 2.5 mM MJ than by untreated cells (p=0.0067 for 2.0 mM and 
p<0.00001 for 2.5 mM MJ). 
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Figure 5.17 
Inhibition of the clonogenic capacity of U-87MG cells by MJ as determined using clonogenic 
assay  
After 24-hour exposure to various concentrations of MJ or vehicle (<0.125% DMSO) U-87MG cells 
were replated at 500 cells per well of a 6-well plate in three replicates and cultured. After 14 days 
cells were fixed with methanol, stained and the number of colonies formed by more than 50 cells was 
determined for each condition as described in Materials and Methods. Columns represent the 
surviving fraction relative to vehicle treated cells (0 mM MJ). The experiment was conducted three 
times, +/- SEM. * p<0.05, ** p<0.01. MJ, methyl jasmonate 
 
5.2.3.2.3 Features of G2/M cell cycle arrest after treatment with MJ  
MJ administration was previously shown to affect cancer cell progression through cell cycle. It was 
reported that exposure of breast cancer and neuroblastoma cells to MJ caused cell cycle arrest at 
G0/G1phase (Tong et al. 2008; Yeruva et al. 2008) whereas in non-small cell lung carcinoma 
(NSCLC) there was cell cycle arrest at G2/M (Yeruva et al. 2006).  
Here, the 24-hour exposure of U-87MG glioma cells to MJ induced a dose-dependent increase in the 
proportion of cells in G2/M phase of the cell cycle as compared to control cells (Figure 5.18). The 
increase was statistically significant for concentrations equal and higher than 1.0 mM MJ (maximal p 
value <0.04).  
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Figure 5.18 
Features of G2/M cell cycle arrest after treatment with MJ as assessed using propidium iodide 
staining and flow cytometry analysis 
1.2 x 10
5
 U-87MG cells per well of a 6-well plate were plated in three replicates and allowed to 
attach. After 24 hours the medium was removed and replaced by medium containing various 
concentrations of MJ. The untreated cells received vehicle (<0.125% DMSO). Following 24-hour 
exposure to treatment media both floating and adherent cells were collected, fixed, stained with 
propidium iodide and analysed by flow cytometry as described in Materials and Methods. The 
experiment was conducted three times, +/- SEM. * p<0.05; ** p<0.01; MJ, methyl jasmonate 
 
5.2.3.2.4 Alterations in the expression of apoptosis-related proteins following MJ exposure 
Human apoptosis proteome array spotted with 35 relevant capture antibodies was used to 
simultaneously determine the effect of MJ exposure on the relative levels of a panel of apoptosis-
related proteins. The results between arrays challenged with lysates from U-87MG cells treated for 24 
hours with 1.5 mM MJ against vehicle treated cell lysates were compared. Figure 5.19 presents the 
markers differentially expressed following MJ exposure with a 1.5-fold cut-off.  
Expression levels of claspin, paraoxonase 2 (PON2), survivin and tumour necrosis factor related 
apoptosis inducing ligand receptor 1/death receptor 4 (TRAILR1/ DR4) were reduced, whereas 
catalase, cellular inhibitor of apoptosis protein 2 (cIAP-2), cleaved caspase-3, heme oxygenase 2 
(HO-2), heat shock protein 27kDa (HSP27), phospho-p53, phospho-Rad17 and Smac/ DIABLO were 
increased after treatment with MJ. The average pixel densities for all proteins are provided in 
Appendix III. 
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Figure 5.19 
Alterations in expression of apoptosis-related proteins following MJ exposure 
Relative expression of proteins was reduced (A) or increased (B) following 24-hour treatment with 
1.5mM MJ as determined using a 1.5-fold cut-off. 
U-87MG cells were treated for 24 hours with medium containing 1.5 mM MJ. The untreated cells 
received medium containing vehicle (<0.125% DMSO). Following treatment cells were lysed and the 
alterations in relative expression of apoptosis-related proteins in the lysates were determined as 
described in Materials and Methods. MJ, methyl jasmonate  
 
To validate the assay results and further investigate potential mediators of the apoptotic function of 
MJ, survivin and cleaved caspase-3 levels were analysed by Western blotting following U-87MG or 
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GaMG cells exposure to a range of MJ concentrations (Figure 5.20 and Figure 5.21).  Consistently 
with the proteome array, a MJ-dependent survivin down-regulation and an increase in caspase-3 
cleavage, the latter indicative of MJ induced apoptosis, were confirmed. 
 
 
Figure 5.20 
Survivin expression following 24-hour exposure to MJ 
Glioma cells (U-87MG and GaMG) were lysed following exposure to a range of MJ concentrations 
and the lysates were analysed by Western blotting for survivin expression (A). Intensity of the signal 
was determined using densitometry and normalised with β-actin (B). 
 
 
Figure 5.21 
Cleaved caspase-3 expression following 24-hour exposure to MJ 
U-87MG cells were lysed following exposure to a range of MJ concentrations and the lysates 
analysed by Western blotting for cleaved caspase-3 expression (A). Intensity of the signal was 
determined using densitometry and normalised with β-actin (B). 
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5.2.4 TSPO silencing effects on the expression of VDAC1 and hexokinases and cell death 
induced by hexokinase/ VDAC1 complex targeting 
5.2.4.1 TSPO silencing has no impact on VDAC1 and hexokinases levels in vitro 
TSPO was reported to physically interact with VDAC1 and ANT (McEnery et al. 1992). TSPO 
depletion could potentially modulate expression of the MPTP components for example due to 
compensatory effects related to loss of MPTP function. To test this hypothesis, TSPO was targeted 
using siRNA oligos as described in Materials and Methods. Here, the impact of TSPO silencing on 
expression of TSPO binding partners was evaluated. TSPO knock-down did not alter VDAC1 and 
hexokinase expression as determined using Western blotting and immunofluorescence (Figure 5.22) 
and this is consistent with the lack of correlation between VDAC1 and TSPO immunostaining results 
in a panel of glioma tissue samples. 
 
 
Figure 5.22 
VDAC1 and hexokinase expression remains unaffected following TSPO silencing 
U-87MG cells
 
were mock transfected (MOCK), transfected with non-targeting siRNA (NT) or 
transfected with TSPO Smart Pool siRNA (siTSPO) as described in Materials and Methods. Cells 
were harvested 72 hours after transfection and lysates were analysed using Western blotting for 
VDAC1, HKI, HKII or TSPO expression. β-actin and HSP60 were used as protein loading control. 
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5.2.4.2  TSPO knock-down does not alter response to MJ 
Following TSPO siRNA transfection, U-87MG cells were exposed to MJ that represents a 
mitochondrial stressor potentially promoting outer mitochondrial membrane permeabilisation. 
Treatment with MJ might be more specific to the proposed in literature TSPO role in apoptosis than 
stimuli used in the previous chapter (serum deprivation and TMZ exposure). 
Again, there was no difference in the response to MJ treatment between cells with silenced TSPO and 
control cells (Figure 5.23). 
Figure 5.23 
TSPO silencing does not alter response to MJ 
Following TSPO siRNA knock-down (MOCK, NT or TSPO Smart Pool siRNA) 4000 U-87MG cells 
per well of a 96-well plate were plated in three replicates. After 24 hours the medium was removed 
and replaced with medium containing 1.0 mM, 1.5 mM or 2.0 mM MJ. The untreated cells received 
medium containing vehicle (<0.125% DMSO). At each of the time-points cells were fixed using 10% 
TCA and quantitated by SRB assay as described in Materials and Methods. The absorbance relative to 
untreated cells was designated as surviving fraction, +/- SEM. 
MOCK, mock transfected cells; NT, non-targeting siRNA transfected cells; siTSPO, TSPO Smart 
Pool siRNA transfected cells  
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5.3 Discussion 
Initially, in this chapter the expression and clinicopathological correlations of proteins associated with 
TSPO were evaluated. The physical interactions of TSPO with VDAC1 and ANT and the formation 
of the hexokinase/ VDAC1 complex have been previously documented (Goldin et al. 2008; McEnery 
et al. 1992). However, the composition and exact stoichiometry of the MPTP is not completely 
established. In the present study there was no correlation between TSPO, VDAC1 and ANT 
expression in glioma tissue samples. Consistently with the lack of correlation in tissue samples, TSPO 
silencing in U-87MG cells did not alter expression of VDAC1.  
In the majority of glioma cases ANT expression assessed using immunohistochemistry was low or 
undetectable. Although this could suggest that ANT loss is implicated in glioma tumourigenesis, 
preserved ANT expression did not correlate with patient survival arguing against ANT significance in 
this neoplasia. To the best of my knowledge, ANT expression has not been evaluated in human 
gliomas previously. The results presented here are arguably limited by the use of an antibody that 
recognises three ANT isoforms (ANT1, ANT2 and ANT3), as it is not possible to determine which 
ANT isoform predominates. On the other hand lack of immunohistochemical positivity allows to 
exclude expression of all three isoforms.  
The immunohistochemical analysis of glioma tissue samples showed that VDAC1 is highly expressed 
in oligodendroglial and astrocytic tumours of low and high grade. VDAC1 expression, similarly to 
ANT, did not predict patient survival. While VDAC1 did not correlate with clinicopathological 
features in the present study, VDAC1 over-expression was previously demonstrated using in vitro 
models to be associated with apoptotic cell death. It was postulated that the apoptotic cell death of 
cells expressing high levels of VDAC1can be prevented when VDAC1 interacts with hexokinase 
(Zaid et al. 2005).    
Although high rate of glycolysis is recognised as an unquestionable feature of high-grade glial 
tumours (Mangiardi et al. 1990), there is only a very limited data available on glycolytic enzymes 
expression in these tumours. Immunohistochemical analysis of HKI and HKII was previously 
performed on tissue samples from 24 high-grade astrocytomas (11 tumours at their initial presentation 
and 13 samples from recurrent tumours) (Charnley et al. 2008). All tumour samples obtained at the 
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initial presentation (1 anaplastic astrocytoma and 10 glioblastomas) expressed HKII with 63.6% of 
cases showing HKII positivity in 10-50% of neoplastic cells. In 63.6% of samples none or less than 
10% of tumour cells expressed HKI. The main focus of that study was to evaluate correlation between 
glycolytic enzymes expression and glucose metabolism measured using [
18
F]fluorodeoxyglucose 
positron emission tomography ([
18
F]FDG-PET). No relationship between results of [
18
F]FDG-PET 
imaging and expression of hexokinases was found (Charnley et al. 2008). However, the study had a 
number of limitations including low number of tumour samples and inclusion of samples obtained 
during biopsies that are frequently not representative of the lesion.  
Results of immunohistochemical evaluation of the expression of hexokinases in 66 glioma samples 
presented here show that the key glycolytic enzymes are frequently expressed in these brain tumours 
and their levels increase with tumour grade. Furthermore, the expression of hexokinases was 
associated with worse patient prognosis in a univariate survival analysis. Importantly, the prognostic 
significance of HKII but not HKI has been confirmed in the survival analysis of large cohort of 
glioblastoma patients (186 cases) from publically available microarray data set (Verhaak et al. 2010), 
demonstrating a potential prognostic significance independent of tumour grade and histology in this 
homogenous patients population.  
The hexokinase/ VDAC1 interaction may be a mechanism that allows cells over-expressing VDAC1 
to evade apoptotic cell death. Having demonstrated that human glioma cells express mitochondrial 
hexokinase and VDAC1, methyl jasmonate (MJ) was used to disrupt the hexokinase/VDAC1 
interaction in vitro.  
The susceptibility of cells to MJ and the mechanisms of response were reported to be cancer cell type 
specific and has not been investigated in the human glioma cells before (Davies et al. 2009; Fingrut et 
al. 2002). The mechanism of MJ action on various tumour cells (neuroblastoma, breast and lung 
cancer, leukaemia) was shown to include a range of apoptotic, cell cycle-related, mitochondrial and 
metabolic effects. It was previously reported that exposure of breast cancer and neuroblastoma cells to 
MJ caused cell cycle arrest at G0/G1phase (Tong et al. 2008; Yeruva et al. 2008) whereas in NSCLC 
there was cell cycle arrest at G2/M (Yeruva et al. 2006). MJ treatment of neuroblastoma cells resulted 
in down-regulation of proliferating cell nuclear antigen (PCNA) and apoptotic cell death with a 
187 
 
decrease in anti-apoptotic X-linked inhibitor of apoptosis protein (XIAP) and survivin expression 
(Tong et al. 2008). In breast cancer cells MJ activated the extrinsic (increased expression of TNF 
receptor 1, activation of mitogen activated protein kinase, MAPK and caspase-8) and intrinsic 
(decrease of the mitochondrial membrane potential and activation of caspase-3) apoptotic pathways 
(Yeruva et al. 2008). Further, in lung adenocarcinoma MJ induced pro-apoptotic Bax and Bcl-XS and 
activated caspase-3 via reactive oxygen species production (Kim et al. 2004). Finally, in leukaemia 
cells MJ caused mitochondrial membrane depolarisation, production of mitochondrial superoxide and 
activation of MAPK pathway (Ishii et al. 2004; Rotem et al. 2003). Several of these effects, including 
apoptosis, disturbed mitochondrial potential, oxidative changes and mitochondrial metabolism 
perturbations, are consistent with the impact of MJ on MPTP and mitochondria but other targets 
cannot be excluded. 
In this project it was demonstrated that the anti-survival mechanisms of MJ involve features of cell 
cycle arrest at G2/M phase (similar to NSCLC model) (Yeruva et al. 2006), apoptosis demonstrated 
by increased caspase-3 cleavage, and down-regulation of survivin that might impact on both cell cycle 
and apoptosis.  
Survivin is a member of the family of inhibitor of apoptosis proteins (IAP). Survivin is over-
expressed in most human neoplasias including colorectal, breast and ovarian cancers as well as brain 
tumours (Athanassiadou et al. 2008; Kawasaki et al. 1998; Kennedy et al. 2003; Xie et al. 2006; Zhen 
et al. 2005). Interestingly, survivin transcript was identified among the top four mRNAs uniformly up-
regulated in human cancers when compared to corresponding non-neoplastic tissue (Velculescu et al. 
1999). The main functions of survivin include the role of the nuclear survivin pool in the regulation of 
mitosis, whereas the cytoplasmic pool is involved in inhibition of apoptosis. Survivin expression is 
higher in gliomas than in normal brain and increases with tumour grade (Kogiku et al. 2008; Zhen et 
al. 2005). In gliomas, similarly to other neoplasms, high survivin expression was associated with poor 
patient prognosis (Kogiku et al. 2008; Saito et al. 2007; Shirai et al. 2009; Uematsu et al. 2005). (Xie 
et al. 2006). In an in vitro model, down-regulation of survivin enhanced radiosensitivity in U251MG 
and D54MG human glioma cells (Saito et al. 2008). 
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These data demonstrate that survivin is a potential target for the treatment of gliomas. Targeting 
hexokinase/VDAC1 interaction that results in survivin down-regulation accompanied by decreased 
cell survival, as demonstrated in two human glioma cell lines, represents a promising strategy for 
development of adjunctive brain tumour therapy and warrants further investigation.  
MJ exposure represents a pro-apoptotic stimulus that targets interactions of mitochondrial proteins 
and probably promotes mitochondrial outer membrane permeabilisation (Flescher 2007). As such, MJ 
is highly relevant to the proposed in literature role for TSPO in apoptosis. However, the potential of 
MJ to induce apoptotic cell death was not altered in cells following TSPO knock-down. This finding, 
in conjunction with data from previous chapter on basal, temozolomide- and serum withdrawal- 
stimulated cell death in TSPO silenced cells, again argues against a direct involvement of TSPO in 
apoptosis. This reiterates the conclusion from the previous chapter that TSPO is unlikely an important 
therapeutic target in gliomas. 
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6 Chapter 6: Final discussion 
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6.1 Synopsis of major findings 
The major hypotheses behind this study were that TSPO up-regulation is associated with disease 
progression and poor clinical outcomes in gliomas, and this is related to TSPO role in the proliferation 
and apoptosis of neoplastic cells. 
TSPO expression was evaluated using immunohistochemistry in astrocytic and oligodendroglial 
tumours. The results presented here confirmed the previously reported high TSPO levels in 
astrocytomas and the correlation between TSPO expression and astrocytic tumour grade (Miettinen et 
al. 1995; Vlodavsky et al. 2007). Conversely, the analysis of oligodendrogliomas showed that the 
expression of TSPO is low and not related to tumour grade. This provides novel evidence that TSPO 
expression delineates these two histotypes. The difference in TSPO protein expression between 
astrocytic and oligodendroglial tumours was further validated at mRNA level using publically 
available independent microarray data sets. TSPO expression was not an independent prognostic 
factor in any of the histotypes examined in neither the immunohistochemical study nor in the analysis 
of microarray data sets. 
The work presented here is the first report indicating that TSPO is a subject of epigenetic regulation.  
It is demonstrated in this project that low TSPO expression in oligodendrogliomas is associated with 
frequent promoter methylation, whereas in astrocytomas, where TSPO is expressed at high levels, the 
promoter typically remains unmethylated. 
The evaluation of the extent of tumour infiltrating microglia and co-localization studies in 
glioblastoma tissue samples showed that TSPO expression is a feature of glioma cells rather than 
microglia. This is in agreement with previously published studies in astrocytomas where TSPO 
expression was attributed to neoplastic cells (Miettinen et al. 1995; Takaya et al. 2007; Vlodavsky et 
al. 2007).  
In the present study the extent of microglial infiltrate increased with grade of astrocytic tumours and 
remained low in oligodendrogliomas irrespective of tumour grade. 
Three main functions of TSPO as suggested by literature were considered in our in vitro phenotypic 
studies: i) role in apoptotic cell death, ii) proliferation and iii) steroidogenesis. siRNA mediated TSPO 
knock-down had no effects on the rates of apoptosis and proliferation in baseline conditions nor 
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following serum starvation or exposure to temozolomide. Expression of steroidogenic markers was 
shown at the protein level in glioma tissue samples, where this correlated with tumour grade, and in 
glioma cells in vitro. However, in the standard tissue culture conditions, the expression of 
steroidogenic molecules was not associated with cortisol synthesis. 
Immunohistochemical analysis of TSPO binding partners showed that majority of tumours examined 
express VDAC1, whereas ANT was frequently undetectable or expressed at low levels, but none of 
these markers was associated with grade, histotype or clinical outcome.  
The interaction between VDAC1 and hexokinase is crucial for the stability of the outer mitochondrial 
membrane and efficient bioenergic metabolism of tumour cells (Pedersen 2008). Using 
immunohistochemistry, we demonstrated that hexokinases are expressed in gliomas and that their up-
regulation is related to poor patient outcome and disease progression. The disruption of the 
hexokinase/ VDAC1 interaction in vitro resulted in the inhibition of cellular proliferation (G2/M cell 
cycle arrest) and apoptotic changes (altered levels of survivin and cleaved caspase-3).  
6.2 Contribution to the field 
6.2.1 TSPO and its binding partners 
TSPO has been long proposed to be linked with apoptotic cell death due to its association with the 
MPTP complex (Anholt et al. 1986; McEnery et al. 1992; Zamzami et al. 2001). On the other hand, 
the literature describing the effects of TSPO on cell death is very conflicting and includes reports of 
both anti- and pro-apoptotic function (Levin et al. 2005; Rechichi et al. 2008). In this study we found 
no evidence for a role of TSPO in apoptosis and proliferation in glioma cells in baseline tissue culture 
conditions, nor following exposure to several cellular stressors. This is consistent with recent studies 
using MPTP-members genetic knock-out models demonstrating that MPTP proteins are not 
indispensable for apoptosis (Baines et al. 2007; Kokoszka et al. 2004). Such a model is not available 
for TSPO as Tspo knock-out animals displayed early embryonic lethality precluding further analysis 
(Papadopoulos et al. 1997a). Potentially this could be re-attempted on a different genetic background 
or with novel technologies such as conditional knock-out as the experiment dates back to before 1997 
and no experimental details are provided.   
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Furthermore, consistent with the lack of pronounced in vitro effects, no evidence for a prognostic role 
of TSPO expression in gliomas when controlled for tumour grade and histotype was found. Although 
TSPO over-expression was previously suggested to predict poor outcome in astrocytomas none of the 
authors demonstrated that this is independent of tumour grade (Miettinen et al. 1995; Vlodavsky et al. 
2007). Further, the levels of neither VDAC1 nor ANT, TSPO-binding MPTP members, were related 
to disease outcome in our patient population.  
Potentially, TSPO might be linked to other phenotypic traits in gliomas rather than cell death and 
proliferation, which are suggested by the huge majority of literature on TSPO in cancer. However, 
this possibility is contradicted by the fact that there is no evidence for a link between TSPO 
expression and patient outcomes.  
While neither the in vitro nor the histological study conducted here is suggestive of a strong impact of 
TSPO on glioma biology, the differential expression of TSPO between oligodendrogliomas and 
astrocytomas has a potential utility in the pre-operative diagnosis of gliomas. TSPO has been long a 
subject of imaging studies and several ligands can be used for its visualization (Dolle et al. 2009; 
Junck et al. 1989; Olson et al. 1988; Starosta-Rubinstein et al. 1987). We therefore propose PET 
imaging with TSPO ligands as a strategy to support pre-operative diagnostic process in gliomas.  
Because of TSPO up-regulation in gliomas, TSPO-ligand conjugated drugs could preferentially target 
neoplastic cells rather than normal tissue. Consistently, PK11195 conjugated to gemcitabine has been 
previously shown to selectively increase the tumoural delivery of this anticancer drug in nude rats 
bearing intracerebral xenografts (Guo et al. 2001). Furthermore, cancer mitochondria could be 
targeted using synthetic molecules such as dendrimers specific for TSPO. The internalization of 
TSPO targeted dendrimer and its binding to mitochondria was shown recently  (Samuelson et al. 
2009). So even though TSPO is not a key player in glioma cell growth and survival, further 
characterization of its associations may guide new therapeutic approaches targeting mitochondria of 
cancer cells. 
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6.2.2 Gliomas  
The outcome of diffusely infiltrating gliomas is strongly associated with tumour grade and histotype.  
In this study evidence for the differential expression of several novel markers in gliomas was 
provided. TSPO, P450c17A1 steroidogenic enzyme, hexokinases I and II as well as CD68 and Iba1 
microglial markers, are all expressed at higher levels in astrocytic as compared to oligodendroglial 
tumours and in high-grade astrocytomas as compared to low grade astrocytic tumours. These markers 
build up a catalogue of changes associated with glioma progression. It is important to understand 
whether they represent a wider inflammatory (CD68, Iba1), metabolic (hexokinases) and 
steroidogenic (TSPO and P450c17A1) switch between the histotypes and grades rather than unrelated 
marker changes. The real advance could be identifying the key players driving such switch events 
during glioma progression. This can be due to epigenetic dysregulation as is the case for TSPO or 
secondary to changes in tumour environment such as hypoxia.  
Of the changes described here only the up-regulation of hexokinase II is consistently related to poor 
patient outcomes and this points to the significance of the metabolic transformation in gliomas. 
Reprogrammed metabolism is a recognised feature of tumour cells in various cancers that has been 
postulated to represent a target for therapy (Tennant et al. 2009; Tennant et al. 2010). Mutations in 
metabolic enzymes IDH1 and IDH2 were found to be frequent genetic alterations in astrocytomas and 
oligodendrogliomas (Yan et al. 2009a). Furthermore, the mutation in IDH1 was shown to result in 
production of the „onco-metabolite‟ (2-hydroxyglutarate) that contributes to malignant progression of 
gliomas (Dang et al. 2009). 
6.3 Future directions 
6.3.1 Pre-clinical studies 
I postulate a study further validating the epigenetic mechanisms in TSPO regulation. I propose in vitro 
treatment of oligodendroglioma cells with a demethylating agent to document TSPO up-regulation 
due to loss of promoter methylation. This experiment was hampered by the fact that there are no 
readily available established oligodendroglioma cell lines. We are currently optimising the ex vivo 
culture of primary glioma cells obtained during surgery in our centre to address this limitation. 
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When this is achieved, apart from the application for epigenetic studies, TSPO could be over-
expressed in oligodendroglioma cells and apoptotic, proliferation and other phenotypes (for example 
migration) assessed. Although there was no obvious impact of TSPO expression manipulation in an 
astrocytoma cell line on the behaviour of the cells, the situation may be different in 
oligodendrogliomas, where TSPO could still drive more aggressive disease.  
As TSPO expression was related to gene expression clusters in two analysed publically available 
microarray data sets of gliomas, I propose to establish whether TSPO depletion would lead to gene 
expression changes. This could be achieved with microarray analysis of astrocytoma cells transfected 
with siTSPO and controls (as optimised here). Pathway/gene ontology analysis could be used to 
assess whether the list of genes obtained is functionally similar to the gene expression clusters that 
TSPO associates with in the clinical microarray data sets. Further, selected candidates genes, likely 
regulated by TSPO, could be carried forward to phenotypic studies, but this should be preceded by 
quantitative reverse transcription PCR validation with two independent siRNA oligos for TSPO. 
Similar experiment, but based on TSPO over-expression, could be also conducted in 
oligodendroglioma cells when available, and an overlapping set of genes altered by TSPO in both 
histotypes sought for. 
Furthermore, I propose an in vitro study to validate whether TSPO ligands could be used to 
preferentially deliver drugs (or initially other conjugates) to glioma cells, which was previously 
suggested for PK11195-gemcitabine conjugates but not studied at the cellular level nor shown to be 
TSPO-dependent. Several cells that differ with respect to TSPO levels (naturally or due to 
transfection) could be exposed to fluorescently conjugated TSPO ligands and the intracellular 
concentration as well as co-localization with TSPO and mitochondria could be assessed with flow 
cytometry and immunofluorescence. The same cells could be xenografted in mice and the potentially 
preferential TSPO-ligand conjugates up-take as well as its relationship to TSPO levels assessed with 
the same techniques. Serial PET imaging could be used to assess the kinetics of the process and 
parameters such as kidney and hepatic accumulation and excretion. Mice could be also observed for 
long term toxicities.  
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I propose to examine in mice xenograft models the impact of hexokinase inhibition via genetic 
approaches e.g. short-hairpin RNA (shRNA) transfection or dissociation from mitochondria with 
agents such as methyl jasmonate. Apart from the anti-tumour activities, the toxicities in normal tissues 
should be assessed.  
6.3.2 Histopathological studies 
I postulate to examine whether TSPO levels and methylation pattern are related to patients outcomes 
and 1p/19q status in oligodendrogliomas as the number of samples I analysed here is likely 
insufficient to unravel statistically significant associations. Further, there are no data sets were large 
numbers of oligodendrogliomas could be re-analysed. Although the prognosis in oligodendrogliomas 
is remarkably better than in astrocytomas it is important to learn how to identify oligodendrogliomas 
that are characterised by poor patient outcomes. 
6.3.3 Clinical studies 
As already suggested in Chapter 4, the steroid synthesis in gliomas should be re-assessed as there are 
several limitations to the in vitro culture model used in the present study. A current study in our 
laboratory in collaboration with Dr Jonathan Bowen, Imperial College London, aims at metabonomic 
identification of steroids and steroid precursors in dialysates obtained intra-operatively from glioma 
patients. The initial technical considerations related to this study were recently published by our group 
(Homapour et al. 2010). This may strengthen the efforts into elucidating the significance of 
steroidogenesis in gliomas and demonstrate that in vitro studies of established cancer cell lines are 
insufficient to answer several clinical problems. 
Most importantly, we propose a PET study with TSPO ligands in patients with gliomas to establish 
whether the histotype-discriminatory role suggested for TSPO in my immunochemical study and by 
the re-analysis of microarray data sets is also relevant in the clinical settings. This study is currently 
developed in collaboration with Professor Karl Herholz from the University of Manchester/ Wolfson 
Molecular Imaging Centre. The study aims to evaluate the diagnostic utility of [
11
C] PK11195 in the 
differential diagnosis of gliomas.   
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6.4 Concluding remarks 
TSPO is not a strong predictor of patient survival in gliomas but its up-regulation driven by epigenetic 
events is associated with tumour progression. TSPO has been long studied as an imaging target and 
the availability of TSPO ligands can be potentially utilised to discriminate glioma histotypes of very 
different biology and prognosis at an early stage of the pre-operative diagnostic process.     
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Control staining for peroxidase immunohistochemistry 
Tissue sections of adrenal were used to optimise and as control tissue for the peroxidase 
immunohistochemistry for TSPO (A), P450scc (F), P450c17A1 (G), pharyngeal tonsil for Iba1 (C) 
and CD68 (D), kidney for ANT (H), breast for VDAC1 (J) and HKI (K) and colon cancer for HKII 
(M). Control sections were included in each run of the immunohistochemical staining.  
The immunoreactions with omission of the primary antibody were performed as negative controls (B, 
E, I, L, N). Representative images are shown. 
Scale bars: A, B, E, F, G, H, I, M, N – 50 µm, C, D, J, K, L – 100 µm. 
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Appendix II 
 
Case 
ID 
Gender 
Age at diagnosis 
(years) 
Histopathology 
Follow up 
time 
(months) 
Status 
Histotype 
Grade 
(WHO) 
 
1p/19q status* 
1 M 42 A II  163 alive 
5 M 40 A II  44 alive 
6 M 36 A II  32 alive 
7 M 37 A II  27 alive 
9 F 31 A II  51 alive 
10 M 23 A II  63 alive 
13 M 35 A III  14 alive 
14 M 33 A III  35 dead 
15 M 38 A III  34 alive 
18 M 40 A III  64 alive 
21 M 52 A IV  120 alive 
22 M 39 A IV  14 dead 
23 F 68 A IV  0 POD 
24 M 58 A IV  11 dead 
25 F 62 A IV  37 dead 
26 F 57 A IV  26 dead 
27 M 56 A IV  16 dead 
28 F 64 A IV  11 alive 
29 F 53 A IV  3 dead 
30 M 65 A IV  5 dead 
51 M 50 A IV  13 dead 
52 M 32 A IV  18 dead 
53 F 57 A IV  14 dead 
54 M 36 A IV  5 dead 
55 M 43 A IV  86 alive 
56 M 60 A IV  41 dead 
57 M 63 A IV  21 dead 
58 F 50 A IV  10 dead 
59 M 66 A IV  17 dead 
60 F 79 A IV  9 dead 
61 F 47 A IV  46 alive 
62 F 53 A IV  22 dead 
63 F 53 A IV  28 dead 
64 F 54 A IV  32 dead 
65 F 43 A IV  10 dead 
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66 F 67 A IV  3 dead 
67 M 51 A IV  12 alive 
68 M 84 A IV  2 dead 
69 M 65 A IV  14 dead 
70 M 46 A IV  17 alive 
71 F 63 A IV  10 dead 
72 M 61 A IV  14 alive 
73 M 56 A IV  5 dead 
74 M 76 A IV  1 dead 
75 M 45 A IV  15 alive 
76 F 45 A IV  1 dead 
77 F 65 A IV  11 alive 
78 F 60 A IV  12 alive 
79 M 72 A IV  3 dead 
80 M 52 A IV  24 dead 
81 F 40 A IV  3 dead 
31 F 34 O II LOH 1p/19q 4 alive 
33 F 31 O II LOH 1p/19q 26 alive 
35 F 46 O II LOH 1p/19q 70 alive 
36 M 43 O II  36 alive 
37 M 29 O II LOH 1p/19q 21 alive 
38 M 32 O II monosomy 19q 33 alive 
40 M 40 O II LOH 1p/19q 82 alive 
41 F 49 O III LOH 1p/19q 27 dead 
42 F 34 O III LOH 1p/19q 49 alive 
43 F 61 O III LOH 1p/19q 40 alive 
44 M 42 O III LOH 1p/19q 14 alive 
45 M 38 O III  27 alive 
46 F 44 O III no LOH 1p/19q 20 alive 
47 F 59 O III monosomy 19q 34 alive 
48 F 69 O III LOH 1p/19q 44 dead 
 
Clinicopathological characteristics of the patient population used for immunohistochemical 
analysis of HKI and HKII expression 
F, female; M, male; A, astrocytoma; O, oligodendroglioma; LOH, loss of the heterozygosity; POD, 
post operative death; *-where available 
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Appendix III 
Target 
 
Pixel densities 
average, normalized with control spots for each array 
 
Untreated 
 
1.5 mM MJ 
 
Bad 0.858 0.597 
Bax 0.504 0.354 
Bcl-2 0.170 0.234 
Bcl-x 0.229 0.215 
Catalase 0.343 0.528 
cIAP-1 0.159 0.313 
cIAP-2 0.115 0.135 
Claspin 0.296 0.143 
Cleaved caspase-3 0.040 0.175 
Clusterin 0.347 0.229 
Cytochrome c 0.733 0.676 
FADD 0.596 0.667 
Fas/TNFSF6 0.985 1.082 
HIF-1α 0.600 0.823 
HO-1/HMOX1/HSP32 0.632 0.962 
HO-2 0.148 0.521 
HSP27 0.463 0.727 
HSP60 0.262 0.357 
HSP70 0.606 0.787 
HTRA2/Omi 0.724 0.717 
Livin 0.149 0.160 
p21/CIP/CDNK1A 0.275 0.220 
p27/Kip1 0.156 0.202 
Phospho-p53 (S392) 0.254 0.400 
Phospho-p53(S15) 0.338 0.521 
Phospho-Rad17 (S635) 0.145 0.375 
Phosph-p53(S46) 0.136 0.361 
PON2 0.443 0.244 
Pro-Caspase-3 1.041 1.207 
SMAC/Diablo 0.531 0.857 
Survivin 0.414 0.264 
TNF RI/TNFRSF1A 0.244 0.305 
TRAIL R1/DR4 0.364 0.182 
TRAIL R2/DR5 0.804 0.806 
XIAP 0.844 0.862 
 
The average pixel densities of 35 apoptosis-related proteins determined in untreated cells and 
following MJ exposure 
 
